

DOE/MAS/RRF-6

RECEIVED
DEC 01 1999
OSTI

RADIATION EFFECTS RESEARCH FOUNDATION

FIVE YEAR

STRATEGIC RESEARCH PLAN

AND

PROGRAM MANAGEMENT, 1997-2001

SUBMITTED BY THE RERF EXECUTIVE COMMITTEE

TABLE OF CONTENTS

FOREWORD	1
Organization of this Strategic Research Plan and Program Management Document	1
Assumptions used in developing this planning document	2
THE FOUNDATION	3
RESEARCH GOALS AND OBJECTIVES	4
RESEARCH PROGRAM STRATEGY	5
CURRENT STATUS OF THE RERF COHORTS	7
The Life Span Study cohort	7
The Adult Health Study (AHS) cohort	8
In Utero Sample	8
The F ₁ cohort	9
THE STRUCTURE OF RESEARCH AT THE FOUNDATION	9
Cancer Studies	9
Noncancer Studies	13
Heritable Mutations	17
Dosimetry	19
Database Development	20
Current Status and Future Plans for RERF Follow-up Programs	22
RESEARCH PLANS BY DEPARTMENT	24
Departments of Clinical Studies	24
Program objectives	25
Major research activities in the next five years	25
A. Core activities (Hiroshima and Nagasaki)	25
B. Special research activities (Hiroshima)	26
C. New research initiatives (Hiroshima)	33
D. Special research activities (Nagasaki)	36
Departments of Epidemiology	38
Program objectives	38
A. Core activities	39
B. Special research activities	41
Site-specific cancer studies	41
Case-control studies in progress	44
C. New research activities anticipated in the next 5 years	45
Cancer	45
Noncancer diseases	46
Department of Genetics	53
The Cytogenetics Program	53
Cytogenetic studies of the survivors	54
Major research activities in the next five years	54

DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, make any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

DISCLAIMER

Portions of this document may be illegible in electronic image products. Images are produced from the best available original document.

A. Core activities	54
B. Special research activities	55
Cytogenetic studies of the children of the survivors	57
Major research activities in the next five years	58
Biochemical Genetics Program	58
Past and recent accomplishments	59
Major research activities in the next five years	59
A. Core activities	59
B. Special research activities	61
Department of Radiobiology	64
Recent achievements	65
Program objectives	65
Major projects in the next five years	66
A. Molecular epidemiology	66
Core activities	67
Special research activities	69
B. Molecular Oncology	70
Core activities	70
Special research activities	71
C. Immunology	73
Core activities	73
Special research activities	74
Department of Statistics	78
Program objectives	79
Major research activities in the next five years	79
A. Core activities	79
B. Special research activities	82
SUPPORTING SERVICES	85
Department of Information Technology	85
Program objectives	85
A. Core activities	86
Publication and Documentation Center	91
Specific roles	91
Radioisotope Facility	92
Management of the RI facility	92
Maintenance of a safe working environment	93
Future of RI facility	93
Secretariat	94
Organization and personnel strength	95
Duties	95
Hiroshima Laboratory	95
Nagasaki Laboratory	96
MAINTENANCE OF AN ADEQUATE INFRASTRUCTURE	99
Personnel	99
Equipment	100
Space	101

SUMMARY 104

FOREWORD

1
2
3 The Foundation recognizes that it functions in a climate of limited resources, and if these
4 resources are to be used cost-effectively and if the Foundation is to fulfill its mission efficiently,
5 there is a need for continued program planning and management. To conduct all of the research
6 that is deemed important within the current funding level and probable future ones, priorities must
7 be established, some research activities will need to be redirected or terminated, and recruitment
8 of additional scientific personnel may be necessary. The intent of this document is to provide a
9 framework for the establishment of research priorities to guide the allocation of resources and the
10 recruitment of personnel.

11 12 **Organization of this Strategic Research Plan and Program Management Document**

13
14 This Strategic Research Plan and Program Management document will give an overview
15 of the origin of the Foundation, its management structure, its mission, its research programs, and
16 its resources. This will be followed by a listing of program objectives, current major research
17 activities and those projected in the next five years, and the related resource requirements for each
18 of the major research departments. This section will be followed by an enumeration of resource
19 and personnel requirements as they relate to the administrative, computer-related, publication and
20 documentation, and radioisotopic services necessary to support the research program. Finally,
21 there will be a section on the maintenance of an adequate infrastructure and a summary and set
22 of conclusions which will also act as the executive summary of this document. Annexes will
23 provide ancillary information too detailed for enclosure in the body of the report.

24
25 There are many reasons why a strategic research plan and program management document
26 is timely and necessary. However, the salient ones are the following:

- 27
28 • The members of RERF's survivor cohorts are aging, and the number of cohort members
29 who remain alive will decrease markedly over the next few years. The research program
30 and data collection procedures must reflect these changes. (See Annex A for the current
31 size of the cohort and projections to the year 2020).
- 32
33 • The revolution in biomedical research in the last several decades has opened avenues of
34 research of potentially great relevance to RERF and the understanding of the biological
35 bases of radiation-related damage.
- 36
37 • Recent years and the next several have seen or will see a significant loss in personnel,
38 largely through retirement. This situation requires renewed emphasis on optimizing the
39 proportions of manpower devoted to research and support functions, and the development
40 of innovative ways of achieving the Foundation's aims without increasing the general staff
41 while maintaining a sound level of scientific personnel, for example, through the judicious
42 use of personal services contracts.
- 43
44 • A series of workshops recommended by the Foundation's Scientific Council were
45 conducted between 1988 and 1993 (see Annex B). The recommendations from these
46 workshops have affected RERF's current research and are influencing plans for future
47 research initiatives.

48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71

Assumptions used in developing this planning document

In this assessment of the Foundation's needs to support its scientific program, the Executive Committee felt it necessary to adopt certain self-imposed restrictions:

- It was assumed that budgetary limitations will prevent a significant expansion of the Foundation as a whole, that is, the level of support provided by its two funding agencies for research will remain more or less constant (with inflationary increases only).
- It was further assumed that it was critically important to maintain the appropriate array of professional, technical, and clerical skills needed to implement the research.

Within these limitations, the Committee believes that its research activities can still expand through increasing efficiency, through savings created by retirements, and, where possible, through transfer of general personnel positions to research-oriented ones.

The Executive Committee has carefully considered which of all potentially desirable research activities *could only be carried out* by the Foundation, which *could best be carried out* by the Foundation, and which *could be carried out elsewhere*, possibly on a collaborative basis. Prioritization along these lines will avoid the inclusion of research that is not specific to the Foundation's needs and potential, and will therefore reduce needed resources to only those that are most appropriate to RERF.

THE FOUNDATION

72
73
74 In the summer of 1945, the residents of Hiroshima and Nagasaki were in all probability,
75 representative of a typical, heterogeneous wartime population of individuals in Japan. In August
76 of that year, atomic bombs were detonated over these two cities. Soon thereafter a group of
77 Japanese and American scientists, known as the Joint Commission for the Investigation of the
78 Effects of the Atomic Bomb, began the task of assessing the physical damage wrought by the
79 bombings and of identifying the early health effects of exposure to atomic radiation. This
80 Commission, in its final report, strongly recommended the establishment, under civilian auspices,
81 of a program of research to evaluate the long-term health consequences of exposure to ionizing
82 radiation. In November 1946, President Truman approved a directive to the US National
83 Academy of Sciences-National Research Council (NAS-NRC) to initiate the long-term
84 investigation recommended by the Joint Commission. With funding provided by the Atomic
85 Energy Commission (AEC), now the Department of Energy (DOE), the NAS-NRC established
86 the Atomic Bomb Casualty Commission (ABCC) in March 1947, and research began shortly
87 thereafter. The Government of Japan, through the Japanese National Institute of Health, became
88 a partner in this endeavor.

89
90 In 1975, the Radiation Effects Research Foundation (RERF) was established and assumed
91 the responsibilities of the ABCC. This private, nonprofit Foundation, a *zaidan hôjin*, is
92 incorporated under Japanese law and its research is equally funded by the Governments of Japan
93 and the United States, through the Ministry of Health and Welfare (MHW) and through the
94 Department of Energy and the National Academy of Sciences, respectively. Administratively, the
95 Foundation is governed by a Board of Directors consisting of 12 individuals, six of whom are
96 Japanese citizens and six of whom are United States citizens. The day-to-day operations are
97 managed by an Executive Committee consisting of four permanent members of the Board of
98 Directors, two from Japan and two from the US, each of whom resides in Japan. The Permanent
99 Directors consist of a Chairman, a Vice Chairman, a Chief of Research, and one other Director,
100 who functions as the head of the Foundation's Nagasaki laboratory. The responsibilities of these
101 individuals, their terms of office, and the like are specified in the Foundation's charter, known as
102 the Act of Endowment.

103
104 Functionally, the Foundation consists of five major research departments, namely, the
105 Departments of Clinical Studies, Epidemiology, Genetics, Radiobiology, and Statistics, supported
106 by the Information Technology Department (ITD), the Publication and Documentation Center
107 (PDC), a Radioisotope Facility, and a Secretariat. The ITD is responsible for the maintenance of
108 the computational capabilities of the Foundation; whereas the Publication and Documentation
109 Center and Secretariat are responsible for the publications (print and online) emanating from the
110 Foundation and the administrative details relating to budgeting, personnel, purchasing, and public
111 affairs, respectively. The Radioisotope Facility serves as a resource for those departments, such
112 as Genetics and Radiobiology, requiring the use of radioisotopic materials.

113
114 The clinical, epidemiological, statistical, and other investigations are conducted in two
115 laboratories, one in Hiroshima and the other in Nagasaki. The management of both laboratories
116 is the responsibility of the Executive Committee, and the research activities conducted in the two
117 laboratories are coordinated by the Chief of Research. To help conduct RERF's research
118 activities properly there is a series of standing committees such as the Research Protocol and

119 Human Investigation committees. Review of the research program and recommendations on the
120 relevance and scientific quality of ongoing investigations, as well as future research directions, are
121 provided to the Board of Directors on an annual basis by a Scientific Council. This Council is
122 composed of ten experts in areas of research relevant to RERF, five of whom are from Japan and
123 five of whom are from the United States. As in the instance of the Board of Directors, the
124 process of selection of these individuals, their terms of office, and their responsibilities are
125 specified in the Act of Endowment. In addition, over the last eight years, the Council has been
126 instrumental in the organization of a series of workshops in specific areas of research to provide
127 guidance on promising approaches for possible implementation in the research programs and many
128 of their recommendations have been implemented. (See Annex B for a listing of the recent
129 workshops.)

130
131 As of 1 April 1996, the Foundation had 335 employees, 258 in Hiroshima and 77 in
132 Nagasaki. Of these 47 represented the professional research staff, 43 in Hiroshima and 4 in
133 Nagasaki.

134
135 The Foundation is housed in Hiroshima in a complex of nine interconnected two-story
136 structures with a gross area of 9,681 square meters (about 105,400 square feet); whereas in
137 Nagasaki, the Foundation occupies a four story building with a gross area of 2,643 square meters
138 (28,780 square feet). The facility in Nagasaki is relatively new, but the bulk of the one in
139 Hiroshima was built in 1950 and is now barely adequate for the Foundation's research needs.

140
141 To conduct a broadly based research program involving the collection, processing, and
142 analysis of extensive data on mortality and morbidity in a population as large as that of the
143 survivors and their children, RERF has developed an organization plan (see Figure 1) for the
144 coordination of epidemiological, clinical, and laboratory research conducted in two widely
145 separated laboratories. This plan is periodically reviewed by the Board of Directors and revised
146 as circumstances warrant.


147
148 It is important to note that the investigations conducted by the Foundation are the only
149 opportunity in existence for determining the late biological effects resulting from a single exposure
150 to ionizing radiation ranging from very low to high doses. The results obtained in these
151 investigations provide information that will lead to improved health care for the survivors as well
152 as individuals who may be exposed to ionizing radiation elsewhere. Furthermore, the results of
153 these investigations are of fundamental importance to an understanding of the effects of ionizing
154 radiation on human beings and are, therefore, essential for estimating radiation risk and setting
155 safe standards for occupational, medical, and general population exposures. Indeed, the data
156 accumulated by the Foundation is the major source of information on which the standards
157 established by national and international radiation protection bodies rest.

158 159 **RESEARCH GOALS AND OBJECTIVES**

160
161 The unique nature and long-term follow-up of this exposed population have provided
162 invaluable information on the early and late health effects of radiation exposure. (See Annex C
163 for some recent summaries of the findings to date.) To ensure that these investigations continue
164 in a productive manner and are focused on radiobiological and health-related issues of importance
165 to the scientific and medical community and the concerned public, it is essential that a careful,

Figure 1.

Organization



166 continuing evaluation of the research program be made, future directions determined or revised
167 as need arises, and research priorities established. This strategic research plan has been developed
168 to achieve these ends.

169
170 To carry out its responsibilities in an orderly and scientifically sound manner and to be
171 responsive to its charter, the broad goals of the Foundation are:

- 172
- 173 • To determine the late health effects, both somatic and genetic, produced in human beings
174 from exposure to ionizing radiation.
 - 175
 - 176 • To obtain information on the temporal pattern of cancer expression and other radiation-
177 related effects and on the role of biological and environmental factors which may modify
178 the effects resulting from exposure to ionizing radiation.

179
180 The strategy for addressing these goals is implicit in the following general research
181 objectives:

- 182
- 183 • To conduct long-term epidemiological studies of a fixed sample of exposed and
184 unexposed individuals to determine the frequency-dose relationships of morbidity and
185 mortality resulting from radiation exposure and to obtain information on the differential
186 sensitivity of various tissues.
 - 187
 - 188 • To conduct case-control and other special investigations on cancer induced in specific
189 tissues or organs to determine the cell types affected and the effects of modifying factors.
 - 190
 - 191 • To conduct research in molecular and cellular biology to detect somatic mutation, cell
192 transformation, changes in immunological competence and other biological events for use
193 in understanding and estimating radiation risk.
 - 194
 - 195 • To utilize all available sensitive and cost-effective approaches for measuring heritable
196 mutation in the children of exposed and unexposed individuals, and for assessing the
197 public health impact of these mutations.

198
199 All research at the Foundation aimed at these goals takes place under published research
200 protocols that must obtain the approval of the Chief of Research, the Research Protocol
201 Committee, the Human Investigation Committee, and the Chairman of the Foundation before they
202 are activated. These protocols are of two kinds, the so-called platform protocols that guide the
203 major or core research activities of the Foundation, and special research protocols. The core
204 activities commonly involve more than one department and are collaborative; whereas the specific
205 research activities may or may not be collaborative. A listing of the currently active protocols will
206 be found in Annex I. Of primary importance to the Foundation are, of course, the core activities
207 since ultimately they are the *raison d'etre* of the institution.

208 209 RESEARCH PROGRAM STRATEGY

210
211 To conduct a successful long-term epidemiological investigation which addresses the goals
212 of RERF, data must be collected on a continuing, prospective basis using specified samples of

213 exposed individuals and a matched group of unexposed individuals when a need for a comparison
214 with the latter arises. These data must be collected in a systematic and epidemiologically
215 acceptable manner to reduce the chance of bias or ambiguity affecting interpretation of the results
216 observed.

217
218 The first major program to be initiated by ABCC was the Genetics Program, which
219 included observations on the occurrence of major congenital abnormalities, sex, birth weight,
220 viability at birth, and survival during the neonatal period of all newborn infants in Hiroshima and
221 Nagasaki. The study, which began in 1947 and continued until 1954, encompassed some 76,626
222 infants, with reexamination of a subsample of approximately 20,000 of these infants at age 8-10
223 months. Although this major clinical program was terminated in 1954, the cohort thus
224 established, with subsequent additions, has been followed for survival since that time, as the F₁
225 Mortality Study.

226
227 Most of the early studies on the survivors themselves were essentially ad hoc, each
228 investigator usually establishing his own study population. In 1955 the Francis Committee
229 reviewed the research on exposed (and unexposed) persons at ABCC and urged the adoption of
230 a Unified Study Program as a permanent research guide. The committee's recommendations were
231 approved and have since provided the basis for much of the current epidemiological and clinical
232 follow-up of the survivors in Hiroshima and Nagasaki. In 1975, prior to the establishment of
233 RERF, a second committee, known as the Crow Committee, reviewed the program and
234 recommended continued investigation of this unique population.

235
236 Implementation of the Francis Committee recommendations resulted in the establishment
237 of four major fixed cohorts:

- 238
- 239 • the Life Span Study (LSS) cohort of survivors and an unexposed comparison group who
240 were alive at the time of the bombings;
- 241
- 242 • the Adult Health Study (AHS) cohort (a subset of the LSS cohort), whose members are
243 encouraged to participate in a program of standardized biennial clinical examinations
244 carried out at RERF;
- 245
- 246 • the in-utero (IU) cohort of individuals who were exposed in-utero and matched controls;
247 and
- 248
- 249 • the F₁ cohort of children born between June 1946 and December 1984 to exposed or
250 unexposed parents.
- 251

252 Follow-up of these cohorts is central to the work of the Foundation. The primary follow-
253 up programs are:

- 254
- 255 • mortality ascertainment for most members of all of the cohorts through the Japanese
256 family registration (*koseki*) system;
- 257
- 258 • ascertainment of cancer morbidity through linkage of the cohorts with the Hiroshima and
259 Nagasaki tumor and tissue registries, which are managed by RERF;

- 260 • a special registry (the Leukemia Registry) of cases of leukemia and malignant diseases of
261 the hematopoietic system;
- 262
- 263 • the offering of standardized biennial clinical examinations for members of the AHS cohort
264 and a (fixed) subset of the IU cohort;
- 265
- 266 • a mail- and telephone-based morbidity surveillance system for AHS cohort members;
- 267
- 268 • occasional mail surveys carried out within the LSS cohort; and
- 269
- 270 • an autopsy program (active from about 1960 through the early 1980's but currently
271 inactive).
- 272

273 Analyses of data from the RERF cohorts make use of individual dose estimates. The basic
274 methods used to compute these estimates were originally developed by researchers at Oak Ridge
275 and other national laboratories. The current dosimetry system, DS86, was the result of a
276 binational effort to reassess the physical data and refine the theoretical models that formed the
277 basis for the dosimetry system (T65D) that had been in use at ABCC and RERF since the late
278 1960's. Japanese and US scientists are currently working to deal with discrepancies between
279 DS86 Hiroshima neutron dose estimates and neutron doses inferred from physical measurements
280 and some biases suggested by RERF biodosimetric data. It is likely that this effort will lead to
281 revised dosimetry within the next five years. As in the past, RERF researchers will be responsible
282 for adapting and applying the new dosimetry for use with the survivors.

283
284
285

CURRENT STATUS OF THE RERF COHORTS

286 In this section we present some information on each of the major cohorts at this time.
287 This discussion provides a limited amount of historical information about the creation of the
288 cohorts since the primary focus concerns the nature of these cohorts today.

289
290
291

The Life Span Study cohort

292 The LSS cohort was constructed from a Master Sample of about 284,000 Japanese atomic
293 bomb survivors (159,000 in Hiroshima and 125,000 in Nagasaki) developed from a special
294 nationwide enumeration of A-bomb survivors carried out as a part of the 1950 National Census.
295 As initially defined, the LSS included all survivors in the Master Sample who were within 2000
296 m of the hypocenter at the time of the bombings (ATB) and alive and residing in Hiroshima or
297 Nagasaki on 1 October 1950 and who met certain other criteria necessary to ensure complete
298 mortality follow-up. There were originally two age and sex matched comparison groups who met
299 the residency and other criteria deemed necessary for adequate follow-up. One of these groups
300 was composed of individuals who were exposed in the cities at distances of 2,500 to 10,000 m
301 from the hypocenter ATB and the other group consisted of individuals who were not in the cities
302 at the time of the bombing. With the introduction of individual dose estimates, the cohort was
303 extended to include all persons in the Master Sample who were within 2,500 m of the hypocenter
304 ATB. Finally, in the early 1980's all remaining distal survivors in Nagasaki (2,500 - 10,000 m
305 from the hypocenter) were added to the LSS to increase the size of the relatively small Nagasaki
306 internal comparison group. With these additions, there are now 120,321 individuals in the LSS

307 cohort, including 93,473 who were in one or the other of the two cities at the time of the
308 bombing.

309
310 As of the fall of 1996, the mortality follow-up records indicate that 49% of the cohort
311 members have died and less than 200 individuals have been lost to follow-up (primarily due to
312 migration out of Japan). The average age of the surviving members of the cohort is 65.4 years.
313 When broken down by age at exposure, it is seen that lifetime follow-up is essentially complete
314 for cohort members who were at least 50 years old at the time of exposure, while more than 90%
315 of those who were under the age of 20 ATB are still alive. (See Annex A.)
316

317 The Adult Health Study (AHS) cohort 318

319 The AHS cohort is a subset of the LSS cohort. This subset was so defined as to include
320 all members (4,990 individuals) in the original LSS cohort who were within 2000 m of the
321 hypocenter and who reported one or more of the cardinal symptoms associated with acute
322 radiation sickness, that is, epilation, oropharyngeal lesions, and purpura. Three age and sex
323 matched control groups were chosen from among (1) the survivors within 2,000 meters who
324 reported no acute radiation symptoms, (2) survivors who were at distances of 2,500 to 10,000
325 m from the hypocenter ATB, and (3) unexposed LSS cohort members. With the introduction of
326 individual dose estimates the AHS cohort was augmented by the addition of all remaining
327 members (2,436 persons) of the LSS whose T65D shielded kerma dose estimate was greater than
328 1 Gy. The examination schedule was set so that in any one month a more or less representative
329 cross section of the entire population would visit the clinic. These examinations are now in the
330 19th cycle; however, over time, attrition has reduced the population to about 50% of the original
331 sample.
332

333 As of the fall of 1996 more than 9,200 of the 17,397 exposed members of the AHS are
334 still alive and about 8,000 of these individuals are living in the clinical contacting catchment area.
335 Among this latter group almost 80% participated in the most recent cycle of AHS examinations.
336

337 In Utero Sample 338

339 The in-utero cohort was assembled from a roster of more than 10,000 individuals whose
340 date of birth was between the date of the bombings and May 1946. This roster was developed
341 from Hiroshima and Nagasaki birth records, records of early ABCC studies, and data from a
342 special survey conducted in conjunction with the 1960 Japanese national census. As currently
343 defined, the cohort includes data from two overlapping samples: a clinical sample defined in the
344 late 1950's and a mortality cohort defined in the early 1960's. As with the other cohorts these two
345 groups were defined in terms of a core set of individuals whose mothers were close (within 1,500
346 m for the clinical and 2,000 m for the mortality samples) together with age and sex matched
347 groups of more distal or unexposed people. The cohort includes 3,654 individuals of whom 1,192
348 were exposed at distances of less than 2,000 m of the hypocenter while 1,356 were exposed at
349 distances of 2,000 to 10,000 m. Complete mortality follow-up is available for all members of the
350 IU cohort other than the 59 individuals who were lost to follow-up due to emigration from Japan
351 or a failure to locate the *koseki* records. There are 755 in-utero survivors who have been included
352 in analyses of IQ and school performance but are not in the main IU cohort. Consideration is
353 being given to initiating routine mortality follow-up for these people. A total of 1,021 members

354 of the IU cohort are invited to participate in the AHS examinations. (This group overlaps but is
355 not the same as the IU clinical cohort whose members were asked to come to ABCC for annual
356 examinations during their late childhood and adolescence.)

357

358 Because of the age of members of this cohort (51 or 52 years in the fall of 1996), there
359 have been few deaths (434) at this time. More than one-third of these occurred during the first
360 few months of life.

361

362 The F₁ cohort

363

364 The original F₁ cohort included 53,518 children born to survivors between 1 June 1946
365 and 31 December 1958 selected from among the 76,626 children identified in the course of the
366 Genetics Program that ran from 1947 through 1953 or from other sources, generally the birth
367 records. The F₁ cohort was subsequently extended to include the children of virtually all
368 proximally exposed members of the Life Span Study cohort and the children of some distally
369 exposed members of this cohort. At this time the cohort includes 88,484 persons. However,
370 mortality follow-up is not being carried out for 11,760 cohort members who were selected for
371 some special clinical studies. Follow-up of these individuals should begin within the next year.
372 As of the fall of 1996, 5,316 members of the F₁ cohort are known to have died and 1,434 cohort
373 members have been lost to follow-up. Most of the deaths were infant deaths. The average age
374 of the surviving cohort members is currently about 38 years. As is discussed below, a mail survey
375 of the full F₁ cohort and a small study of the feasibility of an F₁ clinical examination program are
376 being planned.

377

378 THE STRUCTURE OF RESEARCH AT THE FOUNDATION

379

380 Research at the Foundation can be seen as a matrix with one dimension, the spectrum of
381 health effects resulting from exposure to ionizing radiation, and the other, the disciplinary skills,
382 represented by the research departments, needed to identify and understand the biological events
383 that subtend these effects. This duality of aims is implicit in the Unified Program of research
384 recommended by the Francis Committee and the need to focus most, if not all of the research
385 effort on the fixed samples described above. This focus implies in turn that much of the research
386 is integrative and necessarily collaborative. Indeed, no one of the major research departments at
387 the Foundation stands fully alone; each requires the help of the others either in data collection and
388 management, their analysis, or their biological interpretation. The collaboration can, of course,
389 vary in form. It is instructive, therefore, in describing the Foundation's program of research to
390 view it from both the programmatic perspective and the individual departmental contributions
391 since one illustrates the inherently collaborative nature and broad sweep of much of the research
392 and the other illuminates the individual departmental contributions.

393

394 Cancer Studies

395

396 Cancer is the best established, and most important late effect of exposure to ionizing
397 radiation among the atomic bomb survivors and other exposed populations. There are, however,
398 several important issues remaining unclear regarding the nature of cancer risk.

399

400 *Major LSS reports*

401 The series of general reports on cancer mortality and the recent collection of reports on
402 cancer incidence in the atomic bomb survivors in the LSS are the most visible and influential
403 products of the Foundation's research efforts. As previously stated, lifetime follow-up is
404 essentially complete for cohort members who were 50 years of age or older at the time of the
405 bombings, but for those survivors who were less than 20 years of age then 90% are still alive and
406 are now at, or on the verge of, ages of rapid increases in spontaneous cancer rates. While the
407 total number of cancer cases among those exposed as children is not yet large, the data indicate
408 that, despite a possible decrease in the excess relative risks, excess cancer rates associated with
409 the radiation exposure are continuing to increase. The number of cancer cases in the youngest
410 members of the LSS can be expected to double every 5 to 10 years until well into the next
411 century. Thus, additional follow-up and analyses of these data are central to the development of
412 a comprehensive assessment of the long term impact of radiation exposure on cancer risks in the
413 survivors.

414
415 During the next five years we will produce a new comprehensive cancer mortality report
416 (LSS Report 13) covering the period from 1950 through 1995 as well as an updated report on
417 solid cancer incidence covering the period from 1987 through at least the end of 1992. While
418 there will undoubtedly continue to be a need for both mortality- and incidence-based risk
419 assessments, efforts will be made to present a more integrated, comprehensive picture of the
420 incidence and mortality data. As these analyses are completed we will continue to make the
421 detailed data sets available to other researchers.

422 423 *Site-specific incidence studies*

424
425 The general LSS Reports provide useful summaries of cancer risks in the LSS. However,
426 they cannot provide an in-depth look at the nature of cancer risks for specific tumor types or
427 subtypes. To address this problem, RERF researchers in collaboration with the local medical
428 community and some support from the US National Cancer Institute (NCI) have carried out a
429 number of studies of cancer incidence at specific sites. These studies involve the identification of
430 potential LSS cases from a variety of sources (including tumor and tissue registry records, death
431 certificates, and autopsy reports) using broadly defined selection criteria. The medical records
432 and, where possible, pathologic material for candidate cases are screened by a panel of
433 pathologists in order to arrive at a consensus diagnosis. Cases identified in this way are then
434 analyzed to assess cancer risks.

435
436 The results of site-specific studies on cancers of the breast and salivary glands have been
437 published. Reports on skin, CNS tumors, and liver cancer will be completed soon. Over the next
438 several years studies of thyroid cancer, lung cancer, lymphoid malignancies, and an update of the
439 breast cancer series will be completed.

440
441 In contrast to the general LSS Reports, which appear in radiation-related journals, we are
442 seeking to publish the results of the site-specific incidence studies in the more general medical
443 literature to increase awareness of the RERF findings in the broader scientific community.

444 445 *Patterns of excess cancer incidence among those exposed in childhood*

446
447 As noted above, the excess relative risks associated with radiation exposure among the

448 youngest survivors are higher than those for other age groups and the data suggest that these
449 relative risks may be decreasing with time. These findings have led to a widely held view that
450 people exposed as children are particularly sensitive to radiation effects. However, for most solid
451 cancers excess absolute rates, at a given attained age, appear to be quite similar to those exposed
452 as adults. This may not be the case for some tumors, notably breast and other endocrine tumors.
453 As those exposed as children reach ages at which rates of cancer increase dramatically it will be
454 possible to carry out more detailed analyses of the nature of solid cancer risks among these
455 survivors. Thus, as in earlier RERF reports on the shape of the dose response and on temporal
456 patterns in the excess solid cancer risk, we will produce a short report focused on solid cancer
457 incidence following childhood exposures. This project is being undertaken in collaboration with
458 NCI.

459

460 *Issues in modeling excess cancer risks in the LSS*

461

462 The analysis of the LSS cancer mortality data continues to raise a variety of interesting
463 and challenging statistical problems. A number of innovative methods have been developed to
464 analyze the LSS data. These include extensions of classical regression models for survival analysis
465 to allow for efficient estimation in large cohorts using general relative and absolute risk models,
466 procedures to adjust for biases resulting from random errors in individual dose estimates and to
467 allow for the impact of migration in the analysis of the tumor registry data, and methods for the
468 joint analysis of data on multiple causes.

469

470 There is an increasing interest in the application of biologically-motivated models to the
471 data on radiation and cancer risks. Over the next year or so we expect to complete work on a
472 generalization of the Armitage-Doll multistage model that provides some useful insights into the
473 age and time patterns of the excess risk seen in exposed survivors. We are working on the
474 application of the Moolgavkar-Venzon-Knudson two-stage model to the LSS cancer data.

475

476 Because of the strong interest in the nature of the dose response at low doses, there is a
477 need to consider more flexible alternatives to linearity than the simple quadratic and threshold
478 models generally used. This will involve the development of regression-adjusted nonparametric
479 smoothers.

480

481 Over the next two years studies of inter-site variability in radiation-associated excess
482 cancer incidence and of the comparison of relative risk and absolute rate models in the description
483 of excess cancer risks will be completed.

484

485 *Effect modification by nonradiation factors*

486

487 Use of data from the mail surveys conducted by ABCC-RERF over the past 30 years has
488 largely been limited to assessments of smoking and lung cancer risks. However, these surveys
489 also include information on alcohol consumption, nutrition, reproductive history, and
490 socioeconomic factors. Additional cross-sectional and longitudinal data on non-radiation factors
491 have been obtained directly from participants in the AHS examinations. The serum samples from
492 AHS participants that have been collected and stored are also a valuable resource for the study
493 of nonradiation risk factors and for molecular epidemiological studies.

494

495 Use of these mail survey and clinical data has been limited in part by the problems in
496 collating data from the various sources. This problem is being addressed as a part of efforts
497 (discussed further below) to modernize the RERF research database. Thus over the next few
498 years we plan to undertake a number of projects that will make more extensive use of the mail
499 survey data. These studies include updated analyses of smoking and the incidence of lung or other
500 smoking-related cancers in the LSS, new analyses of alcohol consumption and liver cancer
501 incidence, and analyses of the impact of socioeconomic factors on comparisons of the exposed
502 and unexposed (not-in-city) groups.

503
504 Over the next five years we will conduct a series of case-control studies nested in the AHS
505 to investigate the impact of nonradiation factors on some common but generally nonfatal cancers
506 (breast, thyroid, and skin). The mail survey and clinical data will be useful either directly (as a
507 source of data on risk factors) or indirectly (by providing information enabling more efficient
508 matching of cases and controls) in the design and analysis of such nested case-control studies.

509 510 *Radiation and benign tumor incidence*

511
512 Recent AHS data have suggested that there may be radiation-related increases in the risk
513 of various benign tumors including myoma uteri and parathyroid adenoma among AHS
514 participants. A study of the prevalence of uterine myoma based on ultrasonographic examination
515 will be published within a year and reports on the prevalence of several other benign tumors (liver
516 hemangioma, and ovarian tumor) observed using ultrasound will be completed within the next two
517 to three years. Consideration is also being given to the conduct of a study of benign thyroid
518 tumors and other thyroid disorders among Hiroshima AHS participants. If it is deemed feasible,
519 this study would serve to complement the Nagasaki thyroid study, which indicated radiation-
520 related increases in risks for these conditions. Within the next year a 10-year incidence study on
521 hyperparathyroidism among AHS participants will be completed. It is hoped that this study will
522 provide some hints as to the reason for the elevated serum calcium and parathyroid hormone
523 levels in heavily exposed survivors.

524 525 *Cancer incidence and mortality in the in-utero and F₁ cohorts*

526
527 A major report on cancer mortality in the in-utero cohort for the period from 1950
528 through 1992 is now in press. This report will be supplemented within the next year by reports
529 on cancer incidence and general mortality patterns in this cohort. In view of the age of the in-
530 utero population, the number of cancer cases can be expected to increase dramatically with five
531 additional years of follow-up. Thus it would be appropriate to produce an updated report on
532 cancer mortality and incidence in the cohort in about five years.

533
534 Mortality follow-up for the F₁ cohort will be extended to include all people who have been
535 selected for the BGS study. Once this is done a new report on cancer incidence and mortality in
536 the cohort will be prepared. This report should be completed within about three years.

537 538 *Pooling of RERF data with data from other cohorts*

539
540 While the atomic bomb studies are a major source of information on risk assessment, they
541 cannot address all of the important issues on radiation risks. Comparison of the data on the A-

542 bomb survivors with that from other exposed populations enables us to examine some of these
543 issues, such as dose rate effects and risk transfer. Under the terms of a contract with the NCI,
544 RERF is working with Russian and US scientists on documenting, updating, and improving the
545 data on cohorts of Russian nuclear workers and the general population exposed to large radiation
546 doses as a result of low-dose rate chronic exposures from the operation of the Mayak plutonium
547 production plant located in the Southern Urals. An important part of this work will be the
548 preparation of initial reports on cancer risk estimates for these cohorts together with some
549 (limited) comparison of these estimates with those seen in the LSS. The initial contract will
550 continue until September of 1998. This contract may be extended for several more years
551 depending upon the results of current work and the availability of funds.

552

553 Work being carried out at RERF on a multi-population comparison of breast cancer risks
554 following radiation exposure in six cohorts, including the LSS, should be completed within the
555 next year.

556

557 *Trends in Hiroshima and Nagasaki cancer incidence*

558

559 As noted earlier, RERF operates tumor registries in cooperation with the medical
560 associations in Hiroshima city and Nagasaki city and prefecture. The linkage between these
561 general population registries, which are regarded as among the best in Japan, and the LSS, in-
562 utero, and F₁ cohort data is important to the conduct of RERF research. The registries also
563 provide useful information on cancer risks in the Hiroshima and Nagasaki populations. While the
564 Hiroshima and Nagasaki registry data are routinely published in IARC's *Cancer Incidence in Five*
565 *Continents* volumes, the effort devoted to analysis and publication of these data has been limited
566 (especially in Hiroshima). Over the next five years we will produce a series of short bilingual
567 reports on trends in cancer incidence in these cities and develop procedures for the routine
568 production of summary reports on the status of the registries and the nature of the accumulating
569 data.

570

571 **Noncancer Studies**

572

573 *Noncancer mortality dose response*

574

575 The evidence for a significant association between radiation and noncancer mortality is
576 becoming stronger as the follow-up of the LSS cohort continues. Excess risks are seen not only
577 for cardiovascular disease mortality but also for other broad categories of noncancer disease
578 mortality. LSS Report 12 Part 2, which will be completed within the next year, will describe the
579 basic nature of this effect while addressing the uncertainties and limitations of the mortality data.
580 Over the next five years it will be important to extend the mortality follow-up through at least
581 1995 and to carry out further investigations aimed at clarifying, to the extent possible, issues
582 related to the shape of the dose response and patterns of the excess risk with regard to sex, age
583 and time. Additional follow-up may also help to determine if there are cause-specific differences
584 in risk. Because of the paucity of known biological mechanisms for a radiation effect on
585 noncancer disease we must continue to look for factors that might lead to a spurious association
586 between radiation exposure and noncancer disease mortality in the LSS.

587

588 There is a highly significant excess risk for noncancer diseases of the blood, with the

589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635

excess relative risk per Sv being larger than for any of the solid tumors. A review of these cases is being undertaken in collaboration with the hematologists associated with the Leukemia Registry. Results of this review should be available in one to two years.

Cardiovascular disease

The AHS data enable us to assess the incidence and prevalence of specific cardiovascular diseases and to undertake analyses of conventional risk factors, and thus are essential for the development of a better understanding of radiation effects on cardiovascular disease (and other noncancer diseases). Studies of AHS data on the incidence of cardiovascular disease and stroke will continue beyond the next five years. Analysis of data on various CVD risk factors and related-endpoints obtained from shorter term studies such as the prevalence of aortic and abdominal arch calcification, isolated systolic hypertension, retinal arteriosclerosis, and coagulation rates have all provided evidence of radiation effects. A major objective for the next few years is to publish initial reports on the first 30 years of follow-up and other findings.

These studies are currently being supplemented with studies of the rate of sudden death, the prevalence of peripheral vascular disease (as determined by pulse wave velocity and ankle-arm blood pressure ratio), plasma fibrinogen levels, and new analyses of conventional risk factors, including blood pressure and cholesterol. Research is being planned on several additional risk factors, including case-control studies of *H. influenzae* and homocysteine and the prevalence of latent atherosclerosis (as determined by ultrasonographic examination of the thickness of the carotid artery).

RERF has had a productive, long-term involvement in the Ni-Hon-San study of cardiovascular disease among Japanese in Japan and the US. This collaboration with the Honolulu Heart Program will continue through the next five years and should lead to several publications on general cardiovascular disease epidemiology.

Noncancer effects hypothesis generation

Because of the lack of a known biological basis for a radiation effect on noncancer morbidity, there is a need to develop ideas and, if possible, testable hypotheses regarding this issue. A workshop, such as that proposed by NAS, that would bring together RERF researchers and scientists from a broad range of disciplines to learn about RERF's findings and to discuss and develop ideas for future research in this area should take place in the near future. This will permit us to develop contacts for future collaboration and may inspire others to undertake research in this area. In addition to such a workshop, we need to establish a continuing dialog involving RERF staff and other scientists (particularly those at Geniken in Hiroshima and Nagasaki University) in order to focus more attention on this issue.

Liver disease

These studies will provide important data relevant to the interpretation of the finding of a radiation-related increased incidence of liver cancer and other liver diseases in the LSS and AHS. The serum assay-based study of the relationship between hepatitis-B and hepatitis-C virus infection and radiation dose, initiated in 1993, will be completed within the next two years.

636 We plan to investigate the feasibility and power of a nested case-control study using stored
637 sera to compare HCV infection rates and subtypes prior to the diagnosis of liver cancer or
638 cirrhosis and to look for interactions between radiation dose and HCV infection. Of particular
639 interest is the recent report that HCV infection can mask the concurrent presence of HBV
640 infection, leading to an underestimation of the prevalence of the latter infection. Similar studies
641 on HBV infection have been reported, but in the light of the finding just cited may have to be
642 redone.

643

644 *Longitudinal analysis of clinical and laboratory measurement data*

645

646 The recent report of an association between radiation and age-related changes in
647 cholesterol levels illustrates the usefulness of modern analytical methods in the study of
648 longitudinal clinical data. These methods will be developed further and applied to other blood
649 chemistry and hematology data as well as to blood pressure and other clinical measurements. We
650 will also consider how these methods might be applied in analyses of longitudinal data from
651 electrocardiograms.

652

653 *Menopause*

654

655 Analyses of the Nagasaki menopause incidence study indicate that a decrease in age at
656 menopause is associated with increased radiation dose. A report on these results will be
657 completed in the coming year. The Nagasaki findings have led to the initiation of a longitudinal
658 study of FSH and estradiol levels in peri-menopausal women to characterize better the relationship
659 between self-reported menopause and underlying hormonal changes. Data collection for this
660 study will continue through 1997 with analyses to be conducted in the following two or three
661 years. In Nagasaki, longitudinal observations on peri-menopausal changes in relationship to
662 serum cholesterol and estradiol will continue for the next five years.

663

664 *Aging*

665

666 A study of the relationship between age-related changes in cognitive function and radiation
667 dose has been underway since 1992. This study also includes comparison of data on AHS
668 participants with that for Japanese-Americans in Honolulu and Seattle (NI-HON-SEA study).
669 Data collection will continue for about one more year with analyses taking place over the
670 subsequent three years.

671

672 Osteoporosis is a common age-related disorder influenced by menopause and parathyroid
673 hormone levels which have been shown to be associated with radiation exposure in the AHS. Dual
674 photon absorptiometric measurements of spinal bone density of AHS participants, made since
675 1989, suggest that bone density increases as radiation dose increases. In order to provide a more
676 definitive result, measurements of spine and hip bone mineral density using dual X-ray
677 absorptiometry supplemented with data on total body composition are being obtained for selected
678 AHS participants. An analysis of the baseline data is being carried out at this time. As data on
679 these subjects are obtained in future AHS examinations longitudinal analyses of age-related
680 changes in bone mineral density will be made. Data from this study will also be used in the NI-
681 HON-SAN collaboration.

682

683 Estimates of physiological age were computed for AHS participants on the basis of grip
684 strength, skin elasticity and other factors measured in the 1970-72 AHS exam cycle. These
685 estimates are being used as covariates in an analysis of rates of mortality and morbidity during the
686 following 20 year period. This analysis should be completed within a year. A new assessment of
687 physiologic age based on a broader battery of measurements is being planned.
688

689 *Molecular epidemiology*

690

691 With some effort RERF can play a unique and important role in the search for evidence
692 of so-called finger prints associated with radiation-induced cancers. Work has begun on PCR
693 analyses of the ras and p53 genes using preserved and fresh skin, thyroid, and liver cancer tissues.
694 In the light of recent advances and the relatively large radiation effects for breast and thyroid
695 cancer, studies of tissues from breast and thyroid cancer cases among the high dose survivors have
696 the potential to yield important results. It may also be useful to supplement the search for
697 characteristic gene alterations in cancer cells with a search for evidence of specific mutations
698 associated with cancer development in the blood of cancer-free survivors.
699

700 The success of such studies depends heavily on our ability to obtain appropriate samples
701 for LSS cohort members who are diagnosed with cancer. It is possible to obtain archival material
702 through the tissue registries in Hiroshima and Nagasaki; however, better methods are needed to
703 ensure the availability of the necessary materials from newly diagnosed cases. To facilitate this
704 end RERF is seeking support from the local medical community for the establishment of a
705 community-wide tissue/DNA bank in Hiroshima. This bank would maintain tissue specimens or
706 preserved DNA that could serve as a resource for all groups in Hiroshima engaged in studies of
707 the molecular mechanisms of carcinogenesis.
708

709 It is important to keep abreast of the rapid progress in knowledge of the molecular basis
710 of cancer. The pace at which this field is developing suggests that future studies may be more
711 important than anything that can be done today. This suggests in turn that it would be worthwhile
712 for RERF scientists to work, possibly in collaboration with other groups, on the development of
713 methods to maintain a broad spectrum of DNA in a form that could be used in future studies.
714 Such samples would be particularly useful when it becomes possible to scan the entire genome
715 for evidence of possible changes.
716

717 In view of RERF's limited resources it is important for us to develop a general research
718 plan that defines specific projects that can be done at RERF as well as projects where
719 collaboration is important and establishes mechanisms for seeking this collaboration and, where
720 necessary, support.
721

722 *Immunology*

723

724 One of the major sources of tissues from the A-bomb survivors is from the on-going
725 collection of blood samples. This supply of viable cells from the survivors is a resource for the
726 study of many diseases including those with immune system dysfunction. Reduced immune
727 function can potentially lead to a variety of pathologic consequences including cancer, which is
728 known to show heightened risk among the survivors. RERF has a matchless opportunity to
729 investigate the late effects of radiation exposure on the immune system.

730 We plan to continue our studies of the features and mechanisms of radiation-induced
731 disorders in the hematolymphoid system at the cellular and molecular levels. These studies
732 include radiation effects on the distribution of T-cell subsets in the survivors and of radiation
733 effects on endocrine and hematopoietic growth factor levels as well as the study of stem cells, the
734 progenitors of cells which constitute the immune system.

735

736 Heritable Mutations

737

738 *Permanent lymphocyte cell line cultures*

739

740 The 1984 Genetic Study Conference endorsed an RERF plan to establish immortalized B-
741 lymphocyte cell lines from 1000 families (500 with at least one parent exposed within 2,000 m).
742 A sampling plan was drafted based on the T65D dosimetry. At this time the Biochemical Genetics
743 Laboratory has established cell lines for 800 families (1600 parents and 1200 children) based on
744 this plan. With the introduction of DS86 doses it was discovered that dose estimates were
745 unavailable for one or more of the parents in the remaining families. Over the next two years 200
746 additional Hiroshima and Nagasaki families for whom the parental doses are known will be
747 identified and efforts commenced to establish cell lines for these families in order to achieve the
748 goal of 1000 families. This is the largest cohort-based sample for the detection of radiation effects
749 on the human germline anywhere in the world.

750

751 *Pilot studies of methods for the detection of deletion-insertion-rearrangement mutations (D/I/R)*

752

753 Methods for genome-level (DNA) analyses are developing rapidly. It is likely that the next
754 five years will see the development of new markers and increasingly powerful methods that can
755 be used in the search for evidence of mutation in the children of the survivors. At this time, we
756 are examining several promising approaches. In each approach, mutations are detected by
757 comparison of a child's gel with that of his or her parents. Indications of a mutation include the
758 absence or dislocation of bands or spots as well as changes in intensity. As we learn of (or
759 develop) additional methods it may be necessary to initiate new pilot studies, in conjunction with
760 researchers outside of RERF when necessary.

761

762 Mutations at minisatellite loci

763

764 An initial study of 100 families will be extended by the addition of 100 families in order
765 to provide information for further comparisons of the RERF data with the results of a Belarus-UK
766 study (Dubrova et al 1996, Satoh et al 1996) that has been interpreted as providing evidence of
767 an excess of such mutations among Chernobyl victims.

768

769 Chemiluminescent bands on Southern filters

770

771 Employing a quantitative analysis of chemiluminescent bands on Southern filters, material
772 from the 200 families used in the minisatellite studies will also be screened for evidence of
773 mutation using DNA probes that correspond to the human counterparts of the seven mouse-
774 specific loci and other loci including genes that are suspected to be related to several common
775 chronic diseases, such as hypertension, diabetes mellitus, and hereditary nonpolyposis colorectal
776 cancer.

777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823

Two-dimensional electrophoresis (2-DE) methods

The Biochemical Genetics Laboratory has developed a 2-DE technique based on ³²P-labeled DNA digests created with three sets of restriction enzymes. This method produces three gels per individual having a total number of roughly 2000 spots (fragments) that are suitable for D/I/R mutation detection. A study using DNA samples from 200 BALB/c mice derived from irradiated spermatogonia, conducted primarily to prove that the 2-DE technique is capable of detecting mutations, will be completed within a year. This study will be followed by an investigation of DNA from the 200 pilot study families. It is expected that this pilot study will take at least five years to complete. If the spontaneous mutation rate is 1×10^{-5} / fragment / generation, we would expect to detect five mutations in the 120 children of the 100 control families.

The study (even in its preliminary phase) involves collaboration of a number of groups, including: the Cytogenetics Laboratory for efforts to localize putative mutations and their normal counterparts using FISH or other techniques, the Information Technology Department for help in data management and software conversion/development, the Department of Statistics in dealing with the pattern recognition and other problems arising in the analyses of these complex data. RERF's long-term collaboration with the University of Michigan is also an essential component of this program.

Genetic markers of hypertension

In accordance with the recommendations of the Blue Ribbon Panel, a protocol is being developed for a pilot study to assess markers for genes potentially associated with hypertension. This study, which will include 200 AHS participants (100 normal and 100 with hypertension as defined by the 1993 WHO/ISH guidelines), will make use of DNA from lymphocytes obtained during the routine AHS examination.

F₁ mail survey and health study feasibility

In response to the recommendations of the Blue Ribbon Panel, we are preparing detailed plans to carry out a mail survey of all surviving members of the F₁ cohort and to conduct a small scale study of the feasibility of an ongoing program for ascertainment of disease and disability in the cohort. The mail survey will provide data that can be used to obtain baseline (self-reported) information on health status and serve as a source of risk factor data that can be used in future analyses of cancer mortality and incidence in this cohort. The small clinical study (500 people) will include biochemical genetic studies of several genes related to common diseases (e.g., hypertension and diabetes). The mail survey and clinical feasibility study will last about two years and will be followed by a workshop to determine what additional studies, if any, should be carried out by RERF.

Genetic epidemiology (family studies)

Efforts are currently underway to define a database of family relationships within the LSS, in-utero, and F₁ cohorts. The initial focus is on the families of breast cancer patients in order to

824 look for evidence of genetic predisposition among women who were diagnosed with breast cancer
825 before the age of 35. Data on family relationships in the RERF cohorts and the extensive
826 epidemiological and clinical follow-up data for the cohort members will be a unique resource in
827 the study of the impact of genetic factors on disease. Continued development and use of this
828 resource requires support and collaboration with groups outside of RERF who are active in this
829 area. Progress will be highly dependent on the availability of personnel and special financial
830 support.

831

832 **Dosimetry**

833

834 *Biodosimetric studies*

835

836 Over the past thirty years, RERF has played a central role in the development and
837 assessment of biomarkers of radiation exposure, including structural chromosome aberrations
838 (using conventional staining, G-banding, and most recently FISH methods); mutation assays
839 (including GPA, T-Cell receptor, HPRT, and others); and electron spin resonance (ESR) of tooth
840 enamel. The availability of physical dose estimates, DS86, makes RERF one of the most
841 important centers for developing and assessing various long-term biological dosimeters useful in
842 other populations. As for the mutation assays, only the GPA assay can detect radiation exposure
843 that occurred several decades earlier. However, the frequency of GPA mutants varies widely and
844 thus the GPA assay has not proven to be a useful alternative to the cytogenetic method of
845 estimating individual doses although it can be valuable in estimating collective dose. Therefore,
846 little, if any, work on the development or application of somatic mutation assays will be done
847 during the next few years, and the extensive programs for the analysis of chromosome aberrations
848 in the survivors using conventional and G-band analyses have also ended. However, these
849 cytogenetic studies, as corroborated by our recent work on ESR of 100 teeth and cytogenetic
850 tests of the tooth donors, are useful in estimating individual doses, and the recently introduced
851 FISH method is even more effective. Accordingly, we plan to obtain FISH data on an additional
852 1,000 survivors over the next five years. Our aim is two-fold, namely, (1) to clarify the possible
853 systematic bias in the DS86 dose estimates according to shielding category and (2) to determine
854 the extent of random errors among individuals. We hope to supplement this activity with a
855 program to obtain FISH data from all unsampled AHS participants who were under 20 years of
856 age ATB with DS86 dose estimates in excess of 0.6 Gy (about 1,500 persons) and all parents of
857 families selected for molecular heritable mutation screening studies. ESR analyses of 100
858 additional samples that are currently available will be carried out in the next year. Efforts to
859 obtain more tooth samples (and, when possible, FISH data) from AHS cohort members in
860 Hiroshima will continue.

861

862 Over the next few years effort will be directed toward a variety of comprehensive analyses
863 and comparisons of existing biodosimetric data. These analyses will include: an analysis of all
864 available data from the conventional chromosome aberration studies including assessments of
865 more detailed data (e.g. interchromosomal:intrachromosomal aberration ratios); continued
866 comparison of ESR, chromosome aberration data and GPA data as well as comparison of the
867 correlation between these biological markers and the physical (DS86) dose estimates.

868

869 While further analyses of the nature of the dose response for the various assays are
870 important, recent comparisons of the ESR and cytogenetic data demonstrate that the data are also

871 useful for the detection of errors in individual dose estimates. More importantly, the
872 biodosimetric data will become increasingly important for the identification of potential systematic
873 biases and the characterization of uncertainties in the physical dose estimates. For example, the
874 chromosome aberration data suggest that DS86 dose estimates for Nagasaki factory workers may
875 be too high by a factor of two or more.

876 877 *Revision of the DS86 dosimetry system*

878
879 Ten years after its introduction, there is increasing evidence of systematic errors in DS86
880 dose estimates. Much attention has been focused on a distance-dependent discrepancy between
881 measured and calculated values for neutrons in Hiroshima. While estimates based on the best
882 available information suggest that these changes will have little impact on cancer risk estimates
883 derived from the survivor data, the fact that these discrepancies exist has led to some serious
884 questions about the validity of RERF risk estimates. There is also, as noted above, biodosimetric
885 data suggesting that doses may be over-estimated for Nagasaki factory workers (who account for
886 30-40% of Nagasaki survivors with DS86 doses in excess of 0.5 Gy). It is expected that within
887 the next two to three years the US and Japan senior atomic bomb survivor dosimetry committees
888 will accept a revised dosimetry that will modify the Hiroshima neutrons and, hopefully, address
889 the factory worker problem. Once a consensus has been reached the current RERF dosimetry
890 programs will be revised and doses recomputed for all survivors. This will involve a considerable
891 effort on the part of members of the Department of Statistics and ITD over a period of six months
892 to a year followed by reassessments of the major findings regarding cancer and other risks.

893
894 To prepare for the revised DS86 system, to make the basic dosimetry data more easily
895 available (including shielding histories and acute effects), and to resolve several basic questions
896 about exposure status for some in-utero mothers and F₁ parents, we have been working to
897 reorganize and better document the dosimetry data. This effort, which has also included moving
898 the DS86 system to the new RERF computer system, was begun several years ago and will
899 continue for another year. This project should lead to the incorporation of all of the basic
900 dosimetry data into the RERF research database and to a report that thoroughly describes and
901 documents these data.

902 903 **Database Development**

904 905 *Continued development and documentation of core research database*

906
907 The introduction of distributed computing has led to great progress in the development
908 of a modern, unified research database. The new database is built around a newly created master
909 list of over 700,000 individuals including all members of the major and minor RERF study cohorts
910 as well as people registered in the tumor and tissue registries. The new system has simplified data
911 handling for the mortality and cancer incidence follow-up and led to improvements in data quality
912 through the elimination of redundant copies of data items. Using the new system researchers have
913 quick direct access to current RERF data and can easily link their data to other items in the system
914 to obtain data needed for analysis using standard statistical programs. At this time the database
915 includes demographic, cohort membership, mortality follow-up, basic dosimetry, and tumor and
916 tissue registry data. However, much additional work is needed to ensure that the database fully
917 serves RERF's research needs. These activities include the development of improved

918 documentation (on paper and online) and the implementation of additional consistency checks to
919 ensure data quality along with an effort to make researchers more aware of the capability and
920 accessibility of the new system. In addition to these activities, much of the work on database
921 development over the next several years will focus on the areas mentioned in the following
922 subsections.

923

924 *Clinical follow-up data*

925

926 These complex and voluminous data include longitudinal information on clinical
927 contacting, routine measurement and laboratory test results, the results of special tests, diagnostic
928 information, and more. Work has progressed on the development of the basic design of the
929 clinical follow-up data tables to be added to the core database. This database will include data
930 on the AHS examinations but also data from other special examinations of the in-utero and F₁
931 cohorts. It is hoped that the design and implementation of the major tables (focusing on the AHS
932 data) will be completed in a year or two but the effort to incorporate all of the clinical follow-up
933 data can be expected to take several additional years. In addition to incorporating these data to
934 the RERF research database, a modernized version of the AHS patient tracking and clinical
935 management system is being developed that will serve as the front-end for continued updating of
936 the clinical data.

937

938 *Laboratory data*

939

940 The data collected in the course of RERF's cytogenetic, biochemical genetic, and
941 radiobiological studies are stored in computer files, laboratory notebooks and other formats. It
942 is not practical to add all of these data into the new database at once. However, as new analyses
943 of archival data are undertaken or new programs are introduced we will incorporate these data
944 in the main research database. At the present time the conventional chromosome aberration data
945 are being cleaned and linked to the core database. Over the next year data on other biodosimetric
946 studies will be added to the system.

947

948 The DNA studies being carried out in the Biochemical Genetics Laboratory will generate
949 large amounts of data and analyses will be highly computer-intensive. Thus, there is a need to
950 develop methods for the storage and management of these data. An interdepartmental effort will
951 be undertaken to develop effective methods for handling these data.

952

953 *Detailed dosimetry data*

954

955 As noted earlier, efforts are underway to add all of the basic dosimetric data (survivor
956 location, shielding history, and acute effects data) into the research database. This work has
957 involved developing consistency checks and procedures for resolving differences in data from
958 different sources. The basic work on this project has been completed and the new dosimetry data
959 tables should be ready for formal addition to the main database within a few months. Work on
960 documentation of these data will continue for about a year.

961

962 *Unified inventory of stored samples*

963

964 Over the last 30+ years more than 120,000 sera and other biological specimens have been

965 collected and stored for use in future studies. Advances in molecular biology are increasing the
966 value of this unique resource. At present there is no single inventory of these samples. Over the
967 next two to three years we will develop a unified inventory of stored samples. This inventory will
968 be a part of the research database and will be useful in facilitating the planning and conduct of
969 case-control and family studies that employ stored samples and managing this resource more
970 effectively.

971

972 **Current Status and Future Plans for RERF Follow-up Programs**

973

974 *Mortality ascertainment (koseki check)*

975

976 RERF carries out a program of active mortality ascertainment for all members of the LSS
977 and most members of the in-utero and F₁ cohorts. As noted earlier, plans are being developed to
978 extend the mortality follow-up to include the 11,760 F₁ cohort members who are not currently
979 included in the routine follow-up. Death certificate information for survivors whose *honseki*
980 (place of family registration) is in Hiroshima or Nagasaki is routinely received by RERF. For
981 cohort members whose *honseki* is not in either of the cities, requests for information are sent to
982 the appropriate office once every three years. Because of the decreasing number of surviving
983 members of the LSS cohort and more efficient procedures for handling the data, it should be
984 possible to obtain information on vital status and cause of death every two years, especially for
985 members of the LSS cohort.

986

987 *Hiroshima and Nagasaki tumor and tissue registries*

988

989 RERF manages the population-based Hiroshima city and Nagasaki city and prefectural
990 tumor registries. These registries are recognized as among the best in Japan. The Foundation's
991 role in the management of these registries has allowed us to create and maintain a direct link
992 between the cancer registry data and the RERF cohorts. Without this connection the increasingly
993 important analyses of cancer incidence among survivors and their children would be difficult, if
994 not impossible. The development of the RERF research database has strengthened the linkage
995 between the tumor registries and the LSS cohorts and further development of the database will
996 make this linkage even more useful. Over the next five years we hope to develop increasingly
997 efficient and effective means for obtaining data on cancer incidence among residents of Hiroshima
998 and Nagasaki.

999

000 While it is essential for RERF to continue to play a central role in the management of the
001 tumor and tissue registries, we are working closely with the Hiroshima prefectural government
002 and Hiroshima Medical Association on plans for the development of a new Hiroshima prefectural
003 tumor registry and on the inclusion of the Hiroshima tumor and tissue registry database as an
004 integral part of the proposed new Hiroshima cancer center. It is hoped that in conjunction with
005 these efforts RERF can take a leading role in the creation of a regional tissue bank that would
006 serve as a resource for molecular epidemiological studies carried out at RERF or other
007 institutions, such as Hiroshima University and the Hiroshima Red Cross Hospital. As these plans
008 develop, it should be possible to begin discussions with Nagasaki University and other related
009 groups about the establishment of a similar system in Nagasaki.

010

011 The tumor registries are community resources and it is essential that more effort be

1012 devoted to the presentation and analysis of the accumulated data in ways that benefit the
1013 communities. Steps are being taken to analyze trends for selected cancer types and to publish
1014 regular, standardized summaries of the tumor registry data in a format that will be useful to
1015 physicians and others.

1016

1017 *Leukemia registry*

1018

1019 Special efforts to collect data on cases of leukemia and other hematopoietic malignancies
1020 occurring among the survivors were begun by local physicians and ABCC in the late 1940's.
1021 Over time these efforts evolved into the Leukemia registry. In recent years virtually all
1022 ascertainment of leukemia and related disorders is being done through the tumor registry. It is
1023 now felt that the tumor registries are adequate for the identification of new cases of leukemia and
1024 related malignant conditions. Hematologists and others associated with the leukemia registry are
1025 currently involved in a review of survivor deaths attributed to blood diseases other than leukemia
1026 as well as an effort to reclassify all potential LSS lymphoma and myeloma cases using modern
1027 diagnostic criteria. Over the next five years we plan to incorporate all of the historical leukemia
1028 registry data into the research database.

1029

1030 *Standardized biennial clinical examinations*

1031

1032 Since 1958 RERF has been giving standardized medical examinations to all participating
1033 members of the AHS survivor and in-utero cohorts. This examination currently consists of a
1034 complete physical examination that includes systolic and diastolic blood pressures,
1035 electrocardiography, radiography, abdominal and thyroid ultrasonography as well as special tests
1036 of bone mineral density and cognitive function. Data are also collected on smoking and drinking
1037 habits, diet, and other factors. Overall participation remains high (almost 80% of those who were
1038 still living in the clinical contacting area participated in the most recent examination cycle). Home
1039 visits and hospital examinations are conducted for those survivors too infirm or incapacitated to
1040 participate in examinations at the Foundation's clinic. Participation rates do tend to decline
1041 sharply among the oldest groups of survivors, and as a consequence of this, thought is being given
1042 to plans to increase the examination frequency for some of the older individuals as well as to the
1043 development of cost-effective methods of special morbidity surveillance (see next item).

1044

1045 Special one-time examinations have been carried out for selected subsets of the RERF
1046 cohorts. The major examination programs, included annual examinations during 1956-63 of in-
1047 utero cohort members during adolescence; special examinations of almost 25,000 F₁ cohort
1048 members for the biochemical and cytogenetics studies; and most recently the ongoing
1049 examinations of the F₁ cohort members and parents in conjunction with the establishment of
1050 permanent lymphocyte cell cultures for future genetic studies. As discussed later, plans are being
1051 developed to conduct clinical examinations on a limited number of F₁ cohort members in order
1052 to assess the feasibility of an ongoing clinical examination program for a subset of the F₁ cohort
1053 members.

1054

1055 *AHS mail- and telephone-based morbidity surveillance*

1056

1057 In response to the recommendations of the 1993 Health Monitoring Workshop, a new
1058 AHS morbidity surveillance system was introduced in 1995. This system involves a short mail

1059 survey with subsequent telephone contact at six month intervals. Thus far, response rates have
1060 exceeded 90%. To validate the information obtained from this survey a system of periodic
1061 hospital and home visits by physicians or public health nurses within the regular two year
1062 examination cycle should be introduced.

1063 *Mail surveys*

1064 Since 1965 a number of mail surveys have been carried out on the LSS or AHS cohorts.
1065 These surveys provide important data on risk factors that cannot be determined by means of the
1066 routine mortality surveillance program. As described elsewhere, in response to the
1067 recommendations of the Blue Ribbon Panel, a new mail survey of F₁ cohort members will be
1068 carried out within the next few years.
1069
1070

1071 RESEARCH PLANS BY DEPARTMENT

1072 Research at the Foundation centers on two broad fronts, namely, those programs that will
1073 presumably continue well into the future, such as the periodic reports on mortality and cancer
1074 incidence in the LSS sample, and are commonly designated as the "core activities," and those
1075 programs, the "specific research activities," that are initiated within a single department and are
1076 generally time-limited. As previously noted, the core activities are set forth in the so-called
1077 "platform protocols" whereas the specific research activities are described in individual research
1078 protocols. Largely for convenience, we describe departmental research activities on an individual
1079 departmental basis.
1080
1081

1082 *Departments of Clinical Studies*

1083 The AHS biennial examinations initiated in 1958 continue. The primary purposes of these
1084 examinations have been to determine the types of diseases and abnormalities in physiologically or
1085 biochemically determined values that may have occurred as a consequence of previous exposure
1086 to ionizing radiation and to collate this information with other life experiences and death. The
1087 AHS clinical examination is the only point of direct contact with the survivors and functions as
1088 a source of biological materials for various special studies.
1089
1090

1091 The AHS has greatly increased in importance in recent years as a result of the
1092 accumulation of an enormous body of data on serial medical examinations, with and without the
1093 superimposed radiation aspects. Particularly noteworthy is the accumulating evidence that
1094 cardiovascular mortality may have a positive radiation-dose response. This potentially important
1095 and largely unexpected relationship could never be properly studied using death certificate data
1096 alone. Similarly intriguing and potentially important relationships arise from the clinical studies
1097 on hyperparathyroidism and serum levels of parahormone, calcium, and alkaline phosphatase.
1098 These results suggest that significant deviation in calcium metabolism may be a direct radiation
1099 effect and raise further questions about bone density and osteoporosis among the survivors. Still
1100 another unexpected finding is the retrospective evidence that radiation is associated with
1101 premature menopause and this, in turn, may result in earlier onset of other physiologic conditions
1102 such as an increase in cholesterol levels and cardiovascular disease. However, given the age of
1103 the survivors, the window of time for such studies is growing shorter, and it is imperative that
1104 these opportunities be exploited soon.
1105

1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152

The major research elements in the Department's investigations of the AHS sample can be categorized as follows: (1) characterization of cancer types in relation to various confounders of radiation effects, (2) radiation-related noncancer diseases (benign tumors, cardiovascular diseases, and other chronic diseases), (3) aging associated with exposure, (4) radiation-related changes in physiological, biochemical, and hematological measurements, (5) medical dosimetry, (6) psychosocial changes associated with exposure, and (7) health status of the in-utero exposed.

Program objectives

1. To provide biennial comprehensive medical examinations to the AHS cohort subjects to determine disease occurrence and longitudinal changes in physiological or biochemical parameters in relation to exposure to ionizing radiation and to relate this information to effects on life span.
2. To conduct special in-depth studies to determine the association between ionizing radiation and various health outcomes taking into account the possible effects of other health determinants (for example, life-style factors, physiological and biochemical determinants, prior health history, and menstrual and reproductive history for women).
3. To collect and store biological materials for basic science uses.
4. To utilize the accumulated data for epidemiological purposes in general.

Major research activities in the next five years

A. Core activities (Hiroshima and Nagasaki)

Priority 1

A-1. Basic AHS examination (RP 2-75):

The AHS clinical examinations will be continued in their usual format, but to optimize the quality and quantity of the clinical information considering the aging of the population, a new method of morbidity surveillance was introduced in Hiroshima and Nagasaki in 1995 based on the recommendation of the Health Monitoring Workshop in 1993. This method, with modifications if warranted, will be continued. The new morbidity surveillance consists of a mail survey followed by telephone contact every six months. Since its introduction, the response rate has been more than 90%. To validate the information obtained through this new surveillance program, a system of periodic hospital and home visits by either physicians or public health nurses within the examination cycles should be begun as soon as possible. The utility of introducing an annual health examination for older AHS members, such as those who are 70 years old or older, will also be carefully assessed both from the standpoint of the health of the study participants and research needs.

A-2. Application of new methods of longitudinal data analysis:

1153 A new method of analysis of longitudinal epidemiological data (which takes fuller
1154 advantage of the 38 years of accumulated serial measurements than is possible with cross
1155 sectional analyses) is being developed with support from staff members of the
1156 Departments of Statistics and Epidemiology. The creation of a new AHS database
1157 (diseases and measurements) for this type of analysis is currently underway.
1158

1159 *A-3. Collection and storage of biological materials:*
1160

1161 Collection and storage of biological materials, such as serum, plasma, and lymphocytes,
1162 will be continued with some modification of the method of storage, if necessary. The
1163 collection of teeth extracted for health reasons will be continued to provide materials for
1164 ESR measurements through the new AHS surveillance system.
1165

1166 *A-4. Improvement of clinical examination procedures:*
1167

1168 In addition to the above, clinical examination procedures of recognized benefit to the
1169 study participants, such as early cancer detection or health guidance, that will provide
1170 more services to the AHS participants as recommended by the Blue Ribbon Panel, will be
1171 updated and broadened to maintain a high level of AHS subject participation. However,
1172 it is unrealistic to seek to obtain such equipment as a CT scanner or MRI, and where such
1173 tests are needed, they should be performed through collaboration with local medical
1174 institutions.
1175

1176 Research plan for the next one year (A1-A4):
1177

1178 The plan to produce *AHS Report 8* will be developed. In this report, the study period will
1179 be extended to 1994 and analytic methods will place greater emphasis on confounding and
1180 bias due to long-term follow-up, migration and nonparticipation. The creation of the new
1181 AHS database will be completed. A plan to improve services to AHS participants will
1182 be developed.
1183

1184 Research plan for the next three years (A1-A4):
1185

1186 The *AHS report 8* will be completed and the results published. The new information
1187 obtained through the AHS surveillance program should become available for use in AHS
1188 Report 9. Comprehensive clinical examination procedures of recognized benefit to the
1189 study participants will be introduced in an effort to provide more services to the
1190 participants.
1191

1192 **B. Special research activities (Hiroshima)**
1193

1194 **Priority 1**
1195

1196 **B-1. Benign tumors:**
1197

1198 *a) Hyperparathyroidism (RP 11-86, 2-89):*
1199

1199 Screening for hyperparathyroidism, by measuring serum calcium level, has been underway
since 1986. Continued screening will provide not only incidence data on

1200 hyperparathyroidism but could also offer a clue to the cause of the slightly elevated levels
1201 of serum calcium and parathyroid hormone seen among survivors exposed to higher
1202 radiation doses.

1203

1204 Research plan for the next one year:

1205 Data collection for a 10-year incidence study will be completed.

1206

1207 Research plan for the next three years:

1208 The incidence of hyperparathyroidism will be analyzed for radiation effect, using the data
1209 accumulated in the 10 years from 1988 to 1997.

1210

1211 In collaboration with the Department of Radiobiology, a protocol for a molecular
1212 biological study (PRAD gene analysis) will be developed to elucidate the etiological
1213 mechanism underlying parathyroid adenoma and elevated levels of serum calcium and
1214 parathyroid hormone among individuals exposed to radiation.

1215

1216 *b) Other benign tumor study (RP 6-86):*

1217

1218 Systematic detection of various benign tumors such as myoma uteri, ovarian tumor, and
1219 liver hemangioma are being undertaken using abdominal ultrasonographic techniques.

1220

1221 Research plan for the next one year:

1222 Results of the prevalence study of uterine myoma will be published.

1223

1224 Analysis of the prevalence of liver hemangioma and ovarian tumor determined by
1225 ultrasonography will be completed.

1226

1227 *c) Benign thyroid tumors:*

1228

1229 In Nagasaki, thyroid tumors and disorders were screened for by means of physical
1230 examination, ultrasonography, and thyroid function tests from 1984 to 1987.

1231

1232 Research plan for the next one year:

1233 The feasibility of studying benign thyroid tumors or thyroid disorders in Hiroshima will
1234 be examined.

1235

1236 Research plan for the next three years:

1237 If the decision is made to initiate a thyroid study in Hiroshima, a research plan will be
1238 developed and data collection begun.

1239

1240 *B-2. Cardiovascular disease study (RP 4-85):*

1241

1242 A longitudinal cardiovascular study has been underway since 1965, and the results of this
1243 study, covering the period of 1958-1990, suggest a positive radiation effect on the
1244 incidence of myocardial infarction (MI). The estimated relative risk (RR) at 1 Gy is 1.17
1245 ($p=0.02$, 95% confidence interval: 1.01-1.36). In a Cox regression analysis including such
1246 factors as age, sex, blood pressure, and cholesterol, it was found that exposure dose still

1247 remained a significant factor, though the association was less than that with age, sex, or
1248 blood pressure, suggesting that atomic bomb radiation may be involved in the occurrence
1249 of MI. In addition, the different endpoints of atherosclerosis available in the AHS
1250 database, such as the prevalence of aortic arch calcification, calcification of the abdominal
1251 aorta, blood coagulability, the prevalence of isolated systolic hypertension, and the
1252 prevalence of retinal arteriosclerosis, were analyzed and all of these endpoints suggested
1253 the presence of radiation effects. Studies in progress include those on sudden death and
1254 detection of peripheral vascular disease by pulse wave velocity (PWV) measurements and
1255 ankle-arm blood pressure ratio using Doppler equipment. The analysis of radiation effects
1256 on conventional risk factors, such as blood pressure and cholesterol levels, has been
1257 underway for some time. An analysis of plasma fibrinogen is also underway as a part of
1258 the NI-HON-SAN Study, which will be described in more detail later. Studies on new risk
1259 factors, such as *H. influenzae* infection and homocysteine will be undertaken in the near
1260 future either in cross-sectional fashion or by a nested case-control study using stored sera.
1261 The feasibility of ultrasonographic measurement of the wall thickness of the carotid artery
1262 to detect latent atherosclerosis will be explored. The incidence studies on myocardial
1263 infarction and stroke will continue beyond the next five-year period because the necessary
1264 information can be obtained through routine AHS data collection and it is worthwhile to
1265 continue to try to understand the underlying mechanisms. The other studies are
1266 conducted over shorter periods, such as two years.

1267
1268 Research plan for the next one year:

1269 Manuscripts on myocardial infarction, isolated systolic hypertension, calcification of the
1270 aortic arch, and pulse wave velocity will be prepared and submitted for journal
1271 publication. The analysis of plasma fibrinogen will be completed. Data collection on
1272 ankle-arm blood pressure will be completed. The feasibility of studies of new risk factors
1273 will be carefully assessed.

1274
1275 Research plan for the next three years:

1276 Data collection on the incidence of myocardial infarction and stroke will continue. Results
1277 on plasma fibrinogen will be published. If new proposed studies turn out to be feasible,
1278 data collection will be initiated.

1279
1280 *B-3. Studies of liver disease (RP 9-92):*

1281
1282 Previous studies have shown a higher prevalence of hepatitis B surface (HBs) antigen in
1283 highly exposed subjects, but no difference in the prevalence of anti-HBs antibody was
1284 observed between the two groups.

1285
1286 With the availability of the serum assay for hepatitis-Be antigen (HBe) and hepatitis-C
1287 virus antibody (HCV), a study of liver diseases, such as chronic hepatitis or liver cirrhosis,
1288 was initiated in 1993 to determine the relationship between radiation dose and the
1289 prevalence of infection by B and C hepatitis virus in the AHS sample.

1290
1291 Research plan for the next one year:

1292 Measurements and analysis of the data on HCV antibody, and HB antigen and antibodies
1293 will be completed.

1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340

Research plan for the next three years:

The design of a nested case-control study using stored serum will be developed. Using stored serum collected before onset of hepatoma or liver cirrhosis, the prevalence of HCV or subtypes of HCV in cases and controls will be compared.

Priority 2

B-4. Cancer study (RP 2-75):

Cancers continue to be one of the most prevalent diseases among AHS subjects. For example, from 1969 through 1991, approximately 800 gastric cancers, 280 lung cancers, and 200 breast cancers were found among the AHS subjects in Hiroshima.

Cancer screening will continue to be one of the objectives of the AHS, and special emphasis will be placed on screening for cancers which are often not fatal, such as skin, breast, and thyroid. A new analysis including potential confounders and risk modifiers using the information obtained by various questionnaires and clinical measurements at the time of the routine AHS examinations, such as dietary factors and medications, will be initiated. A case-control study will be conducted on various cancers related to nutrients, hormones and potential carcinogens such as viral infections using stored serum. This study will continue beyond the next five years because all of the necessary information is obtained through routine AHS operations.

Research plan for the next one year:

An attempt will be made to create a new data set for longitudinal analysis using currently available information on confounders and/or risk modifiers. An inventory will be initiated of stored sera for each cancer case for use in future case-control studies.

Research plan for the next three years:

If a new data set is constructed, longitudinal analysis will be initiated to identify confounders or risk modifiers of radiation in cancers among atomic bomb survivors. Once the inventory of stored sera on cancer cases is completed, similar steps will be taken for controls. Then, a comprehensive study method will be developed including noncancer diseases for nested case-control studies.

B-5. Aging and radiation:

Priority 1

a) Osteoporosis study (RP 3-91):

Osteoporosis is a common aging-related disorder among Japanese, and bone density is influenced by premature menopause and parathyroid hormone levels which are known to be radiation-related. Measurement of spinal bone density using dual photon absorptiometry has been underway since 1989, and the results suggest a significant positive relationship between radiation exposure and spinal bone mineral density. However, the apparent increase in bone mass measurements may have been a confounding

1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387

effect caused by calcification of the abdominal aorta which is positively associated with radiation dose. To solve this problem, bone mineral density in the spine and hip using dual X-ray absorptiometry was begun in 1994. Total body composition (fat, lean body mass, bone) among the selected AHS samples has been measured using the same equipment.

Research plan for the next one year:

Radiation effects on bone mineral density and body composition including various potential risk factors will be analyzed.

Research plan for the next three years:

A longitudinal analysis will be undertaken to look at the radiation effects on changes in bone density with aging.

b) Senile dementia (RP 5-92):

A dementia study was begun in 1992 to assess the association between radiation exposure and a decline in cognitive function and to determine whether the prevalence of senile dementia increases as radiation dose increases. The epidemiological survey method being used was developed through international collaboration under a program known as the NI-HON-SEA study, which will be described later. This study may make it possible to examine the effects of ionizing radiation on the mature central nervous system.

Research plan for the next one year:

Cognitive function tests have been conducted on about 70% of AHS participants at this time; the remainder will be tested next year.

Research plan for the next three years:

Case ascertainment of senile dementia by a neurologist will be complete, and the results of an analysis of the data will be written up for publication.

c) Menopause study (RP 5-93):

Menopause is a general biological marker of aging in women. Information on age at menopause has been obtained in past epidemiological surveys in Hiroshima and Nagasaki. In Nagasaki, self-reported date of last menstrual period has been routinely obtained at the time of the biennial chest X-ray examinations. Incidence of menopause among Nagasaki participants was analyzed in 1993 using this self-reported information. The results suggest that the higher exposed group experienced an earlier onset of menopause. A longitudinal study using hormone measurements as an indicator of menopause was initiated in 1994 and is expected to take four years to complete. The subjects of this prospective study are premenopausal women who were younger than 10 years old or were in-utero when exposed to A-bomb radiation..

Research plan for the next one year:

The level of two important perimenopausal hormones (FSH and estradiol) will be measured every six months until 1997.

1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434

Research plan for the next three years:

The relationship between radiation exposure and the levels of these perimenopausal hormones will be analyzed.

Priority 2

d) Physiologic aging study (RP 4-86):

Accelerated aging resulting from irradiation has been a scientific concern for several decades. Earlier studies of the AHS participants have failed to reveal evidence of such an effect; however, these studies were conducted almost twenty years ago. It is important, therefore, to repeat them using a broader battery of physiological measures and several endpoints that reflect aging. The endpoints to be used for analysis are the incidence of myocardial infarction and stroke, cardiovascular mortality, and the prevalence of aortic arch calcification. The physiological measurements to be used are hand grip strength and skin elasticity which are measured as part of the routine AHS examinations in Hiroshima.

Research plan for the next one year:

Data analysis will be carried out using new endpoints, and a manuscript will be prepared.

Research plan for the next three years:

A new research plan including the use of new statistical methods will be developed.

B-6. Medical dosimetry (RP 7-86, 8-86):

Information on exposure to X-irradiation (radiological examinations at ABCC/RERF, radiological examinations elsewhere, and radiation therapy) has been obtained in the course of the AHS examinations. The examination of ionizing radiation exposure for medical reasons may facilitate assessment of the role of medical X-ray exposures in the follow-up studies of the A-bomb survivors. However, this is an issue which requires careful consideration since it will be difficult to incorporate these data into the various analyses conducted at RERF.

Research plan for the next one year:

Data collection will continue.

B-7. Psychosocial studies and others (RP 2-75):

Few studies have been done on the psychosocial effects of exposure to the atomic bombing, although it is well recognized that they vary greatly in association with socioeconomic factors. Nonetheless, it is possible that psychosocial factors may have influenced the occurrence of disease or at least the stage of development when disease is recognized.

Research plan for the next one year:

A study will be designed to assess the frequency and nature of the social and psychological problems experienced by the survivors with the cooperation of psychological specialists.

1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481

The possibility of international collaboration with scientists at the State University of New York will be explored.

B-8. Measurements:

Priority 1

a) *AHS Clinical measurements (RP 2-75)*

In the AHS, an enormous amount of information has been obtained on laboratory measurements, and it has now become possible to analyze the changes in these measurements over time. In collaboration with the Department of Statistics, growth curve analyses of the information on total serum cholesterol and blood pressure showed that heavily exposed individuals had higher levels of total serum cholesterol. This elevated cholesterol level associated with radiation exposure may have been one of the confounding factors in the increased cardiovascular morbidity and mortality seen among atomic bomb survivors.

Research plan for the next one year:

Results of the longitudinal analyses of cholesterol and blood pressure will be published. The other longitudinal data, including height, weight, and hematological information, accumulated since 1958 will be analyzed.

Research plan for the next three years:

Autoanalyzers for biochemical measurements were introduced into the Hiroshima Clinical Laboratory in 1986 and into Nagasaki in 1987. Longitudinal analyses will be performed on twenty different biochemical measurements accumulated from 1987 to 1996.

Priority 2

b) *Benign monoclonal gammopathy (RP 6-85):*

Benign monoclonal gammopathy has been shown to be suggestively related to radiation dose, a finding of potential importance since this disease has the possibility of being transformed into multiple myeloma. Screening with protein electrophoresis will be continued for detection of cases with monoclonal spike. Cases will be further tested for confirmation.

Research plan for the next one year:

Screening by protein electrophoresis will continue as before.

Research plan for the next three years:

The study of the incidence of this condition will be summarized and the results published.

B-9. *National and international collaboration (RP 4-85, 5-92, 3-91):*

There are three major international collaborations underway in Hiroshima. These are the

1482 NI-HON-SAN Study, the NI-HON-SEA Study, and the Japan-Hawaii Osteoporosis
1483 Study. All of these studies have been beneficial to RERF because the epidemiological
1484 methods developed through collaboration have been applied to other radiation research,
1485 and they have been producing important results in elucidating effects of radiation on
1486 noncancer diseases.

1487
1488 At its outset, the NI-HON-SAN Study was a study of cardiovascular diseases among
1489 Japanese men and men of Japanese descent living in Honolulu and San Francisco. It was
1490 initiated in 1965. Although follow-up of the San Francisco cohort ceased in the mid-
1491 1970s, the Japanese and Hawaiian cohorts are still being studied. A symposium to
1492 commemorate the study's 30th anniversary was held on 2 September 1996 in Hiroshima.

1493
1494 The NI-HON-SEA Study is a study of senile dementia among Japanese men living in
1495 Japan and men of Japanese descent living in Honolulu and Seattle. It began in 1992.

1496
1497 The Japan-Hawaii Osteoporosis Study was initiated in 1991.

1498
1499 We have been involved in several national collaborative studies sponsored by the Ministry
1500 of Health and Welfare. Through these collaborations, it has been possible for us to develop
1501 epidemiological methods to study radiation effects on noncancer diseases and to provide
1502 diagnostic services to AHS participants that otherwise would not have been possible. For
1503 example, we have been able to obtain free use of a modern bone mineral densitometer to conduct
1504 studies of osteoporosis as part of a national collaborative study.

1505
1506 Research plan for the next one year:
1507 NI-HON-SAN Study: Results of comparisons of mortality, glucose intolerance, and
1508 fibrinogen levels will be summarized and published.

1509
1510 NI-HON-SEA Study: Data sets will be created to compare the prevalence of senile
1511 dementia in the different study cohorts.

1512
1513 Japan-Hawaii Osteoporosis Study: In collaboration with the Hawaii Osteoporosis Center,
1514 a comparative study of bone mass, bone loss, and potential risk factors of osteoporosis
1515 among Japanese and Japanese-Americans will be analyzed.

1516
1517 Research plan for the next three years:
1518 NI-HON-SAN Study: Results of comparisons of ankle-arm blood pressure index, EKG
1519 changes, and pulmonary function will be summarized and published.

1520
1521 NI-HON-SEA Study: Results will be summarized and published.

1522
1523 Japan-Hawaii Osteoporosis Study: Results will be summarized and published.

1524
1525 C. New research initiatives (Hiroshima)

1526
1527 Priority I

1528

1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575

C-1. Molecular epidemiological study:

There are many studies describing the importance of oncogenes and tumor suppressors in the development of malignant disorders, but the role of ionizing radiation in the activation or suppression of these genes is still unclear. In addition, recent studies suggest that some of these genes may be involved in the development of atherosclerosis. A molecular epidemiological study on the AHS population will be initiated with inter-departmental collaboration to examine these issues. For this study, collection of fresh biological materials from surgery, such as tissues of cancers, benign tumors, blood vessels and skin, is desirable through a more intensive morbidity surveillance, in addition to the preservation of lymphocytes of the AHS subjects.

Research plan for the next one year:

A study plan will be developed.

Research plan for the next three years:

If a study is thought to be beneficial for RERF, collection of biological materials will be initiated and appropriate techniques for their use will be developed.

C-2. Feasibility of an F₁ clinical study

In response to the recommendations of the Blue Ribbon Panel, the feasibility of a full-scale study of chronic disease among the F₁ will begin with a mail survey involving all members of the F₁ mortality cohort, to be followed by the clinical examination of a small set of these individuals, about 500 persons, and biochemical genetic studies of several genes known to be related to common chronic diseases.

Research plan for the next one year:

The feasibility study will last for two years.

Research plan for the next three years:

A workshop will be convened to determine whether a full-scale study should be conducted.

Priority 2

C-3. Lenticular opacities:

A new system of grading the degree of lenticular opacification, developed by the research group at NASA, will be introduced and grading will be done using illustrations from the cases of cataracts detected in previous ophthalmological surveys. This will be part of an international collaboration with NASA that aims to test hypotheses regarding the relationship between degree of opacification and radiation dose. For those survivors who were young at the time of the bombing and have not been included in previous surveys, we will consider the use of stereolaminographic images of the lens to provide a more objective and permanent basis for the evaluation of changes that may occur in the future.

1576 Research plan for the next one year:

1577 A study plan will be developed.

1578

1579 Research plan for the next three years:

1580 If the study plan is thought to be beneficial, data collection will be initiated.

1581

1582 **Project time lines (Hiroshima)**

1583

1584		1997	1998	1999	2000	2,001.00
1585	Core program: AHS (RP 2-75)	--	--	--	--	--
1586	Special studies					
1587	Cancer study (RP2-75)	--	--	--	--	--
1588	Parathyroid (RP11-86)	--	--	--	--	--
1589	Other benign tumor (RP6-86)	--	--	--		
1590	Cardiovascular (RP4-85)	--	--	--	--	--
1591	Liver disease (RP9-92)	--				
1592	Aging and radiation					
1593						
1594	Osteoporosis (RP3-89)	--	--	--	--	
1595						
1596	Dementia	--	--	--		
1597						
1598	Physiologic aging (RP4-86)	--	--	--		
1599						
1600	Menopause (RP5-93)	--	--			
1601	Medical dosimetry (RP7-86,8-86)	--	--	--	--	--
1602	Psychosocial (RP2-75)	--	--	--		
1603	Monoclonal gammopathy (RP6-85)	--	--	--		
1604	National-international collaboration					
1605						
1606	NI-HON-SAN (RP4-85)	--	--	--	--	--
1607						
1608	NI-HON-SEA (RP5-92)	--	--	--		
1609						
1610	Osteoporosis (RP3-91)	--	--	--		
1611	Molecular epidemiology	--	--	--	--	--
1612	Cataract		--	--	--	--
1613						
1614						
1615						

1616 **Personnel requirements (Hiroshima)**

1617

1618

Year	1996	1997	1998	1999	2000	2001
1619 Research Scientists*	6	6	6	6	6	6
1620	(5+0.5 x2)					
1621 Assistant Adm. Chief	1	1	1	1	1	1
1622 Nurses*	9	8	7	7	7	7
1623						
1624 Technicians (X-ray)	3	3	3	3	3	3
1625						
1626 Technicians (Lab)	8.5	8	8	8	8	8
1627						
1628 Contactors**	9	11	12	12	12	12
1629						
1630 Clerks*	13	12	12	12	12	12
1631						
1632						
1633 Total	49.5	49	49	49	49	49

1634 *: If clinical examination of the F₁ is introduced, the number of physicians, nurses and contactors must be increased.

1635 #: Replacement should be made by nurse or public health nurses.

1636 Need more contactors due to aging of the population and newly introduced surveillance program.

1637 +: Replacement should be made by research assistants.

1638

1639 **Space requirements (m²) (Hiroshima)**

1640

	1996	1997	1998	1999	2000	2001
1641 Administration	134.50					
1642 Medicine	78.50					
1643 Nursing	185.30					
1644 Radiology	169.21					
1645 Clinical Lab	236.06	+10*	+30**			
1646 Contacting	59.80					
1647 General affairs	286.83					
1648						
1649 Total	1,150.20					1,190.20

1650 *: Room for hematology currently in use needs expansion for smooth daily operation.

1651 **: Additional space for storage of serum and plasma is needed.

1652

1653 **Equipment budget (Hiroshima) (x ¥ 1,000)**

1654

Fiscal year	1997	1998	1999	2000	2001
1655 Laboratory equipment	3,760	2,533	13,528	0	7,283
1656 Computer equipment	4,612	1,952	2,682	712	4,282

1657

1658

1659 **D. Special research activities (Nagasaki)**

1660

1661 **Priority 1**

1662

1663 *D-1. Effects of menopause on risk factors for ischemic heart disease - a longitudinal*

1664 *study of the Nagasaki Adult Health Study sample (RP 1-95).*

1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1720

The purpose of this study is to look for an association between perimenopausal changes in the level of total serum cholesterol and its fractions and changes in serum estradiol. The results of this study will produce hypotheses on cardiovascular mortality and its relationship to radiation dose in women, because radiation seems to accelerate the onset of menopause, that is, radiation may cause earlier deterioration of the atherogenic cholesterol profiles.

At the outset of the study 63 of 73 study participants had not yet experienced menopause. This study will continue for 4 to 6 years.

D-2. The Nagasaki Department of Clinical Studies will implement all RPs except for RP 4-86, RP 3-89, RP 3-90, RP 3-91, RP 6-92, and RP 2-95 in the same manner as conducted by the Hiroshima Clinical Studies Department.

Project time lines (Nagasaki)

Project	1997	1998	1999	2000	2001
Menopause	⇒	⇒	⇒	⇒	⇒

Personnel requirements (Nagasaki)

Fiscal Year	1997	1998	1999	2000	2001
Physicians ¹	2.5	2.5	2.5	2.5	2.5
X-ray technicians	3	3	3	3	3
Clinical Laboratory	9	9	9	9	9
Nursing Section	5	5	5	5	5
Contacting Section	9	9	9	9	9
Administration	9	9	9	9	9

¹ Dr. Midori Soda is included as half-time in the Nagasaki Department of Clinical Studies.

Space requirements (m²) (Nagasaki)¹

Fiscal Year	1997	1998	1999	2000	2001
Internal Medicine	73	73	73	73	73
X-ray	171	171	171	171	171
Clinical Laboratory	298	298	298	298	298
Nursing Section	143	143	143	143	143
Contacting Section	81	81	81	81	81
Administration	103	103	103	103	103

¹ Personnel strength and floor space must be expanded if a full-scale study of chronic disease among the F₁ is initiated.

721 **Equipment budget (Nagasaki) (x ¥ 1,000)**
722

723

Fiscal Year	1997	1998	1999	2000	2001
Laboratory	19045	0	0	3000	0
Computer Equip.	1072	1052	2252	452	852

724
725

726
727 ¹ The standard equipment budget was calculated on the basis of the present cost of the respective pieces of
728 equipment. Annual inflation and price increases due to equipment upgrading may affect this five-year projection.
729 Equipment approaching the end of its working life may malfunction and would also alter this estimate as would the
730 initiation of new research protocols.

731
732 **Departments of Epidemiology**
733

734 Until the mid-1980s, epidemiology, statistics, and computing were combined in a single
735 Department of Epidemiology and Statistics at the Foundation. It became clear, however, that this
736 was neither an efficient nor cost-effective organization of resources and skills. During 1984-85,
737 these disciplines were established as independent research or support departments. In 1994, the
738 Departments of Epidemiologic Pathology, responsible for the conduct of pathology studies and
739 the tumor and tissue registries, were merged with the Departments of Epidemiology.
740

741 **Program objectives**
742

743 The Departments of Epidemiology play a central role in the conduct of the long-term
744 follow-up of the three cohorts, LSS, in-utero, and F₁. The follow-up of these cohorts has long
745 relied on mortality surveillance through the use of the nationwide family registration system, the
746 *koseki*. Recently, cancer incidence data from improved tumor registries in Hiroshima and
747 Nagasaki have become available on these cohorts, adding new dimensions to our studies of
748 radiation cancer risks. Continued follow-up of these cohorts is essential in clarifying the temporal
749 patterns of cancer risk as young subjects reach ages when background cancer risk is increased.
750 In addition, the emerging excess noncancer mortality risk is of particular concern as the nature of
751 the risk is still unclear. Although the numerous mail surveys conducted in the LSS provide
752 potentially valuable data on the role of nonradiation risk factors, little effort has been made to
753 incorporate these data into RERF analyses. We must place increased emphasis on the studies of
754 nonradiation risk factors in relation to cancer and noncancer disease risks.
755

756 Because of the nature of the RERF research, the Departments of Epidemiology should and
757 will play a key role in the design and conduct of various interdepartmental research activities. As
758 indicated in the Blue Ribbon Panel report, one of the most important multidisciplinary programs
759 at the present time is the molecular epidemiology of cancer, which will require close
760 interdepartmental and interdisciplinary communication. In addition, the Departments of
761 Epidemiology must also play a more active role in generating new ideas for studies to answer
762 questions arising from the ongoing epidemiological studies, which are being conducted in
763 collaboration with other RERF departments or outside research groups.
764

765 The epidemiological research activities in Hiroshima and Nagasaki are carried out
766 following common research protocols and procedures. The professional staff in the Department
767 of Epidemiology in Hiroshima currently consists of three epidemiologists supplemented by one

1768 pathology consultant and one visiting pathology investigator. The professional staff in the
1769 Nagasaki Department of Epidemiology consists of one epidemiologist and one physician. The
1770 epidemiology staff work closely with the staff in the Department of Statistics in study design, data
1771 analysis, and preparation of major reports; they also work with the Departments of Statistics and
1772 Information Technology in database design and development.

1773

1774 A. Core activities

1775

The core activities of the Epidemiology research program are as follows:

1777

1778 A-1. *Publication of periodic general reports*

1779

1780 The Departments of Epidemiology working together with the Department of Statistics will
1781 continue to produce periodic and specific reports on cancer and noncancer mortality as
1782 well as cancer incidence resulting from continued follow-up of the LSS, in-utero and F₁
1783 cohorts. In view of the uncertainty regarding the cancer risk for the young survivors,
1784 continued follow-up of the LSS and in-utero cohorts in the next decade and beyond is
1785 considered critical. Principal periodic reports that are expected within the next 5 years
1786 include LSS Report 13 on updated cancer and noncancer mortality (through 1995), an
1787 updated LSS cancer incidence report (through 1992 or later), an in-utero cancer incidence
1788 report, and F₁ mortality and cancer incidence reports.

1789

1790 Investigations of the noncancer mortality data will be particularly challenging because of
1791 the multiplicity of factors that must be considered and the paucity of relevant biological
1792 models. As the survivors age, further follow-up of the cohort will provide increasingly
1793 useful information on this important question. At the same time, it will be equally
1794 important to define working hypotheses to account for the excess noncancer disease risks
1795 and to develop and carry out research programs in collaboration with other RERF
1796 departments and outside research groups.

1797

1798 A-2. *Conduct of site-specific cancer studies*

1799

1800 Several site-specific cancer studies are currently active. These studies are designed to
1801 provide detailed data on pathological features of tumors associated with radiation
1802 exposure accompanied by in-depth risk analysis, providing insights into the biological
1803 bases of radiation-induced tumorigenesis. A number of reports from this series of site-
1804 specific cancer studies will be forthcoming in the next several years.

1805

1806 A-3. *Continued management of the Hiroshima and Nagasaki tumor and tissue registries, 1807 and development of a tissue bank*

1808

1809 The Foundation continues to manage the Hiroshima and Nagasaki tumor and tissue
1810 registries which provide high-quality cancer incidence data. They are among the few
1811 registries in Japan whose incidence data have been included in several volumes of *Cancer
1812 Incidence in Five Continents* (by IARC/IACR), a worldwide compilation of cancer
1813 incidence data. The LSS cancer incidence data published in 1993 and 1994 and the
1814 current series of site-specific cancer incidence studies would not have been possible

815 without RERF's direct involvement in the registry operations. While we will continue to
816 publish the Hiroshima and Nagasaki incidence data in future volumes of the above
817 IARC/IACR monograph series, it is important that we also produce our own
818 comprehensive and more detailed analyses of population-based cancer incidence data.
819

820 RERF, together with the local medical societies, also continues to manage the tissue
821 registries. These registries have the potential to be developed into a tissue bank linked to
822 the LSS, which will be a tremendously valuable source for molecular oncology studies.
823 Therefore, the Departments of Epidemiology must continue to be involved in the
824 management and further development of the tumor and tissue registries.

825
826 *A-4. Design and conduct of case-control and other special studies to address specific*
827 *questions*
828

829 The Epidemiology department also conducts ad hoc case-control or other studies to
830 investigate specific hypotheses prompted by regular analyses of the A-bomb survivor data
831 or other research developments. Such studies involve personal interviews to elicit specific
832 information, make use of existing information, or require biological samples such as tissues
833 and frozen sera. Case-control studies nested in the cohort are particularly useful for
834 providing answers to the questions of current interest. Illustrative examples include
835 studies of liver cancer and viral hepatitis infection (ongoing), breast cancer and detailed
836 reproductive history (completed), and stomach cancer and serum ferritin (completed).
837 The Department will continue to generate new studies of this kind to gain insights into the
838 nature of cancer and noncancer diseases.
839

840 *A-5. Studies of radiation and nonradiation factors using mail survey data*
841

842 During the course of the LSS follow-up several mail surveys have been conducted to
843 obtain epidemiological information on lifestyle factors such as smoking, alcohol intake,
844 diet, and occupation. To date use of this information has been limited to the smoking data
845 as related to cancer. Studies of conventional risk factors are also critically important in
846 elucidating the nature of the excess noncancer vascular, digestive, and respiratory diseases.
847 While some work has been done in the last few years, further effort should be devoted to
848 the study of nonradiation risk factors.
849

850 These studies are covered by the following platform research protocols:
851

852 **Priority 1**

853
854 *Research plan for RERF studies of the life span of A-bomb survivors, Hiroshima and*
855 *Nagasaki (RP 1-75)*
856

857 *Research plan for RERF studies of the potential genetic effects of atomic radiation:*
858 *Hiroshima and Nagasaki, Part 1. Mortality study of children born to atomic bomb*
859 *survivors (RP 4-75)*
860

861 *Tumor registry study in Hiroshima and Nagasaki (RP 18-61)*

- 1862 *Detection of leukemia and related disorders (RP 29-60)*
 1863
 1864 *Pathology studies in Hiroshima and Nagasaki, revised research plan (RP 5-89: Formerly*
 1865 *RP 3-75)*
 1866
 1867 *Guidelines for the conduct of site-specific cancer incidence studies among A-bomb*
 1868 *survivors, Hiroshima and Nagasaki (RP 9-88)*
 1869

1870 **B. Special research activities**

1871

1872 **B-1: Site-specific cancer studies**

1873

1874 Under the platform protocols regarding tumor and leukemia registries (RP 18-61, RP 29-
 1875 60) and pathology studies (RP 5-89, RP 9-88), various site-specific cancer studies are now under
 1876 way. Standardized pathology reviews are conducted by panels of pathologists (from Hiroshima
 1877 and Nagasaki) using contemporary classification schemes, and special effort is made to ascertain
 1878 cases beyond those routinely reported to the tumor and tissue registries. Pathology slides and
 1879 tissue blocks obtained for these studies facilitate the conduct of molecular epidemiological studies.
 1880 These site-specific studies in various stages of completion are summarized in the next table,
 1881 followed by a description of the objectives for each study.

1882

1883 **Priority 1**

1884

1885 *Incidence of lymphoid malignancies among the atomic bomb survivors, 1950-90 (RP 3-*
 1886 *94):*

1887

1888 This study is designed to provide more definitive data on the rather inconsistent evidence
 1889 thus far available on the risk of lymphoid malignancies in the LSS. The objective is to
 1890 investigate all lymphopoeitic tumors (lymphomas, multiple myeloma, lymphocytic
 1891 leukemias) between 1950 and 1990 in the LSS. Emphasis is on the confirmation and
 1892 classification of cases using modern techniques. The study involves both hematologists
 1893 and pathologists engaged in lymphoid tumor research. Non-Hodgkin's lymphomas are
 1894 classified by immuno-histochemical studies into T- or B-cell lymphomas, and the diagnosis
 1895 of adult T-cell leukemia is based on detection of proviral DNA of HTLV-I using archived
 1896 tissues.

1897

1898 *Studies of lung cancer incidence among the atomic bomb survivors, 1950-90 (RP 1-94):*

1899

1900 Lung cancer is a late effect of radiation exposure, but several specific issues and questions
 1901 remain to be addressed. These include the specificity of various cell types involved in
 1902 radiation- versus smoking-related cancers, confounding and joint effects of smoking in
 1903 relation to radiation exposure, delineation of the temporal trend with allowance given to
 1904 the age-at-exposure and attained-age effects. ICRP also has recently published a new
 1905 report on lung cancer risk from inhaled radionuclides modeled on an anatomical basis in
 1906 terms of lung "compartments." New information on anatomical distribution of lung
 1907 cancers resulting from uniformly distributed radiation may be useful for evaluating the
 1908 ICRP model. This RP was developed to address these questions and issues.

Current and Planned Site-specific Cancer Studies

Site	Year study began	Specific objectives	Current status/Plan
<u>Currently active</u>			
Liver	1990	Incidence; role of hepatitis infection (case-control)	Preliminary results presented at Jpn. Soc. Path. Mtg., '96; Paper on incidence to be submitted within a year; HCV assays in progress
Salivary gland	1991	Benign & malignant tumors; major & minor glands	Results presented at Jpn. Soc. Path. Mtg., '95 One paper published; another submitted; To be completed within a year
Skin	1991	Cell types and UV effect	Results presented at Jpn. Soc. Path. Mtg., '95; Data presented One paper submitted; another paper in preparation; To be completed within a year
Thyroid	1991	Benign & malignant tumors; microcarcinomas	Ready for analysis; Papers to be prepared in the next 2-3 years
Ovary	1992	Benign & malignant tumors	Preliminary results presented at Jpn. Soc. Path. Mtg., '96; Analysis in progress; To be completed in 2-3 years
Nervous system	1992	Neurilemmoma, meningioma, pituitary tumors; benign and malignant	Results presented at Jpn. Soc. Path. Mtg., '95 Two papers in preparation; To be completed within a year
Breast	1993	Update of the continuing series; risk for young women	Paper in preparation; To be completed within a year
Lung	1994	Topographic distribution, cell types and smoking; time trend	Pathology review in progress; Expected to be completed in 4-5 years
Lymphoid	1994	Lymphoma, multiple myeloma; T-cell and B-cell origin	Pathology review started; Expected to be completed in 4-5 years
<u>Planned</u>			
Colon		Different sub-sites; parallel molecular study	To be started
Stomach		Histological subtypes; EB virus infection	To be started
Bone/connective tissues		Bone tumors	To be started

- 1968 *Breast cancer incidence study among atomic bomb survivors, 1950-90 (RP 6-93):*
 1969
 1970 This is the latest (started in 1993) of a series of breast cancer incidence surveys, extending
 1971 the follow-up through 1990. Data collection for this series has been completed, adding
 1972 261 newly accessed cases (250 for the period of 1986-1990 and 11 prior to 1986). Of
 1973 these, 58 cases were exposed at <10 years of age, and this should strengthen risk estimates
 1974 for this age-at-exposure group.
 1975
 1976 *Incidence of tumors of the central nervous system among A-bomb survivors (RP 4-92):*
 1977
 1978 In the recent solid cancer incidence report, a suggestive dose response was found among
 1979 those survivors exposed at ages <20 years for tumors of the nervous system except for the
 1980 brain. These findings prompted the present study. The objective is to ascertain malignant
 1981 and benign tumors of the central nervous system in the LSS from 1950 to 1987.
 1982
 1983 *Studies of ovarian tumor incidence among the RERF extended Life Span Study cohort,*
 1984 *1950-87 (RP 2-92):*
 1985
 1986 The present study extends the previous ovarian cancer series by 7 years (through 1987)
 1987 and also includes a systematic ascertainment of benign tumors.
 1988
 1989 *Studies of thyroid tumor incidence among the RERF extended Life Span Study cohort,*
 1990 *Hiroshima and Nagasaki, 1950-87 (RP 6-91):*
 1991
 1992 This investigation was started in 1991 with the aim of updating and expanding the earlier
 1993 thyroid cancer incidence series (through 1979), including both benign and malignant tumor
 1994 cases diagnosed between 1950 and 1987. The increased number of cases over the
 1995 extended study period should allow more detailed risk analyses than were available
 1996 previously.
 1997
 1998 *Studies of skin cancer incidence among the RERF extended Life Span Study cohort,*
 1999 *Hiroshima and Nagasaki, 1950-87 (RP 2-91):*
 2000
 2001 The completeness of the ascertainment of skin cancer from the tumor registries is
 2002 questionable and diagnoses of skin cancer are highly variable among physicians and
 2003 pathologists. The present study is designed to provide extended case-finding and a
 2004 standardized pathology review for histological typing of skin tumors. All work related to
 2005 case ascertainment that began in 1991 has been completed, and analyses have almost been
 2006 completed. A significant dose response is demonstrated for basal cell carcinoma but not
 2007 for squamous cell carcinoma of the skin. Noteworthy is the absence of a suspected
 2008 combined effect of UV and ionizing radiation exposure and a strong effect of age at
 2009 exposure on basal cell carcinoma.
 2010
 2011 *Studies of salivary gland tumors among the RERF extended Life Span Study cohort,*
 2012 *Hiroshima and Nagasaki, 1959-87 (RP 1-91):*
 2013
 2014 This study was initiated in 1991. The objective was to study both benign and malignant

015 tumors of the major and minor salivary glands diagnosed between 1950 and 1987. All
016 phases of the study are virtually completed. Analysis shows a significant dose response
017 for both benign and malignant tumors. Most of the dose response for malignant tumors
018 is provided by an exceptionally strong dose response for a particular type, mucoepidermoid
019 carcinoma, and most or all of the dose response is attributable to Warthin's tumor.
020

021 *Primary liver cancer incidence study among atomic bomb survivors, Hiroshima and*
022 *Nagasaki, 1958-1987 (RP 5-90):*
023

024 Since diagnostic misclassification is a major concern for liver cancer, the primary objective
025 of this study is to assess the relationship between atomic bomb radiation and liver cancer
026 based on data confirmed by a panel of pathologists. Another objective is to investigate,
027 in a nested case-control study, the possible role of HBV, and possibly HCV, infection in
028 radiation-related liver cancer. The pathology review extends from histologic classification
029 of liver cancer to diagnosis of any accompanying liver cirrhosis and testing for HBV
030 markers. In the companion study conducted in the Department of Radiobiology (RP 5-
031 90), molecular techniques are being used to characterize the HB and HC viruses more
032 precisely.
033

034 **B-2: Case-control studies in progress**

035
036 In addition, case-control studies are being conducted to investigate factors other than
037 radiation exposure that may interact with radiation. Information is obtained, primarily by
038 retrospective interview, on personal habits, and other life-style factors, medical history,
039 reproductive factors, and other suspected cancer risk factors.
040

041 **Priority 1**

042
043 *Interaction between radiation dose and host factors. An epidemiological case-control*
044 *study of female breast cancer in atomic bomb survivors (RP 14-79):*
045

046 This study, started in 1979, continues to investigate reproductive and other known risk
047 factors in association with radiation. In a study of 196 breast cancer cases and 566
048 controls, the risk was found to be positively associated with age at first full-term
049 pregnancy, in agreement with the literature; whereas negative, and partially independent,
050 associations were observed with number of births and total cumulative period of breast
051 feeding. Significant positive associations were also found with history of treatment for
052 dysmenorrhea and uterine or ovarian surgery. Neither age at menarche nor age at
053 menopause was significantly associated with breast cancer. Multiplicative relationships
054 were found between radiation exposure and age at first full-term pregnancy, number of
055 children, and cumulative total period of lactation.
056

057 A plan is underway to revise this case-control study by adding reproductive and family
058 information from various Master-File documents kept at RERF (an example of a record-
059 based case-control study).
060

061 **Priority 2**

2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108

Thyroid cancer (RP 12-85):

The study includes 365 cases with histologically diagnosed thyroid cancer and their matched controls. Personal interviews have been completed to obtain retrospective information on major risk factors such as diet and nutrition, reproductive experiences and previous medical history. Factors that have been found to be associated with thyroid cancer are: history of cancer in sisters, previous histories of goiter, tonsillectomy, ovariectomy, and breast disease, and increased body mass index. Analysis is almost completed, and a paper is being prepared for publication. Data from this study are included in a pooled analysis of thyroid case-control data from various countries undertaken by the NCI.

Priority 3

Nutrients and cancer (RP 11-85); hormones and cancer (RP 10-85):

These two studies utilize stored sera for nutritional and hormonal assays. Preliminary analysis shows a relationship between total estradiol and breast cancer risk. Following the first paper on serum ferritin and stomach cancer risk (TR 14-89), the second paper on serum selenium and zinc in association with the subsequent development of lung and stomach cancer was published (*Cancer Epidemiology, Biomarkers & Prevention*). In this study of 208 cases with stomach cancer, and 77 cases with lung cancer and matched controls, a slightly increased risk of lung cancer was found to be associated with low serum levels of selenium but little association was found with either lung or stomach cancer across normal selenium or zinc ranges. A paper on breast and other cancers in relation to hormone assays is under preparation and is expected to be completed shortly.

C. New research activities anticipated in the next 5 years

As mentioned above, a number of important specific issues have been identified through the follow-up of the major cohorts. These are summarized below:

Cancer

Increased cancer risks have been clearly substantiated as a late effect of radiation exposure among the survivors. However, several issues regarding cancer risk remain to be clarified.

- **Cancer risk among the young:** The temporal pattern of cancer risk among the survivors exposed as children, that is before the age of 10, as they reach the ages at which background cancer risk is increased.
- **Confounding and modifying effects of nonradiation factors:** Because smoking and other life-style factors are important determinants of cancer, cardiovascular and other diseases, more research is needed to study the possible confounding and modifying of effects of nonradiation factors. This is an area which has received little attention in the past and will require collaboration with researchers in other RERF departments and outside RERF.

- 2109 • Mechanistic models for radiation-induced cancer: Initial attempts by Donald Pierce and
2110 Mortimer Mendelsohn to develop a mechanistic model for radiation-induced cancer using
2111 the LSS data have provided some interesting and useful insights into how to interpret the
2112 age and time dependence seen in the solid cancer risks. There is also increasing interest
2113 in other biologically motivated models for radiation carcinogenesis. These models may
2114 provide useful insights into temporal patterns, sex differences and other aspects of the
2115 radiation-induced excess risk. While most of the developmental work will rely on the
2116 Statistics staff, RERF provides an environment for close interaction with radiation
2117 biologists. More effort at RERF along these lines of research seems warranted.
2118
- 2119 • Organ-specific cancer risks: Observed differences in site-specific cancer risks are difficult
2120 to interpret because of statistical variability and the relatively small excess number of cases
2121 involved. The joint analysis approach initiated by the Department of Statistics on this issue
2122 is promising and will be further pursued working with members of the Departments of
2123 Epidemiology.
2124
- 2125 • Incidence vs mortality: While mortality follow-up will continue to be the primary basis of
2126 risk assessment, cancer incidence patterns will play an increasingly important role,
2127 especially for breast, thyroid, and other less fatal cancers. The availability of both cancer
2128 mortality and incidence data now enables us to provide more comprehensive assessment
2129 of the radiation risk, starting from cancer onset to death. However, it has also become
2130 necessary to pay attention to how to interpret results from mortality and incidence data.
2131 It is important to develop methods to provide an integrated presentation of the mortality
2132 and incidence data. It will be useful too to develop measures of detriment using both
2133 results. While some work has already been done on mortality/incidence comparison and
2134 risk of second primary cancers, much more work is needed in this area.
2135

2136 Noncancer diseases

2137
2138 The evidence of an excess noncancer mortality risk in the LSS data is becoming more
2139 compelling. Thus, another outstanding issue is further characterization of the noncancer risks in
2140 the LSS.
2141

- 2142 • Working with the Department of Statistics, we will attempt to clarify essential
2143 characteristics of the noncancer excess including such issues as the shape of the dose
2144 response, patterns of risk by age, sex, and time, etc. Since the excess risk appears to be
2145 continuing, we can expect that further follow-up will make possible more detailed analyses
2146 and improve characterization of these risks.
2147
- 2148 • The AHS is the source of clinical data on diseases and laboratory measurements that are
2149 immensely useful for characterizing noncancer events. Therefore, it will be essential that
2150 we work with the Departments of Clinical Studies and Statistics to develop studies that
2151 integrate the LSS and AHS data on radiation effects on noncancer endpoints.
2152

2153 Some other important questions to be examined are as follows:

- 2154 • Misclassification: We have already shown that the misclassification of cancer to noncancer
2155

2156 on death certificates contributes only a fraction of the observed excess noncancer mortality
 2157 and that a noncancer excess exists even after the correction for such misclassification.
 2158 More work is needed to learn how best to deal with misclassification between different
 2159 noncancer diseases and how this misclassification affects the risk estimates.
 2160

- 2161 • Confounding, biases and indirect effects: Whether the observed noncancer excess mortality
 2162 results from confounding or indirect effects of other factors, selective or other biases,
 2163 remains a central question. While all available data should be used to examine these issues,
 2164 new ideas are also needed to initiate new research and analyses.
 2165
- 2166 • Plausible disease mechanisms: A serious problem with the noncancer risk is the paucity of
 2167 biological models for radiation induction of noncancer diseases at low dose levels. This
 2168 is an area in which the development of new innovative research ideas requires close
 2169 interaction with biologists and clinical investigators. Such collaborations should help us
 2170 generate and test hypotheses regarding plausible mechanisms for the effects.
 2171

2172 New research will be generated in the following areas. These topics are not covered under
 2173 the existing platform or individual research protocols, but new specific RPs will be developed as
 2174 needed.
 2175

2176 Priority 1
 2177

2178 *Molecular epidemiology of cancer*
 2179

2180 As mentioned in the Blue Ribbon Panel recommendations, research on molecular oncology
 2181 requires specific hypotheses or models that can be tested in this unique population of
 2182 radiation exposed individuals. Contributions from the Departments of Epidemiology will
 2183 be several-fold.
 2184

2185 First, because of the involvement of the departments in the tumor and tissue registries and
 2186 their long-standing relationships with the local medical communities, we must take a
 2187 leading role in establishing collection and management procedures for tissues and other
 2188 biological samples to ensure that appropriate samples are available for this research. It will
 2189 be essential that we develop as the first step an efficient database management system, in
 2190 collaboration with ITD and others, to catalogue all available tissues together with relevant
 2191 information linked to the RERF cohorts. Second, the Departments of Epidemiology
 2192 should provide intellectual input by identifying important research questions based on the
 2193 ongoing analysis of cancer data and by being involved in study design, analysis, and
 2194 interpretations of the results.
 2195

2196 *F₁ mail survey*
 2197

2198 As part of the planned clinical examination of the F₁ population, the Departments of
 2199 Epidemiology will be involved in a mail survey on this cohort. It is anticipated that basic
 2200 information obtained from this mail survey will provide data useful for assessing the
 2201 feasibility of a full-scale investigation and the factors which may be considered as
 2202 confounders in future analyses of the mortality and morbidity data and reproductive

203 performance among the F₁ cohort.

204
205 *Site-specific cancer studies*

206
207 Most of the currently active site-specific cancer incidence studies will be completed within
208 the next few years. As they are completed, new studies will be initiated to update the case
209 series or to investigate additional tumor sites of interest. These include such sites as colon,
210 stomach, and bone and connective tissues (see table).

211
212 **Priority 2**

213
214 *Family pedigree studies and genetic epidemiology*

215
216 The setting in which the three RERF cohorts were established presents a unique
217 opportunity for identifying family members within these cohorts and conducting a long-
218 term prospective follow-up of the role of genetic and other familial factors in the
219 occurrence of cancer and other common, chronic diseases. Some preliminary work has
220 been undertaken in collaboration with the Departments of Statistics, Clinical Studies and
221 Information Technology to set up a family pedigree database. In view of the evidence
222 relating genetic predisposition for breast cancer, a pilot study is now underway to
223 construct family pedigrees for young breast cancer patients as well as older breast cancer
224 patients (as a comparison group). To obtain useful results, more formal research protocols
225 will be developed in association with geneticists and statisticians. To implement this
226 research may require the additional help of individuals who are familiar with Japanese
227 kinship terms in establishing genealogical relationships and the use of the koseki records
228 to verify the stated relationships.

229
230 **Personnel requirements (Hiroshima)**

231
232 In the last few years, the number of epidemiologists in the department's professional staff
233 in Hiroshima has decreased from 6 (4 Japanese and 2 US) to 3 (Japanese only), while that in
234 Nagasaki has remained at 2 (both Japanese). In view of the ongoing and anticipated research
235 activities, the current size is woefully inadequate. The minimum staff requirement for Hiroshima
236 is 6 professionals as it was in 1994. Because of the generally high level of epidemiologists trained
237 in the US and some European countries, efforts are underway to recruit two epidemiologists
238 through NAS. We also plan to recruit one Japanese epidemiologist. Finally, in anticipation of
239 the retirement of the current Department Chief in 5 years, we should begin to consider the recruitment
240 of another Japanese M.D. or Ph.D. level epidemiologist.

241
242 The Epidemiology support staff for Hiroshima has also decreased in size and currently
243 consists of 35 full-time and 4 part-time employees. The support staff provides research assistance
244 (data preparation, tabulation and analyses), technical assistance (the management of the Master-
245 File and tumor registry database, the abstraction of medical records for the tumor registry
246 operation, and histo-pathology work for specific cancer studies), clerical work (Master-File and
247 tumor registry) and secretarial and administrative assistance. The current total size of 39 is
248 adequate.

2250
 2251
 2252
 2253
 2254
 2255
 2256
 2257
 2258
 2259
 2260
 2261
 2262
 2263
 2264
 2265
 2266
 2267
 2268
 2269
 2270
 2271
 2272
 2273
 2274
 2275
 2276
 2277
 2278
 2279
 2280
 2281
 2282
 2283
 2284
 2285
 2286
 2287
 2288
 2289
 2290
 2291
 2292

Hiroshima

Area	Fiscal Year					
	Current	1997	1998	1999	2000	2001
Research scientists						
Epidemiology	1.5	4.5	4.5	4.5	4.5	4.5
Tumor registry	1.5	1.5	1.5	1.5	1.5	1.5
Total	3	6	6	6	6	6
Support staff						
Research assistants	3	3	3	3	3	3
Master File	17 (1) ¹	18	18	18	18	18
Tumor registry	11 (2)	13	13	13	13	13
Pathology	2 (1)	3	3	3	3	3
Administration	2	2	2	2	2	2
Total	35 (4)	39	39	39	39	39

¹ Part-time employees shown in parentheses.

Space requirements (m²) (Hiroshima)

Area	Fiscal Year					
	Current	1997	1998	1999	2000	2001
Research scientists	73	105	105	105	105	105
Administration	18	20	20	20	20	20
Research assistants	20	20	20	20	20	20
Master File	307	210	210	210	210	210
Tumor registry	112	210	210	210	210	210
Pathology	181	180	180	180	180	180
Other Support ¹	57	40	40	40	40	40
Total	768	785	785	785	785	785

¹ Includes half of the area of the conference, computer, and copier rooms which are shared with the Department of Statistics and of the visiting scientists office, which is also shared with Statistics.

Equipment budget (Hiroshima) (x ¥ 1,000)

Computer hardware and software are the primary equipment used by the Epidemiology staff. A three-year schedule for the replacement of computers and a continuing need to expand network storage capacity have been assumed. It also is assumed that replacing or upgrading hardware and software will occur on a regular basis. In addition, laboratory equipment for the Pathology Laboratory will be needed.

Hiroshima, Research and Administrative

Budget category	Fiscal Year				
	1997	1998	1999	2000	2001
Computer hardware replacement/upgrade ¹	6,060	6,000	6,200	6,140	6,140
New computer hardware and software ²	660	780	640	760	760
Pathology lab	970+	150	150	150	150
Total	7,690	6,930	6,990	7,050	7,050

1. There are currently 26 PCS, of which 8 will be replaced each year.
2. There are currently 7 printers, one of which will be replaced each year. Also one new PC will be added each year.
- + Incubator, microtome, cleaner

Hiroshima, Research

Budget category	Fiscal Year				
	1997	1998	1999	2000	2001
Computer hardware replacement/upgrade ¹	4,292	4,200	4,390	4,298	4,348
New computer hardware and software ²	549	617	536	608	608
Pathology lab ³	970+	150	150	150	150
Total	5,811	4,967	5,076	5,056	5,106

1. 75% use for research assumed.
2. 75% use for research assumed.
3. 100% use for research assumed.

Personnel requirements (Nagasaki)

There are two Japanese professional staff in Nagasaki and the size is appropriate. However, we need one research assistant who has a sound knowledge of epidemiology, statistics and the computer sciences, and who will be expected to obtain a Ph.D. within 5 years.

The epidemiology support staff for Nagasaki has decreased in size and currently consists of 20 full-time employees. The support staff provides technical assistance (the maintenance of the computer system, the management of the Master-File and tumor registry database, the

2338
2339
2340
2341
2342
2343
2344

abstraction of medical records for the tumor registry operation, the histopathology work for cancer studies, etc.), clerical work (Master-File and tumor registry) and secretarial and administrative assistance. The current total size of 20 should be increased to 21 through the employment of the one additional research assistant mentioned above.

Nagasaki

Area	Fiscal Year					
	Current	1997	1998	1999	2000	2001
Research scientists						
Epidemiology	0.8	0.8	0.8	0.8	0.8	0.8
Statistics	0.2	0.2	0.2	0.2	0.2	0.2
Tumor registry	0.8	0.8	0.8	0.8	0.8	0.8
Clinics	0.2	0.2	0.2	0.2	0.2	0.2
Total	2	2	2	2	2	2
Support staff						
Research assistant	0	1	1	1	1	1
Master File	9	9	9	9	9	9
Tumor registry	6	6	6	6	6	6
Pathology	3	3	3	3	3	3
Computer technicians	2	2	2	2	2	2
Total	20	21	21	21	21	21

2351
2352
2353
2354
2355
2356
2357
2358
2359
2360
2361
2362

Space requirements (m²) (Nagasaki)

Area	Fiscal Year					
	Current	1997	1998	1999	2000	2001
Research scientists	28*	50	50	50	50	50
Research assistant	0	10	10	10	10	10
Master File	146	146	146	146	146	146
Tumor registry	61	70	70	70	70	70
Pathology	82	82	82	82	82	82
Computer technicians	18	22	22	22	22	22
Other Support ¹	96	96	96	96	96	96
Total	431	476	476	476	476	476

2372
2373
2374

¹ Includes space for data and document storage (52m²), network communication servers and equipment (18m²) and underground storage of pathology samples (26m²).

Equipment budget (Nagasaki) (x ¥ 1,000)

Budget category	Fiscal Year				
	1997	1998	1999	2000	2001
Computer hardware replacement/upgrade	2,570	2,500	1,000	0	3,000
additional	570				
Printer replacement/upgrade	1,900	700	1,500	700	1,900
Software upgrade	968	144	1,044	144	1,044
additional	190				
Pathology lab	1,618	30	30	30	30
Total	7,816	3,374	3,574	874	5,974

Survey Expenses (x ¥ 1,000)

	Projection								
	1993	1994	1995	1996	1997	1998	1999	2000	2001
Mortality surveillance									
Hiroshima	13,509	13,524	13,450	17,082	17,000	17,850	17,850	18,740	18,740
Nagasaki	7,489	7,337	7,423	11,294	11,000	11,550	11,550	12,130	12,130
Total	20,998	20,861	20,873	28,376	28,000	29,400	29,400	30,870	30,870
Tissue registry									
Hiroshima	12,000	12,000	12,000	12,000	12,000	12,000	12,000	12,000	12,000
Nagasaki	12,000	12,000	12,000	12,000	12,000	12,000	12,000	12,000	12,000
Total	24,000	24,000	24,000	24,000	24,000	24,000	24,000	24,000	24,000
F1 mail survey Hiroshima & Nagasaki					13,300	13,300	13,300	13,000	
Grand Total				52,376	65,300	66,700	66,700	68,170	54,870

- 1) Mortality surveillance: Projections based on a 5% biennial increase in fees for koseki request plus postage.
 2) F1 mail survey: Estimates for 71,000 subjects currently alive, costs include survey form, envelope, labels and postage for residence check (¥6,350); fees for koseki (¥24,880); and postage for koseki and mailing (twice on the average)(¥22,050) for 71,000 subjects (alive)(Total: ¥53,280) equally distributed over the four year period 1997-2000.

2415
2416
2417
2418
2419

Construction of LSS-based Family Pedigree Database
Hiroshima and Nagasaki Combined Estimates (x ¥ 1,000)

2420	Current	1997	1998	1999	2000	2001
2421 2422	Koseki check	19,450	19,450	19,400	19,400	19,400
2423	Supplies	150	150	140	140	140
2424	Total	19,600	19,600	19,540	19,540	19,540

2425
2426
2427

Estimates for 120,000 subjects based on fees for original koseki and postage (¥97,100) and supplies (¥720) equally distributed over the 5-year period 1997-2001.

2428
2429
2430
2431

Department of Genetics

2432
2433
2434
2435
2436
2437

The current research activities of the Department of Genetics have two major thrusts, namely, a cytogenetics program that focuses on the occurrence of chromosomal abnormalities in the survivors as well as their offspring, and a biochemical genetics program that centers on the detection of gene-mutational events and the development of the requisite technology to achieve this end. These two programs have been carried out by the Cytogenetics Laboratory and the Laboratory of Biochemical Genetics, respectively.

2438
2439
2440
2441
2442
2443
2444
2445
2446
2447
2448

In the past, screening for chromosomal abnormalities and gene mutations occurring in germ cells were carried out in the two laboratories by examining the children of the survivors selected from the same F₁ cohort. However, in the last 10 years, the cytogenetics program focused on screening for somatic chromosome abnormalities in the survivors in order to establish biological dosimetry as an alternative to physical dose estimation through the application of electron spin resonance (ESR) of tooth enamel obtained from the survivors. The efforts of the biochemical genetics program have been concentrated on developing technologies for the detection of germ cell DNA mutations in the children of the survivors and establishing cell lines from 1000 parent-child trios, with half of the trios including at least one proximally exposed parent.

2449
2450
2451
2452
2453
2454
2455

In the next five years, in each program, on-going projects will be continued. In addition, the FISH (fluorescence in situ hybridization) technique will be utilized for the physical localization of unreported genes or new mutations in specific genes detected in the biochemical genetics program by using single probes of DNA fragments and a subsample of the 1000 trios whose lymphocytes and cell lines have been stored in our cell bank for the biochemical genetics program will be examined for the detection of chromosomal germline mutations.

2456
2457

The Cytogenetics Program

2458
2459
2460
2461
2462

The research objectives of the Cytogenetics Laboratory are two fold. First, to collect cytogenetic information on the survivors and to use this information to strengthen the DS86 dose estimates, either by validating them or by indicating possible biases in them. Second, to determine by means of the F₁ cytogenetic studies whether parental exposure to A-bomb radiation caused an increased frequency of chromosomal abnormalities in their progeny. Since these aims entail

63 different studies, we describe them separately.

64 65 **Cytogenetic studies of the survivors.**

66
67 Past experience has confirmed that the conventional Giemsa staining method can detect
68 nearly two-thirds of all reciprocal translocations. However, even with the best technique and
69 highly qualified investigators, the chromosome aberration data on each survivor scatter quite
70 widely when regressed on the individual DS86 doses. This statistical "overdispersion" could be
71 attributable to two possible sources of error, one physical and the other biological. The former
72 includes errors in the physical estimation of the DS86 dose itself and in the interview information
73 regarding location and shielding conditions ATB. The latter includes possible differences in
74 radioresponse among individuals due to genetic factors, age ATB, sex, and life-style, including
75 smoking habits, for example. To estimate the relative contributions of these possible confounding
76 factors, it has long been considered desirable to estimate dose using another biodosimetric marker
77 independent of the cytogenetic results.

78
79 The frequency of mutations in somatic cells was once considered a good candidate, and
80 several assays were investigated by the Department of Radiobiology to see if they could serve as
81 alternative biodosimetric tools. However, among some five different assays, only the glycophorin
82 A (GPA) assay in erythrocytes can detect exposures to radiation that occurred several decades
83 earlier. Furthermore, the overdispersion of mutant frequency is even greater than that seen in the
84 chromosome data, most likely due to a "jackpot-type" event (an occasional large "payoff-type"
85 event) stemming from the relatively small number of bone marrow stem cells (the target cells for
86 mutation by radiation exposure revealed by the GPA assay) which are actively producing mature
87 red blood cells. Thus, the erythrocyte-based GPA mutation assay does not seem capable of
88 serving as an alternative tool for biodosimetry on individuals.

89
90 Electron spin resonance (ESR) to detect radicals in tooth enamel has been used by a
91 number of laboratories as another indicator of past radiation exposure. Since installation of ESR
92 equipment in the cytogenetics laboratory (January 1995), 100 teeth selected from over 300
93 samples donated during the past nearly 10 years have been examined. The results show a close
94 association with the cytogenetic data from the tooth donors, and the ESR method appears to be
95 a promising alternative means to estimate individual doses, which in turn supports the cytogenetic
96 data on the survivors. Since ESR can be applied only to extracted teeth whereas chromosome
97 tests require only 1 to 2 ml of blood that can be readily obtained from most of the survivors, ESR
98 cannot supplant cytogenetic tests but serves to reemphasize the value of the latter.

99 **Major research activities in the next five years**

1 **A. Core activities**

2 **Priority 1**

3 ***A-1. FISH examination of Hiroshima and Nagasaki survivors (RP 8-93):***

4
5
6
7
8 A recent summary of the cytogenetic data on over 2000 survivors revealed two important
9 issues with respect to the accuracy of the dose estimates based on physical grounds.

2510
2511
2512
2513
2514
2515
2516
2517
2518
2519
2520
2521
2522
2523
2524
2525
2526
2527
2528
2529
2530
2531
2532
2533
2534
2535
2536
2537
2538
2539
2540
2541
2542
2543
2544
2545
2546
2547
2548
2549
2550
2551
2552
2553
2554
2555
2556

First, the dose-response relationship for Nagasaki survivors exposed in factories was unusually shallow, only one-half as steep as that for the survivors exposed in Japanese houses. This implies that the DS86 system overestimated the doses of these workers. Second, among the survivors exposed in Japanese houses, the dose responses were similar in both cities, but the Hiroshima curve is consistently above the Nagasaki one, suggesting the possibility of a small systematic error in the calculation of the DS86 doses. However, because the conventional staining method used in cytogenetic studies is known to be affected by observer bias (the Hiroshima and Nagasaki survivors were examined separately in the two laboratories by different investigators), we need to confirm these findings using FISH, the most objective method of scoring stable-type chromosome aberrations. This will be undertaken in the Hiroshima laboratory exclusively.

In 1994, collection of blood samples began with the aim of applying the FISH technique to about 200 survivors a year for five years. In 1995, the sampling scheme was extended to include an additional 200 survivors of specific interest (for example, tooth donors for ESR, carriers of clonal chromosomal aberrations, and mothers of the in utero exposed). Further extension is planned in the near future to maximize sampling of those survivors who were below 20 years of age ATB and have DS86 doses of about 0.5 Gy or more. (The total number of subjects will be about 1,500.)

The motivation for this large scale survey comes from our recent finding, based on tooth enamel ESR and the cytogenetic data on the tooth donors, that the cytogenetic data are closely related to the real radiation dose. To document the apparently higher proclivity of the youngest cohort to develop excess cancers, evaluation of biases in DS86 dose estimates is critical and only cytogenetic data can provide the necessary information. For this purpose, information on middle to high dose survivors is important not only because they have the higher risks for cancer but also the fraction of LSS cohort members with such doses included in the AHS is larger (the fraction is 85% for those with DS86 doses of above 1 Gy).

B. Special research activities

Priority 1

B-1. Characterization of the ESR assay (RP 1-92):

Because the ESR assay is rather new, laboratory techniques differ in the various steps of the assay procedure. Creation of international guidelines for standardization of the assay is in progress, and we are eager to compare our technique with that of others to reduce possible laboratory-specific errors in estimating the dose. The major advantage of the ESR assay is that the measurement itself is not destructive and the same specimen can be repeatedly measured. ESR results for the first 100 tooth samples along with the cytogenetic data on the tooth donors will be published in 1997.

We propose to examine an additional 100 teeth in the future and to couple this examination with the FISH technique using lymphocytes from the tooth donors to strengthen the current results. At the same time, tooth collection will continue.

2557
2558
2559
2560
2561
2562
2563
2564
2565
2566
2567
2568
2569
2570
2571
2572
2573
2574
2575
2576
2577
2578
2579
2580
2581
2582
2583
2584
2585
2586
2587
2588
2589
2590
2591
2592
2593
2594
2595
2596
2597
2598
2599
2600
2601
2602
2603

B-2. Clonal chromosome aberrations (RP 8-93):

In the past studies using conventional staining methods, some 20 survivors were identified who carry identical chromosome changes in 3 or more lymphocytes, defined as clonal aberrations. A priori, clonal expansion can occur in two ways. Either the stem cells proliferated extensively and produced a large number of progeny or the mature lymphocytes proliferated after being stimulated by certain antigen(s). In the former case, clonal aberrations are expected to be seen mainly in naive T cells (CD45RA⁺), whereas in the latter case, mainly in memory T cells (CD45RO⁺). Studies using separated lymphocytes (CD45RA⁺ or CD45RO⁺) are in progress and results will be obtained within 2 years.

Depending upon the findings, further detailed examinations (for example, CD4⁺ vs CD8⁺ lymphocytes) may be necessary. This research will be performed in collaboration with the Department of Radiobiology.

B-3. FISH examination of exposed parent(s) in the F₁ molecular genetics study sample (RP 8-93):

We now know that the DS86 dose estimates contain potentially systematic errors. Because the molecular genetics study sample is a small subsample of the AHS cohort, and a considerable fraction of the high dose survivors in Nagasaki consists of factory workers whose DS86 doses seem to be overestimated, it would be prudent to examine the exposed parent(s) with assigned DS86 doses above a certain level (say, 1 Gy) for the chromosome aberration frequency of lymphocytes to validate their gonadal doses. Because most of the exposed parents are in the AHS, they will be included in the routine FISH examination and the total number of parents examined will be about 200. This study will require at least one AHS examination cycle (two years) or possibly two (four years), and the participation of the Departments of Clinical Studies.

B-4. Detailed comparison of ESR dose with DS86 dose (RP 1-92):

The 100 tooth samples that have been examined by ESR were derived from 69 survivors. The ESR estimated tooth dose and DS86 kerma dose show a positive correlation, but considerable variation exists. In some cases, the chromosome data and the ESR data fit one another closely but deviate substantially from the DS86 estimates. As previously said, these discrepancies are likely to be due to errors in the information on survivor location ATB and are most likely unrelated to errors in the program designed to compute the DS86 dose. It would be useful to scrutinize the relationships among ESR dose, cytogenetic information, and DS86 dose in the remaining cases so that consistent deviations related to shielding conditions and other factors can be detected.

Priority 2

B-5. Scrutiny of ESR and DS86 doses for tooth donors (RP 1-92):

As mentioned in the previous section, ESR data are the first physical measurements of

2604
2605
2606
2607
2608
2609
2610
2611
2612
2613
2614
2615
2616
2617
2618
2619
2620
2621
2622
2623
2624
2625
2626
2627
2628
2629
2630
2631
2632
2633
2634
2635
2636
2637
2638
2639
2640
2641
2642
2643
2644
2645
2646
2647
2648
2649
2650

gamma dose on individual survivors, and they should be carefully compared with the DS86 estimates. In 1995, Dean C. Kaul (SAIC) expressed an interest in the DS86 dose information on the tooth donors. A collaborative program with SAIC would be valuable if the necessary internal administrative agreements can be reached.

B-6. Domain structure of chromosomes in interphase nuclei (RP 8-93):

Brenner's hypothesis states that the ratio of interchromosomal versus intrachromosomal aberrations, termed the F-value, decreases from over 10 to nearly 5 as the LET of radiation increases. Current data, both in vivo and in vitro, obtained in the Cytogenetics Laboratory do not seem compatible with this hypothesis. There is no evidence that "the majority of the effective dose received by individuals in Hiroshima ... came from neutrons" as described by Brenner (1996), but the most recent tooth enamel ESR versus translocation data show that the majority of the cytogenetic effects are due to gamma-ray exposure.

Because the hypothesis is derived from the domain structure of chromosomes in interphase nuclei, several approaches from independent angles should be helpful to understand the issue. For example, do reciprocal translocations occur randomly among chromosomes? Do inactive X chromosomes in females undergo translocation less frequently? Are translocation breakpoints distributed homogeneously throughout a chromosome arm? Most of these questions can be answered by careful analysis of data presently available (both by G-band and FISH), and no extensive new experiments are required.

B-7. Research on genetic instability

Recent studies, both in vivo and in vitro, suggest that radiation exposure causes genetic instability in cells. We plan two approaches. One is to carefully examine previously collected G-band data to see if cells which have undergone a chromosomal change have an increased chance of having a second change. Second, if radiation exposure can cause instability which lasts for the lifetime of the individual, the frequency of unstable aberrations (dicentric) would be expected to increase with dose. Scrutiny of the previously collected large set of cytogenetic data based on conventional staining procedures should provide an answer to this.

B-8. Assessment of errors in the DS86 system

As previously stated, recent ESR results on tooth enamel revealed that the ESR estimated dose more closely correlates with chromosome aberration data on the tooth donors than DS86 estimates. This finding along with in vitro studies indicate that chromosome data are good measures of the true dose. The extensive body of cytogenetic data collected in the past should be reviewed to estimate the distribution of true dose at different levels of DS86 dose.

Cytogenetic studies of the children of the survivors

2651
2652
2653
2654
2655
2656
2657
2658
2659
2660
2661
2662
2663
2664
2665
2666
2667
2668
2669
2670
2671
2672
2673
2674
2675
2676
2677
2678
2679
2680
2681
2682
2683
2684
2685
2686
2687
2688
2689
2690
2691
2692
2693
2694
2695
2696

Using conventional staining methods, an extensive cytogenetic survey was conducted in the past involving nearly 16,000 F₁ persons (8,000 born to exposed parent(s) and 8,000 to the unexposed). The results showed only one de novo autosomal mutation in each group, although not all of the parents of aberration-carrying individuals could be cytogenetically examined. Thus, no evidence of a radiation effect on the germ cells has been observed so far.

Major research activities in the next five years

Priority 1

C-1. Examination of EBV-transformed B-cell lines by the G-banding method

Because the previously used conventional staining method can detect only gross structural changes and is not suitable for detecting small deletions, it will be necessary to apply the G-banding method which can detect small changes.

EBV-transformed B-cell lines established from trios of families for molecular genetic studies in the Laboratory of Biochemical Genetics would be an appropriate source of materials, both in terms of sample size, estimated gonadal dose, and availability of cells from the parents. The work will require 3 to 4 years.

Priority 2

C-2. Development of FISH using a single probe

One application of the FISH technique is mapping using a single gene probe or a probe for a specific DNA segment. In the future, in the Laboratory of Biochemical Genetics, we anticipate that mutant genes will be detected using molecular analysis of the children born to the survivors. FISH mapping of the mutated gene would be useful in characterizing the mutation.

Project time lines (Cytogenetics)

Fiscal Year	1997	1998	1999	2000	2001
1. FISH examination of survivors	⇒	⇒	⇒	⇒	⇒
2. FISH by a single probe	⇒	⇒			
3. Chromosome domain structure	⇒	⇒			
4. Genetic instability	⇒	⇒			
5. Assessment of DS86 errors	⇒	⇒			

Biochemical Genetics Program

The primary objective of the biochemical genetics program is to determine whether an increase in mutations measurable at the molecular level has occurred in the children born to A-bomb exposed parents in Hiroshima and Nagasaki.

2697
2698
2699
2700
2701
2702
2703
2704
2705
2706
2707
2708
2709
2710
2711
2712
2713
2714
2715
2716
2717
2718
2719
2720
2721
2722
2723
2724
2725
2726
2727
2728
2729
2730
2731
2732
2733
2734
2735
2736
2737
2738
2739
2740
2741
2742
2743

Past and recent accomplishments

Extensive studies of the children of the survivors of the atomic bombings of Hiroshima and Nagasaki, using various endpoints such as untoward pregnancy outcomes, mortality, chromosome aberrations, and gene mutations screened at the protein level, have thus far yielded no statistically significant increases in genetic effects compared to a control population.

Because it is important to determine the mutation rate induced by radiation in this unique population, detecting mutations at the DNA level has been explored in a feasibility study. Establishment of cell lines from parent-child trios was recommended by the Genetic Study Conference held in 1984. It is anticipated that immortalized B-lymphocyte cell lines from 1000 families, one-half of them from a proximally exposed parent(s), will be maintained at RERF. Cell lines from 800 families composed of 1600 parents having DS86 estimates and 1200 children are now in the cell bank. This is the largest properly selected population in the world for the detection of radiation effects on human germline mutations. The Human Germline Mutagenesis Workshop held in 1991 recommended starting a pilot study using 100 families (50 exposed and 50 control families), a subsample of the 800 families, to compare various types of DNA as potential targets for the detection of germinal mutations with various techniques, because there was no information about the genes sensitive to radiation-induced mutagenesis. In keeping with this recommendation, microsatellites, minisatellites and various functional single-copy sequences in 124 children and both parents of the 100 families have been examined to determine whether deletion/insertion/rearrangement (D/I/R) type mutations or mutations causing other types of quantitative changes, all commonly produced by radiation, as well as nucleotide substitutions, exist at higher frequency in the children of the exposed parents.

Preliminary studies have failed to reveal a significant difference between the children of the exposed and the control parents in the mutation rates at the microsatellite and the minisatellite loci, both of which are repetitive sequences dispersed through the human genome.

We have developed two techniques to screen for D/I/R type mutations in single-copy sequences. One is the quantitative measurement of intensities of chemiluminescent bands on Southern filters and the other is the two-dimensional electrophoresis (2-DE) of DNA digests followed by a quantitative image analysis of ³²P-labeled spots. Each technique can detect a 50% decrease or increase in band intensity or spot intensity that is derived from the D/I/R events on the totality of a single allele. Thus, these techniques are suitable to detect a fresh D/I/R type mutation because a fresh mutation would usually be detected in a heterozygote for a normal and a variant allele.

Major research activities in the next five years

A. Core activities

Priority 1

A-1. Pilot studies for the detection of D/I/R type mutations

In addition to the original 100 families, a new set of 100 families (50 exposed and 50

044 control families) will be selected and screened for mutations at the minisatellite loci during
045 the first two years. It is important to use a larger body of data to confirm our preliminary
046 results, which showed no effect of A-bomb radiation on genetic instability at the
047 minisatellite loci in human germ cells obtained from the original 100 families, including
048 children derived from 65 exposed gametes with a mean dose of 1.9 Sv. We have
049 assumed that the 65 gametes received, on average, the doubling dose estimated by Neel
050 et al. (1990)), namely, 1.7-2.2 Sv. For a locus with a spontaneous mutation rate of 0.02
051 per gamete, which is the mean mutation rate of the six minisatellite loci examined in the
052 previous study, using standard power function statistics (a Type I error of 0.05 and a Type
053 II error of 0.2), we calculate that we would need to survey two samples (exposed and
054 unexposed) of 1,188 germ cells each to observe a significant difference at the 0.05 level.
055

056 By examining 60 children from an additional 50 exposed families, each one of them having
057 one exposed parent and the mean gonadal dose of the parent being 1.9 Sv, it is anticipated
058 that we can examine the required number of alleles for each sample. Dubrova et al.
059 reported that mutation rates at minisatellite loci in 79 children of parents who lived in
060 heavily polluted areas of Belarus after the Chernobyl accident were twice that of 105
061 control children from the United Kingdom although the estimated individual dose from
062 external and internal chronic exposure to ¹³⁷Cs of inhabitants of those areas was less than
063 5 mSv per year. By comparing their data with our new data based on the projected
064 additional sampling, it may be possible to determine whether there is a difference in the
065 biological effects of radiation between acute external exposure and chronic internal
066 exposure.
067

068 The pilot study for the screening of D/I/R mutations will be carried out with the
069 quantitative measurement of intensities of chemiluminescent bands on Southern filters on
070 two hundred families (the original 100 families and the new 100 families). Probes to be
071 used are DNA fragments from the human counterparts of the seven mouse specific loci,
072 other genes located nearby, and genes supposedly related to common chronic diseases
073 such as hypertension, diabetes mellitus and hereditary nonpolyposis colorectal cancer
074 (HNPCC).
075

076 The 2-DE technique will be used in the pilot study. DNA samples from the 200 families
077 will be examined using this technique after digestion with three sets of restriction enzymes,
078 that is, NotI/EcoRV-HinfI (NotI/EcoRV and HinfI being used before and after the first
079 dimensional electrophoresis, respectively), NotI/EcoRV-PvuII and NotI/EcoRV/PvuII-
080 HinfI, products of each set of enzymes being different from those produced with the other
081 two sets of enzymes. These three kinds of DNA digests labeled with ³²P from one
082 individual will be electrophoresed separately, and the resulting three gels will be
083 quantitatively analyzed. A total of 2000 spots (fragments) will be suitable for the
084 detection of the D/I/R type mutations among 6000 spots (fragments) visualized on the
085 three autoradiograms from the three gels. With the current research design (2000 diploid
086 fragments scored on three gels per individual), 5 mutations would be detected in 120
087 children from 100 control families, if we assume that the spontaneous mutation rate is 1×10^{-5} /fragment/generation.
088
089

090 Image analysis is an essential part of any 2-DE study of DNA fragments, and this will

2791
2792
2793
2794
2795
2796
2797
2798
2799
2800
2801
2802
2803
2804
2805
2806
2807
2808
2809
2810
2811
2812
2813
2814
2815
2816
2817
2818
2819
2820
2821
2822
2823
2824
2825
2826
2827
2828
2829
2830
2831
2832
2833
2834
2835
2836
2837

require support of the Information Technology Department (ITD) in the rewriting of the 2-DE software developed at the University of Michigan and currently in use in the Department of Genetics. This software was developed for older computer operating systems and cannot be readily used with the system upgrades that have occurred and that are contemplated in future computer system upgrades at RERF. In addition, to organize the data from the various DNA examinations and perform analyses, support from the ITD and the Department of Statistics will be required.

Physical localization of mutant genes and their normal counterparts will be carried out using the FISH technique in collaboration with the Cytogenetics Laboratory. To understand the characteristics (physical nature and functional effects) of new mutations, not only molecular biological data but also physical data are essential.

In each of the 100 exposed families, at least one parent belongs to the most heavily exposed group among the approximately 400 exposed parents on whom permanent cell lines have been established. Therefore, if the mutation rate detected in the children of the exposed group is significantly higher than that in the children of the control group, and the efficiency of the technique we propose is sufficiently high to warrant screening a larger number of samples, the study will be expanded to determine the dose response relationship. However, if there is no significant difference in the mutation rates between the two groups or the efficiency of the technique is too low, the study will not be continued and new methods will be introduced or developed.

A-2. Culture of permanent lymphocyte cell lines as sources of biological samples for the study of germ cell mutations

Initially, families for this program were selected on the basis of T65DR doses since the DS86 system did not exist when the original selections were made. Some of the cell lines already established are from families including parents whose DS86 doses are unavailable. New families where parental DS86 doses exist will be selected and cell lines will be established keeping the original goal of 1000 families in mind. This means we shall try to add 200 families in Hiroshima and Nagasaki over the next two years.

In the beginning of the pilot study for the detection of mutations, DNA extracted from cell lines established from members of the 100 families, a subsample of the 1000 families of the cell-line project, was used. However, recently, in order not to exhaust the cell lines, portions of the cell lines have been proliferated and the resulting "re-cultured cell lines" have been used for routine purposes. For the additional new 100 families to be examined in the pilot study, "re-cultured cell lines" will be produced and they will be used as sources of DNA.

B. Special research activities

Priority 1

B-1. A feasibility study on the ascertainment of disease and disability among offspring of the survivors (Feasibility of F₁ health study)

2338 The Blue Ribbon Panel urged that consideration be given to the feasibility of studying
2339 diseases and disabilities of late onset among the offspring (F₁ generation) of the survivors.
2340 A protocol for the feasibility study has been written. It includes a mail questionnaire
2341 survey for a total of 82,000 F₁ (F₁ Mortality Sample and the so-called BGS Extension
2342 Samples), physical examination of approximately 500 F₁ (F₁ reporting chronic illness and
2343 those not doing so) in the Departments of Clinical Studies, and analyses of genes related
2344 to common diseases such as hypertension and diabetes mellitus in approximately 50 F₁.
2345 It is anticipated that it will take two years to complete the study. As soon as the results
2346 of the feasibility study are obtained, a workshop will be held to determine whether a full-
2347 scale study is practical and warranted. This feasibility study will be carried out as a
2348 collaborative undertaking involving the Departments of Clinical Studies, Epidemiology,
2349 Statistics and Genetics.

2351 *B-2. Assessment of detectability of germ cell mutations by the 2-DE technique*
2352 *(Detectability of mutations by 2-DE: Approved by Chief of Research Donald Harkness*
2353 *on 14 March 1995)*

2355 A pilot study, which was begun in 1996 for the assessment of detectability of the 2-DE
2356 technique of radiation-induced germ cell mutations in mammals, will be continued for one
2357 more year. DNA samples from 100 control mice (BALB/c) and from two groups of 100
2358 F₁ mice, one derived from spermatogonia irradiated with 3 Gy and the other from
2359 spermatogonia irradiated with 5 Gy, are being examined with the 2-DE technique after
2360 digestion with two sets of restriction enzymes (NotI/EcoRV-Hinfi and NotI/EcoRV-
2361 PvuII). The search for D/I/R type mutations that result in spots with 50% decreased
2362 intensity at the normal positions among 1000 spots on a gel are being carried out using
2363 quantitative image analysis. Among DNA samples from 43 F₁ mice of 5 Gy irradiated
2364 male parents, examined in 1996, one mutation was detected. Results of the study will
2365 provide basic information for the estimation of the number of children of A-bomb
2366 survivors that should be examined in order to obtain statistically significant results.

2368 *B-3. Pilot study to evaluate various markers in potential candidate genes associated with*
2369 *hypertension. (Pilot study for the hypertension markers)*

2371 Suggestive radiation-related increases in cardiovascular disease incidence and the
2372 prevalence of aortic arch calcification and systolic hypertension have been reported. The
2373 Blue Ribbon Panel states that further studies are required to confirm a real association
2374 between radiation exposure and atherosclerosis. This indicates the importance of studying
2375 at the molecular level the hypertension observed in the AHS population. A protocol is
2376 being prepared for a pilot study to evaluate several markers in potential candidate genes
2377 associated with hypertension. Some 100 individuals each from the normal group and the
2378 hypertension group, defined by the 1993 WHO/ISH classification among the participants
2379 of the AHS, will be examined for their polymorphic markers in several candidate genes.
2380 DNA will be extracted from lymphocytes in the blood samples obtained in the biennial
2381 physical examination conducted at the Departments of Clinical Studies. Because some
2382 AHS participants with hypertension are parents of the cell line project for the germinal
2383 mutation study, family studies for the potential markers associated with hypertension can
2384 be carried out if the need arises.

2885 **Project time lines (Biochemical Genetics)**

2886

2887	Project	1996	1997	1998	1999	2000	2001
2888	Feasibility for F ₁ -health study		⇒	⇒			
2889	Detectability of mutations by 2-DE	⇒	⇒				
2890	Pilot study for the hypertension markers		⇒	⇒			

2891 **Personnel Requirements (Department of Genetics)**

2892

2893

2894	Fiscal Year	1996	1997	1998	1999	2000	2001
2895	Research Scientists						
2896	Cytogenetics	5	5	5	5	5	5
2897	Biochem. Genet.	4+0.5 ¹	5	5	5	5	5
2898	Technicians						
2899	Cytogenetics	5	6	6	6	6	6
2900	Biochem. Genet.	11 ²	12	12	12	12	12
2901	Clerks						
2902	Cytogenetics	1	1	2	2	2	2
2903	Biochem. Genet.	2.2 ³	3	3	3	3	3

2904 ¹ One visiting scientist (Dr. Murakami) is concurrently assigned to the Departments of Genetics (50%) and Clinical Studies (50%). Her employment as a permanent research scientist is required.

2905 ² One young technician retired at the end of FY95 and no replacement has been made.

2906 ³ One clerk is assigned to the Department of Genetics (20%) and the Publication & Documentation Center (80%).

2907 **Space requirements (m²) (Department of Genetics)**

2908

2909

2910

2911	Fiscal Year	1996	1997	1998	1999	2000	2001
2912	Bench Research						
2913	Cytogenetics	146.2	146.2	146.2	146.2	146.2	146.2
2914	Biochem. Genet.	402 ¹	442	442	442	442	442
2915	Support Space						
2916	Offices cytogenetics	73.2	83.2 ²	83.2	83.2	83.2	83.2
2917	Biochem. Genet. ³	100	100	100	100	100	100
2918	Slide Storage(Cytogenetics)	7.3	17.3 ⁴⁵	17.3	17.3	17.3	17.3
2919	Storage Space(Biochem Genet.)..	23	23	23	23	23	23
2920	Total						
2921	Cytogenetics	226.7	246.7	246	246.7	246.7	246.7
2922	Biochem. Genetics.	525	565	565	565	565	565
2923							
2924	Grand Total	751.7	811.7	811.7	811.7	811.7	811.7

¹ Some corridor space where various research equipment, refrigerators and incubators are installed for daily use is included.

² Computer space (+10 m²).

³ Space used for image analysis of the 2-DE gels and other types of gel analyses is included.

⁴ Nagasaki slide storage (+10 m²).

⁵ Space for liquid nitrogen tanks, deep freezers and glassware for experiments.

Equipment Budget (× ¥ 1,000)

Fiscal Year		1997	1998	1999	2000	2001
Equipment						
Routine	Laboratory ¹	2,149	3,695	4,789	0	0
Replacement	Computer ¹	2,641	326	1,127	1,116	2,929
	Computer ²	421	326	560	588	533
Routine New	Computer ¹	2,200	850	890	930	490
	Computer ^{2,3}	600	150	155	160	50
Major New Acquisitions/Repl.		13,000 ^{4,5)}	5,000 ⁶⁾	22,880 ⁷⁾	0	0
Total		21,011	10,347	30,381	2,794	4,002
Lab Supplies/Reagents ⁸⁾		24,000	26,400	28,800	31,200	33,600

¹⁾ Laboratory and computer equipment for research purpose. For computer, 80% of the cost for hardware and 50% of that for software are included in this category.

²⁾ Equipment for administrative/service-related. For computer, 20% of the cost for hardware and 50% of that for software are included in this category.

³⁾ All new hard disks are for research purposes.

⁴⁾ Software for 2-DE Analysis (¥10,000,000): For 2-DE analysis, the software developed at the University of Michigan has been used. It was developed for older computers and cannot be readily used with the upgrades that have occurred. If a computer scientist outside of the RERF rewrites the program, the estimated cost is about ¥10,000,000.

⁵⁾ Pulsed Field Gel Electrophoresis Apparatus (¥3,000,000): DNA digests are electrophoresed by this apparatus for the detection of deletion mutations in DNA by quantitation of band-intensity on a Southern filter. One of the two apparatuses which we have been using for these 8 years is broken and cannot be repaired because the parts are unavailable. A new apparatus is essential to the continuation of our research.

⁶⁾ Photon camera (¥5,000,000): For the quantification of the intensity of chemiluminescent bands on a Southern filter and for the detection of deletion mutations, images of the bands on the filter are taken by photon camera. The sensitivity to photons of the camera we have been using for the past 5 years is decreasing. The old camera should be replaced by a new one.

⁷⁾ Bio-Imaging Analyzer with Imaging Plates and Cassettes (¥22,880,000): In the 2-DE analysis, the spot pattern on a gel is visualized by making an autoradiogram which requires at least two weeks or more. This will be a big problem in the screening for mutations using the 2-DE technique. By using this image analyzer, the problem will be solved and the accuracy of the measurement of spot intensity will be much improved because it has high sensitivity for radioactivity.

⁸⁾ A 10% yearly increase is included.

Department of Radiobiology

The Department of Radiobiology came into existence in August 1985 at the time of the

2973
2974
2975
2976
2977
2978
2979
2980
2981
2982
2983
2984
2985
2986
2987
2988
2989
2990
2991
2992
2993
2994
2995
2996
2997
2998
2999
3000
3001
3002
3003
3004
3005
3006
3007
3008
3009
3010
3011
3012
3013
3014
3015
3016
3017
3018
3019

reorganization of the Foundation's Department of Pathology. The primary objectives of the department are to determine the late effects of exposure to ionizing radiation on immune system function, on somatic cell mutation and altered gene expression; on cell survival and transformation; and to maintain serum and tissue resources for epidemiological, histopathological, and radiobiological investigations.

Recent achievements

The Department of Radiobiology has conducted research in three areas, namely, immunology, somatic mutation, and molecular oncology. Recent achievements in these areas can be summarized as follows:

a). The immunologic studies have revealed that among atomic-bomb survivors immune function, such as mitogen and alloantigen responsiveness of T-cells, lymphocyte subpopulation numbers, and anti-Epstein-Barr virus immunity, is still compromised fifty years after the atomic bombings.

b). The department has established various mutation assays, namely, the HPRT, HLA, Fcγ RIII, TCR, and GPA assays, and applied these to ascertain radiation doses among atomic bomb survivors and to estimate the risk of cancer development. These studies have shown that the somatic mutation frequency at the glycophorin A locus increases with increasing dose of A-bomb radiation, suggesting that various diseases among the A-bomb survivors, including cancer, develop in part from genetic alterations induced by radiation.

c). The molecular oncology/epidemiology study was initiated six years ago to elucidate possible unique molecular finger prints in cancers among A-bomb survivors. Technical problems in using formalin-fixed paraffin-embedded samples from the A-bomb survivors have been resolved. The molecular analyses of liver cancer and skin cancer are on going.

In addition to the above mentioned studies, new research areas have been opened up to understand the precise mechanisms of radiation-induced damage, which might be important in cancer development. It is now evident that alterations of cancer-specific genes, such as RET oncogene activation and BCR-ABL translocation, can be induced by radiation.

Program objectives

The survivors of the atomic bombings represent a population of individuals who have been exposed to a wide range of doses of ionizing radiation; therefore, the primary objective of RERF has been to ascertain the effects that might have been produced in the exposed individuals and their children as a result of exposure to A-bomb radiation, and to relate these changes to dose and to the subsequent health effects which may have occurred. Consequently, until recently, research at RERF has focused primarily on the long-term epidemiological studies of A-bomb survivors to ascertain morbidity and mortality of the exposed population, specific investigations on health-related effects that might be related to radiation exposure, and genetic studies to ascertain the mutation rate resulting from radiation exposure in the children of the survivors but clearly there is a need for molecular and cellular studies aimed at revealing the underlying bases of this morbidity and mortality. It is thus important to bear in mind that if the Foundation is to achieve

020 its goals it must necessarily maintain a balance between mechanistic studies aimed at
021 understanding the biological bases of radiation-induced changes and the statistical description of
022 risk. It behooves the Foundation, therefore, to establish a credible and strong program in
023 molecular and cellular research if the biological origin of radiation-related damage is to be
024 understood.

025
026 Accordingly, the mission of the Department of Radiobiology is to study the molecular
027 mechanisms of radiation-induced carcinogenesis in A-bomb survivors. We also believe that it is
028 our mission to clarify what the biological effects of radiation are on human health and why and
029 how disease is induced as a consequent process.

030 031 **Major projects in the next five years.**

032
033 In the coming 5 years, as we explain in the next several pages, some current studies will
034 be phased out, others will be continued, and new ones will be introduced. The determination of
035 the fate of these studies will be based on their relevance to several factors. Simultaneously the
036 department will concentrate its energy on three major core activities, namely, molecular
037 epidemiology, molecular oncology, and immunology.

038
039 The studies will be prioritized by the direct impact they are projected to have on these
040 three core fields. That is, the highest priority studies will be the ones that can potentially produce
041 supportive evidence for the radiogenic etiology of diseases occurring in the A-bomb survivors via
042 damage of key molecules and their pathways.

043 044 **A. Molecular epidemiology**

045
046 A major objective of the molecular epidemiological study is to identify radiation-induced
047 gene alterations in cancer and normal tissues of A-bomb survivors, and thereby to provide
048 significant insights into the molecular mechanisms of human radiation carcinogenesis and disease
049 development. To accomplish this goal, we will analyze cancer-associated genes such as
050 oncogenes and tumor suppressor genes in archival and surgical specimens of normal and tumor
051 tissues obtained from A-bomb survivors.

052
053 Molecular epidemiology at RERF combines powerful data analysis methods for revealing
054 trends in disease development among the A-bomb survivors with state-of-the-art techniques in
055 molecular biology. Such a partnership of disciplines can produce the first line of attack for
056 understanding the mechanisms behind the observed human diseases following exposure to the A-
057 bomb radiation. There are now many epidemiological studies demonstrating an effect of the A-
058 bomb on the survivors; and with these results are hypotheses that try to explain them. For
059 example one belief is that cancer incidence is heightened among the exposed because the radiation
060 inflicted damage to the DNA of cells led to the loss of function of some crucial genes that
061 controlled growth. But what are these genes? In which tissues are they most affected? Why does
062 sex, age, ATB, dose of exposure make a difference? There are no clear answers to these and many
063 other questions. Generation of some of these answers may help in the treatment and prevention
064 of diseases in numerous groups such as other radiation exposed people, chemically exposed
065 people, and cancer patients, as well as in the A-bomb population. But study of the A-bomb
066 survivor population, because of its size and because it and its tissues have been so well catalogued

3067
3068
3069
3070
3071
3072
3073
3074
3075
3076
3077
3078
3079
3080
3081
3082
3083
3084
3085
3086
3088
3089
3090
3091
3092
3093
3094
3095
3096
3097
3098
3099
3100
3101
3102
3103
3104
3105
3106
3107
3108
3109
3110
3111
3112
3113
3114
3115
3116
3117
3118
3119
3120
3121

and followed up for nearly a lifetime, will provide the best opportunities for such analyses.

The large repository of archival tissues makes possible extensive retrospective molecular epidemiological studies. As indicated in the following table, high priority studies will include those cases showing the highest relative risk with sufficient number of high dose, histologically verified samples such as the female breast, thyroid, and skin. Because analysis of these cancers, given that 33 of 43, 12 of 17, and 15 of 22 breast, thyroid, and skin cancers, respectively, are due to radiation, have the highest probability of producing the most statistically significant difference between the exposed and control groups.

Estimation of the cancer cases due to radiation

Cancer site	ERR 1 Sv	0.01 - 0.99 Sv			1.0 Sv			HV (%)
		mean dose	No. of cases	Fraction of cases due to radiation	mean dose	No. of cases	Fraction of cases due to radiation	
Female Breast	1.6	0.18	252	0.22	2.01	43	0.76	96.7
Thyroid	1.2	0.17	115	0.16	1.83	17	0.69	93.3
Skin	1.0	0.18	76	0.15	2.22	22	0.69	96.4
Bladder	1.0	0.16	108	0.14	1.63	7	0.62	82.9
Ovary	0.99	0.16	60	0.14	1.65	6	0.62	84.2
Colon	0.72	0.16	201	0.10	1.63	22	0.54	80.7
Liver	0.49	0.16	262	0.07	1.72	22	0.46	38.8
Stomach	0.32	0.16	1227	0.05	1.71	80	0.35	72.8
Prostate	0.29	0.16	56	0.04	1.61	5	0.32	85.7

HV: Histological verifications;

Mabuchi, et al., RERF CR3-91; Thompson, et al., RERF TR5-92

Core activities (Molecular epidemiology)

A-1. Oncogenes and tumor suppressor genes in A-bomb survivors with cancer (RP 7-92, 3-93, 7-93, 2-94):

Cancer development is believed to be a multi-step process. The steps are not known but major roles appear to be played by oncogenes and tumor suppressor genes. The former act to accelerate cell growth and the latter to suppress it. Radiation can potentially damage either or both which can lead to uncontrolled growth -- a hallmark of cancer. Such damage is presumed to be the key in the increased risk of various cancers in the survivors. One especially important gene to study is p53 because it is the most commonly mutated gene in human cancers suggesting that it is a major player in multi-step carcinogenesis. Differences in the frequencies of mutations or types of mutation between the exposed and unexposed are anticipated.

A-2. Tissue collection

The success of such studies depends heavily on our ability to obtain appropriate samples

22 from LSS cohort members who are diagnosed with cancer. It is possible to obtain
23 archival material through the tissue registries in Hiroshima and Nagasaki; however better
24 methods are needed to ensure the availability of the necessary materials from newly
25 diagnosed cases. To achieve this end RERF is seeking support from the local medical
26 community for the establishment of a community-wide tissue/DNA bank in Hiroshima.
27 This bank would maintain tissue specimens or preserved DNA that could serve as a
28 resource for all groups in Hiroshima engaged in studies of the molecular mechanisms of
29 carcinogenesis.

30
31 Tissues to be collected will have to have an associated RP describing their use. Once the
32 collected tissue samples are registered in the "tissue bank", they will be available for use
33 internally or by outside collaborators. Registration will include entry of the tissues into
34 a database that will catalogue and link them to relevant RERF cohorts.

35 36 A-3. *Molecular analyses*

37
38 The usefulness of preserved tissue specimens from A-bomb survivors has been
39 demonstrated by means of the PCR method. PCR is a method for the amplification of
40 DNA by over a million-fold. Thus PCR makes it possible to study the genes of A-bomb
41 survivor using microscopic quantities of archival tissues from as far back as 1950.

42 43 A-3-1. *Skin cancer (RP3-93):*

44
45 We have already prepared DNA from 60 tissue samples of skin cancer and are currently
46 analyzing the ras and p53 genes. We will continue this analysis and start an analysis of the
47 patched gene, which has been cloned and found to be frequently mutated in skin cancer.

48 49 A-3-2. *Liver cancer (RP2-94):*

50
51 In addition to skin cancer, molecular analyses of liver cancer (total sample number is 800)
52 are on going. Currently studies of mutation in the p53 tumor suppressor gene and
53 genomic integration of the hepatitis B and C viruses are being carried out. It may take two
54 more years to complete these analyses.

55 56 A-3-3. *Thyroid cancer (RP7-93):*

57
58 Thyroid cancer should also be analyzed at the molecular level since it is among the cancers
59 with the highest risk seen in the A-bomb survivors, implying that this cancer may be one
60 of the best candidates for the identification of an A-bomb radiation-induced unique
61 fingerprint, if such exists. Thyroid samples will be analyzed for aberrations in RET by
62 immunohistochemistry using monoclonal antibodies against the RET proteins, which is
63 not expressed in normal thyroid tissues.

64 65 A-3-4. *Female breast cancer (RP7-92):*

66
67 Breast cancer has one of the highest increased risks in the survivors. The risk is even
68 higher for those survivors exposed at a young age with an ERR at 1 Sv of 3.21 and 2.61

3169
3170
3171
3172
3173
3174
3175
3176
3177
3178
3179
3180
3181
3182
3183
3184
3185
3186
3187
3188
3189
3190
3191
3192
3193
3194
3195
3196
3197
3198
3199
3200
3201
3202
3203
3204
3205
3206
3207
3208
3209
3210
3211
3212
3213
3214
3215

for age ATB of 0 - 9 years and 10 - 19 years, respectively. Moreover, breast cancer is a potential familial cancer that may predispose some women to radiogenic breast malignancies. These studies will be complemented by research on the genetic background of cancer patients among the A-bomb survivors (see special research activity B). BRCA1 and 2 have so far shown the best prospects as genes in the cause of the disease.

Breast samples will be screened for BRCA1 mutations by immunohistochemistry since antibodies to detect mutations are commercially available.

A-5-5. Others

Salivary cancer is another important candidate for analysis at the molecular level, since it has been revealed recently that the ERR is 3.47 at 1 Sv which makes it the highest risk cancer among the survivors. Specific salivary gland cancer related genes are currently unknown. At present p53 may be the best candidate.

Special research activities (Molecular epidemiology)

Priority 1

B. Genetic background of cancer patients among A-bomb survivors

It is suspected that certain genetic backgrounds may be involved in radiation carcinogenesis. The genes involved in some cancer prone diseases, such as those associated with the recessively inherited ataxia telangiectasia (AT) and the dominantly inherited hereditary non-polyposis colon cancer (HNPCC), in which individuals who possess abnormalities in these genes have high susceptibility to radiation damage and high genetic instability, will be surveyed to define the involvement of genetic background in cancer development among A-bomb survivors.

Individuals who were exposed at young ATB and developed early breast cancer will have priority in the survey of such gene mutations. A strong association has been reported between radiation-induced chromosomal damage and breast cancer in cells from AT heterozygotes, and thus peripheral lymphocytes would seem a logical starting point in this screening activity. Screening will be done using available antibodies for the ATM and BRCA1 gene products. Suspect cases will then be molecularly analyzed at the gene level by sequencing. The total number of cases to be initially screened will be 200 breast cancer patients among the survivors. If mutations are detected, family members will be tested. This study will be an interdepartmental collaboration with the Departments of Clinical Studies, Epidemiology and Statistics.

Priority 2

C. Molecular analyses of non-cancer diseases in A-bomb survivors

Epidemiological studies are beginning to reveal increased risks in various non-cancer diseases such as myoma uteri, atherosclerosis and hyperparathyroidism among the A-

216 bomb survivors. It is expected that this trend will increase with the aging of the survivor
217 population. As the target genes become evident, molecular analyses will be required to
218 illuminate the mechanisms.

219
220 *C-1. Parathyroid disease*

221
222 In parathyroid disease one candidate gene is PRAD1. PRAD1 is a mutant gene caused
223 by a translocation of a gene associated with a cell growth regulating factor and the gene
224 that regulates parathyroid stimulating hormone expression. This will be a cooperative
225 study with the Department of Clinical Studies.

226
227 *C-2. Atherosclerosis*

228
229 In atherosclerosis one possibility is the ras oncogene. Screening will be conducted by
230 immunohistochemistry. This study will be in collaboration with the Department of Clinical
231 Studies.

232
233 **B. Molecular Oncology**

234
235 Molecular oncology is closely related to molecular epidemiology. Whereas the latter
236 produces trends of molecular changes in radiogenic cancers, the former provides the explanation
237 or mechanism for how these changes work to cause cancer. Such results will supply the direct
238 evidence for the carcinogenic effect of A-bomb exposure on the survivors. Knowledge of the
239 mechanism will allow improved management of exposure to ionizing radiation as well as provide
240 information in the treatment and prevention of related diseases.

241
242 As stated earlier, molecular epidemiology will provide much of the basis for other
243 molecular studies. To delve deeper into the mechanisms, more manipulative experiments will be
244 necessary. Manipulations will include working with live human cells from the A-bomb survivors,
245 other human populations, and with human tissues in animal models, in that order of priority. Live
246 cells are necessary to recreate as accurately as possible the events and responses of the cells in the
247 survivors after A-bomb exposure. In the light of recent advances and the relatively large radiation
248 effects for breast and thyroid cancer, studies of tissues from breast and thyroid cancer cases
249 among the high dose survivors have the potential to yield important results. It may also be useful
250 to supplement the search for characteristic gene alterations in cancer cells with a search for
251 evidence of specific mutations associated with cancer development in the blood of cancer-free
252 survivors.

253
254 The Blue Ribbon panel emphasized the necessity to determine the shape of the dose-
255 response curve for radiation carcinogenesis at low doses of radiation. The recommendation
256 suggested initiation of a molecular oncological study to clarify the molecular mechanisms in
257 human radiation carcinogenesis.

258
259 **Core activities (Molecular oncology)**

260
261 *A. Alterations in cancer-associated genes among A-bomb survivors*
262

3263
3264
3265
3266
3267
3268
3269
3270
3271
3272
3273
3274
3275
3276
3277
3278
3279
3280
3281
3282
3283
3284
3285
3286
3287
3288
3289
3290
3291
3292
3293
3294
3295
3296
3297
3298
3299
3300
3301
3302
3303
3304
3305
3306
3307
3308
3309

It was observed in the recent somatic mutation study that the GPA mutation frequencies increased with increasing A-bomb radiation doses, and the dose-response curve is very similar to that for solid tumor incidence among the A-bomb survivors. We can expect that since radiation may cause DNA damage randomly in the cell, cancer-related gene alteration could have been induced and remained in the cells of the A-bomb survivors. Based on the multi-step carcinogenesis theory, it may be suspected that cells carrying cancer-related gene alterations and proteins exist in blood cells among the A-bomb survivors.

A-1. Detection of the cells carrying mutations

Recent advances in flow cytometry make it possible to analyze translocation of cancer-associated genes by in-cell PCR methods using fluorescent primers. BCR-ABL and Bcl2 translocations are both associated with blood malignancies and can be detected in peripheral blood lymphocytes by this method.

Newly developed antibodies against oncogenes and tumor suppressor gene products will be used to detect cells carrying cancer-associated gene alterations in the blood among A-bomb survivors. This technique can demonstrate the existence of mutant gene products or changes in levels of normal gene products which may be especially pertinent in cases of deletion of tumor suppressor genes like p53 and possibly the ataxia telangiectasia mutated (ATM) gene. The projected number of samples to be studied is a 300 (control and high risk group). These approaches could provide meaningful information for understanding the molecular mechanisms of human radiation carcinogenesis and cancer risk estimation.

Special research activities (Molecular oncology)

Priority 1

B. Human radiation carcinogenesis (RP 18-81):

Strategically, not only are studies directly looking at tissues from the A-bomb survivors important, but studies taking advantage of experimental models could be very helpful in interpreting effects on the survivors. In the experimental system we have developed, we can examine the first and consequent events occurring in the cell at the cellular and molecular levels which may have crucial roles in human carcinogenesis.

B-1. Models

The severe combined immunodeficient (SCID) mouse-human chimera makes it possible to study radiation effects on humans in vivo, and thereby provide more relevant and meaningful information than those obtained in vitro or from other non-human animal models. We have already established a transplantation system of normal human tissues (skin, intestine, thyroid and bone marrow) to SCID mice which preserves in situ histology, structure and function. These models will be improved so that they are as close to the human situation as possible and will be applied to the studies on radiation response (see

310 B-2) and radiation carcinogenesis (see B-3) described below.

311
312 *B-2. Radiation Response*

313
314 We will analyze cellular and molecular changes in human tissue/cell after radiation
315 exposure, especially at low doses. This system will enable us to follow the various
316 molecular changes in vivo in human tissues following irradiation. For example, this model
317 demonstrated the dose-response and cellular mechanism of human radiation-induced
318 epilation, which were not clear from the survivor study. Preliminary findings using the
319 SCID-hu intestine model suggest that human crypt stem cells in the intestine are extremely
320 resistant to radiation-induced apoptosis in comparison to mouse stem cells.

321
322 *B-3. Radiation Carcinogenesis*

323
324 The approach will make possible studying the process of carcinogenesis at the molecular
325 level and to specify radiation specific gene alterations which induced cancers in the A-
326 bomb survivors.

327
328 *B-3-1. Thyroid cancer*

329
330 We established a model of SCID-hu mice with human thyroid tissue, in which the normal
331 histological features of the human thyroid can be maintained in the mammary fat pads of
332 SCID mice for as long as 1 year. Using this model we will attempt to induce thyroid
333 cancer by radiation. Preliminary data indicate that high-dose X-irradiation induces RET
334 inversions in thyroid grafts, which have often been observed in the thyroid papillary
335 cancers and the childhood thyroid cancer of Chernobyl victims. Furthermore, since the
336 RET inversions were found to be sustained as long as 3 months in the grafts, we will
337 follow-up the development of thyroid cancer in the SCID-hu mice.

338
339 *B-3-2. Skin cancer*

340
341 We have already established a SCID-hu mouse model for the analysis of human epilation
342 by implanting human skin. This model will also be applied to human radiation-induced
343 carcinogenesis. This project, unlike the thyroid study where no other laboratory has
344 successfully maintained human tissues in SCID, can be a collaboration with outside
345 researchers such as Professor Taisei Nomura of Osaka University, because his laboratory
346 was the first to succeed with a SCID-hu skin model.

347
348 **Priority 1**

349
350 *C. Radiation-susceptibility of somatic cells in radiation carcinogenesis (RP 7-87):*

351
352 It is still unclear whether interindividual variation exists in the susceptibility to radiation,
353 especially in radiation carcinogenesis. Individual variation in susceptibility to radiation
354 carcinogenesis is believed to be partly due to a difference in cellular responses to ionizing
355 radiation.
356

3357 For analysis of interindividual variation in cellular responses, we will establish assay
3358 systems using molecular and flow cytometric techniques for the quantitative analysis of
3359 radiation-induced physiological and biochemical changes in key molecules responsible for
3360 cell apoptosis, signal transduction, and cell cycle regulation such as in ATP, oxygen
3361 radicals and protein phosphorylation.

3362
3363 These measurements will be used to evaluate interindividual variation in 100 non-cancer
3364 and 100 cancer patients among A-bomb survivors with the same exposure dose. This will
3365 be a collaborative effort with the Departments of Clinical Study, Epidemiology and
3366 Statistics.

3367

3368 C. Immunology

3369

3370 A major objective of the immunological study is to demonstrate the late effects of A-bomb
3371 radiation exposure and the combined effect of radiation exposure, age and sex on the
3372 hematolymphoid system and to identify the relationship between altered immune function and
3373 radiation-related disease, especially cancer. A-bomb radiation-induced alterations in the immune
3374 system may have caused the development of cancer. To achieve this objective we plan to
3375 continue our studies of the features and mechanisms of radiation-induced disorders in the
3376 hematolymphoid system at the cellular and molecular levels. These studies include radiation
3377 effects on the distribution of T-cell subsets in the survivors and of radiation effects on endocrine
3378 and hematopoietic growth factor levels. The survey of immune functions in A-bomb survivors
3379 will contribute to the health monitoring of the survivors.

3380

3381 Core activities (Immunology)

3382

3383 *A. Disorders in the hematolymphoid system of A-bomb survivors (RP 3-87, 7-89, 2-90,*
3384 *1-93):*

3385

3386 The functionality of the hematolymphoid system is a key measure of the ability of A-bomb
3387 survivors to respond to infectious disease. Abnormalities in this system also lead to
3388 carcinogenesis and autoimmune disease. Aging, sex and radiation exposure affect immune
3389 competence, altering lymphocyte subsets in their number and in their differential
3390 responsiveness when challenged by various stimuli. Therefore, study of the
3391 hematolymphoid system is crucial to assessing the radiation-induced effects that may
3392 affect the long-term health of the survivors.

3393

3394 *A-1. T-cell (RP 3-87, 1-93):*

3395

3396 Since our previous studies demonstrated age-related dysfunctions of T cells in the high
3397 dose exposed, we should focus on the cellular and molecular mechanisms of disorders in
3398 T-cell differentiation and function. One of the approaches is the analysis of T-cell
3399 receptor (TCR) repertoire in A-bomb survivors, which is currently underway and will be
3400 finished within FY96. Another approach is to analyze helper T-cell differentiation into
3401 two functionally different subsets, Th1 and Th2, which are believed to have different roles
3402 in immunity to pathogens and malignant cells. Th1 helper T cells are mainly involved in
3403 cellular immunity; whereas Th2 cells are involved in humoral immunity. Our hypothesis

404 is that the balance between these two subsets is altered in the exposed. These subsets will
405 be analyzed for about 1,000 Hiroshima survivors by flow cytometry using fluorescence-
406 labeled antibodies to interferon gamma and Interleukin (IL)-4 which are specifically
407 expressed in Th1 and Th2 cells, respectively. This study will take about 3 years.
408 Expression of cytokines and other functional molecules in T-cells will be analyzed at the
409 single cell level by using a combination of PCR and cell sorting techniques, which have
410 been established in our department.

411
412 *A-2. B-cell and stem cell (RP 3-87, 7-89):*

413
414 As previously reported, white-blood cell production including B-lymphopoiesis is
415 significantly increased with radiation dose, especially in female survivors. We have also
416 observed a dose-dependent increase in hematopoietic stem cell functions in female A-
417 bomb survivors. Based on these findings, we should focus on the analysis of the
418 molecular mechanism of radiation-associated hyperfunctions of hematopoietic stem cells.
419 We will measure some hematopoietic factors such as stem cell growth factor and IL-6,
420 both associated with white-blood cell production and B-lymphopoiesis. It has been
421 suggested by previous mouse studies that the endocrine system such as sex hormones
422 (estrogen) is involved in the control mechanism of hematopoiesis. It was proposed that
423 the decreased level of estrogen after menopause enhances the production of interleukin
424 6 and osteoclasts and thereby causes osteoporosis in female. Based on these findings, we
425 will compare the onsets of menopause and these hematopoietic growth factors for about
426 500 female survivors. This will take about 2 years. This study will be in collaboration with
427 the Department of Clinical Studies.

428
429 *A-3. Blood cell preservation (RP 2-90):*

430
431 To ensure that appropriate materials will be available for future studies of the late effects
432 of exposure to A-bomb radiation, and to allow the exploitation of potential future
433 technological advances and scientific discoveries, we are cryopreserving live blood cells
434 from AHS participants in Hiroshima and Nagasaki. From 1990 to 1996, (3 AHS cycles),
435 lymphocytes and granulocytes from 4,420 Hiroshima and 3,766 Nagasaki survivors were
436 cryopreserved. We will continue this effort to complete all AHS participants. In the near
437 future, retrospective study of immunological functions using these cryopreserved materials
438 will be possible for the survivors who eventually develop cancer or other disease.

439
440 **Special research activities (Immunology)**

441
442 **Priority 1**

443
444 *B. Clonal expansion (RP 3-87, 7-89, 1-93):*

445
446 *B-1. Mutant stem cells*

447
448 After the atomic bombing, the number of hematopoietic stem cells decreased by cell killing
449 and bone marrow death occurred in many survivors. Several months after the bombing
450 the number of these cells should have returned to the normal level. Clonal expansion of

3451 stem cells should have been involved in this recovery process in many survivors. We will
3452 focus our efforts on clonal expansion of hematopoietic stem cells carrying mutations and
3453 chromosome aberrations. So far two such cases have been documented by mutation and
3454 cytogenetic markers; further study is needed to illustrate that clonal expansion occurs as
3455 a result of A-bomb exposure. We will survey such cases using somatic mutations in blood
3456 cells (T-cells and granulocytes) as a marker. Stem cell expansion will also be analyzed at
3457 the molecular level for CD34⁺ cells isolated from survivors' peripheral blood by a cell
3458 sorter. This work will be in collaboration with the Cytogenetics Laboratory.

3459

3460

B-2. Memory T cells

3461

3462

3463

3464

3465

3466

3467

3468

3469

3470

3471

3472

Priority 1

3473

3474

C. Immunity to tumor-associated viruses in A-bomb survivors

3475

3476

3477

3478

3479

3480

3481

C-1. Hepatitis C virus (HCV)

3482

3483

3484

3485

3486

3487

3488

3489

3490

3491

3492

3493

C-2. Epstein-Barr Virus (EBV)

3494

3495

3496

3497

The Epstein Barr virus (EBV) is another candidate to be studied because our previous study demonstrated a dose-dependent increase in the level of anti-EBV antibodies. Recent reports suggest the possible involvement of EBV infection in stomach cancer

498 development. Therefore, alteration of immunity against EBV in the survivors may be
499 related to radiation-induced stomach carcinogenesis. We will measure lymphocyte
500 response against whole EBV in culture for the same subjects as in the HCV studies.
501 Recently developed PCR methods for measuring the frequency of EBV-infected B-
502 lymphocytes in peripheral blood will also be applied in these 1,000 subjects.
503

504 Priority 2

505 *D. Somatic mutations (RP 7-88):*

506
507 As mentioned in the response to the recommendations of the Blue Ribbon Panel, the
508 somatic mutation studies seem to have reached a logical end, because many of the somatic
509 mutation assays are not particularly valuable dosimeters for A-bomb survivors. However,
510 since many scientists still request RERF to measure mutation frequencies in exposed
511 people, maintenance of the mutation assays, albeit at a much reduced level, is necessary
512 for international collaborations. Also, these assays are useful in the assessment of various
513 aspects of aging and cancer risk.
514

515 *D-1. Follow up study (RP 7-88):*

516
517 We will follow-up cancer incidence and life span for the survivors (n=2,000), whose GPA
518 mutation frequencies have been measured to determine the relationship between somatic
519 mutation and cancer risk or aging. This study will be carried out at a lesser effort than in
520 the past.
521

522 Priority 3

523 *E. Immunity to oncogene products in A-bomb survivors*

524
525 Recent progress in tumor immunology allows us to assess lymphocyte reactivity to the
526 products of cancer-associated genes such as p53 and ras. Such tumor specific immunity
527 of T-cells may be disordered in the exposed. Proliferative response of T-cells against a
528 mixture of peptide fragments of p53 gene products will be measured for about 1,000 A-
529 bomb survivors, the same subjects as in HCV studies for 4 years. Furthermore, we will
530 explore natural killer cell functions to autologous mutant cells lacking the expression of
531 a single HLA class I allele as a model for natural immunity to transformed cells at an early
532 stage of cancer development.
533

534 *F. Somatic mutations among the in-utero exposed A-bomb survivors*

535
536 As yet only a very limited amount of information on the occurrence of somatic mutations
537 among the in utero exposed is available and it is not clear whether they will or will not
538 exhibit a greater sensitivity to ionizing radiation as reflected in an increased frequency of
539 mutation in comparison with the exposed A-bomb survivors. It should be emphasized
540 that, although the fraction of the in-utero exposed to more than 0.1 Sv is 13.9 % of the
541 3,289 RERF cohort (*in utero* mortality, Clinical, and LSS), it is important to ascertain
542 whether the mutation frequencies are different from those of the exposed. This project
543
544

3545
3546
3547
3548
3549
3550
3551
3552
3553
3554
3555
3556
3557
3558
3559
3560
3561
3562
3563
3564
3565
3566
3567
3568
3569
3570
3571
3572
3573
3574
3575
3576
3577
3578
3579
3580
3581
3582
3583
3584
3585
3586
3587
3588
3589

is expected to be finished within four years.

Molecular and cellular biology is a rapidly moving field which requires constant upgrading of technique. For the department of Radiobiology to maintain pace with the rest of the scientific world, new methods of analysis have to be developed as well as introduced.

Establishment of in-cell PCR will allow careful scrutiny of individual cells for studying EBV integration frequency or Bcl2 and BCR-ABL translocation in blood samples, for example. Differential display is a potentially powerful technique that may reveal differences in transcription of various genes between tumor and normal cells. The tumor and normal parts of archival tissue sections can be separated and compared for changes that may have occurred in cancer related genes as a result of A-bomb exposure. A similar comparison technique is comparative genomic hybridization (CGH) which can scan the entire genome for possible changes, such as relatively large (10^7 bp) deletions, in cancer DNA versus normal DNA.

The introduction of new technologies is also important as new problems arise. After arrival of the new confocal microscope system, we will be able to study various new facets of radiation effects on cellular function and cellular structure. New studies that can be initiated are alterations of signal transduction in radiation induced tumors or molecular analysis of a single or a few cells from surgical and paraffin embedded archival tissues of the survivors. Such abilities will help to increase sensitivity and resolution for detection of changes in tissue samples.

Finally, it should be noted that most of the studies in the Department of Radiobiology cannot be performed without collaboration with the Departments of Clinical Studies, Genetics, Epidemiology, and Statistics. In view of RERF's limited resources it is important for us to develop a general research plan that defines specific projects that can be done at RERF and projects on which collaboration is important and establishes mechanisms for seeking this collaboration and, where necessary, support.

Project time lines

	1997	1998	1999	2000	2001
a) Genetic background	⇒	⇒	⇒	⇒	⇒
b) Non-cancer diseases			⇒	⇒	⇒
c) Human carcinogenesis	⇒	⇒	⇒	⇒	⇒
d) Susceptibility to radiation	⇒	⇒	⇒	⇒	⇒
e) Clonal expansion	⇒	⇒	⇒		
f) Viral immunity	⇒	⇒	⇒	⇒	
g) Somatic mutations	⇒	⇒	⇒	⇒	⇒
h) Immunity to oncogene products		⇒	⇒	⇒	⇒
i) Somatic mutation in-utero	⇒	⇒	⇒	⇒	

Personnel requirements

The present staff is barely adequate to conduct the studies in radiobiology outlined above.

In order to perform the studies, the following are needed;

1. a permanent researcher who can conduct molecular and pathological analysis of cancer is essential for molecular epidemiology because identification of tumors is the *sine qua non* of the study.

2. allocation of the proper support staff to the molecular epidemiology program for tissue collection.

Fiscal Year	Present	1997	1998	1999	2000	2001
Research Associates						
Immunology	5	5	4	4	4	4
Molecular epidemiology and oncology	5	6	7	7	8	8
Technicians						
Immunology	10	7	7	5	5	5
Molecular epidemiology and oncology	3	7	8	10	10	10
Technician helpers						
	2	2	2	2	1	1
Clerks						
	5	5	4	4	4	4
Total	30	32	32	32	32	32

Space requirements (m²)

Fiscal Year	(1996)	1997	1998	1999	2000	2001
Bench Research						
Immunology	292	292	292	292	292	292
Molecular epidemiology and oncology	91	200	200	200	200	200
Support Space and Offices	97	157	157	157	157	157

Room G105 (temporarily used by the department of radiobiology; 53m²) is not included.

Equipment budget

See Annex J.

Department of Statistics

The Department of Statistics provides expertise to all of the other research departments in the matter of study design, data analysis, and the construction of databases.

3636
3637
3638
3639
3640
3641
3642
3643
3644
3645
3646
3647
3648
3649
3650
3651
3652
3653
3654
3655
3656
3657
3658
3659
3660
3661
3662
3663
3664
3665
3666
3667
3668
3669
3670
3671
3672
3673
3674
3675
3676
3677
3678
3679
3680
3681
3682

Program objectives

The Department of Statistics plays an important role in virtually all RERF research activities. Collaboration and the provision of guidance on statistical analyses and data management to researchers throughout RERF is a major function of the Department of Statistics. An equally important activity of RERF statisticians involves methodological research aimed at improved understanding of the statistical questions raised by the RERF data and the development and implementation of improved statistical methods for analyses of the broad range of data arising from RERF studies. The Department is also playing a leading role in the design of modern databases to make the RERF data more accessible to all RERF researchers. Finally, the Department of Statistics is responsible for management of the dosimetry data and the computation of individual dose estimates.

Major research activities in the next five years

A. Core activities

The core research and analysis activities carried out by the Department of Statistics focus largely on the need for continued analysis and improved presentation of the RERF epidemiological, clinical, and laboratory data. In addition to direct collaborations with other RERF researchers, RERF statisticians are actively involved in research that leads to the development and implementation of statistical methods applicable to the RERF data.

Preparation of the RERF reports on the epidemiologic follow-up of the survivors and their children require significant contributions from both the Departments of Epidemiology and Statistics. As a consequence of the need for more sophisticated statistical analyses and a shortage of epidemiologists, statisticians have taken increasingly central roles in work on LSS reports and other epidemiological studies at RERF. Because of staff reductions in the Department of Statistics we have had to devote an increased proportion of our resources to the epidemiological studies, which has made it difficult for us to address the statistical needs of RERF's clinical and laboratory programs. Over the next few years it will be necessary to maintain (or even slightly increase) our current level of support for the epidemiologic studies, but it is especially important for us to provide a greater level of support for the statistical needs of RERF's clinical and laboratory research programs.

It should be stressed that the work of the department is largely determined by the nature of statistical issues that arise in the course of RERF research. Thus, other than stating that RERF research will continue to be a source of interesting and challenging statistical problems it is difficult to make specific predictions about future statistical research at RERF.

Priority 1

A-1 Assessment of mortality and cancer morbidity for the LSS, in-utero, and F₁ cohorts

A significant portion of the work of RERF statisticians is concerned with ongoing analyses of the LSS follow-up data. This work is carried out in close collaboration with members of the Departments of Epidemiology. Over the next year we plan to complete the final

583 part of LSS Report 12 dealing with noncancer mortality for the period from 1950 through
584 1990. Within the next three years we intend to produce general summary reports
585 extending mortality data through 1995 and tumor registry-based cancer incidence data
586 through at least 1992. In preparing these updated reports we hope to develop methods
587 for merging the mortality and incidence reports. Members of the in-utero and F₁ cohorts
588 are now reaching ages at which mortality and cancer incidence rates increase markedly.
589 A series of reports on mortality and cancer morbidity among the in-utero exposed will be
590 completed in the coming year. Work on similar reports for the F₁ cohort is underway.
591 It is likely that the in-utero findings will be updated during the coming five years since the
592 number of deaths and cancer cases can be expected to increase rapidly with the
593 lengthening follow-up.

594
595 RERF statisticians are also taking a leading role in the analysis and preparation of the
596 reports on cancer risks based on the results of detailed site-specific pathology reviews,
597 including those of the central nervous system (CNS tumors), liver cancer, and thyroid
598 cancer. An important part of the department's work on these studies concerns the
599 development of standards for the management of data arising from these site-specific
600 studies in order to ensure that the findings are reflected in the tumor registry and are
601 available for use in future analyses.

602
603 While RERF statisticians, together with members of the Departments of Epidemiology,
604 plan, carry out and report the results of the analyses of these data, the statisticians' most
605 important contributions concern the development and application of analytical methods
606 and software needed to analyze and summarize these data and the development of
607 procedures to address specific problems which arise in the course of work with the RERF
608 data. These problems include: the development of a general class of statistical models that
609 can be used for the description of and inference about patterns in the excess relative risks
610 and excess absolute rates associated with radiation exposure; methods for the joint
611 analysis of site-specific risk data; the development of procedures to adjust for biases in
612 risk estimates caused by random errors in individual dose estimates; development of
613 methods to determine the impact of death certificate misclassification on cancer and
614 noncancer risk estimates; the development of methods to adjust for the impact of
615 migration in analyses of the LSS cancer incidence data; statistical issues related to RBE
616 estimation from the LSS data; and the development and application of "mechanistic"
617 models for radiation carcinogenesis.

618
619 As noted below, an effort is now underway to incorporate the data obtained from the
620 various mail surveys into the RERF research database. As this effort progresses it will
621 become possible to make more effective use of these data in analyses of confounding and
622 effect modification in RERF's epidemiological studies.

623 624 *A-2 Analysis of Clinical Studies Data*

625
626 The clinical data are an important and underutilized RERF resource. The Department of
627 Statistics role in making more effective use of these data includes the application of recent
628 developments in the analysis of complex longitudinal data sets to the RERF data and the
629 development of more effective ways to store and access these data. While some progress

3730
3731
3732
3733
3734
3735
3736
3737
3738
3739
3740
3741
3742
3743
3744
3745
3746
3747
3748
3749
3750
3751
3752
3753
3754
3755
3756
3757
3758
3759
3760
3761
3762
3763
3764
3765
3766
3767
3768
3769
3770
3771
3772
3773
3774
3775
3776

on analysis of these data has been made in recent years, there is a need to devote more of the departmental resources to the issues related to the clinical data. An area of particular importance over the next few years concerns studies that integrate the epidemiological and clinical data related to the finding of an association between radiation exposure and noncancer mortality. These analyses will undoubtedly lead to challenging statistical problems.

A-3 Analyses of Laboratory Data

The investigations carried out by the staff of the Departments of Genetics and Radiobiology often require statistical collaboration for planning and analysis. At the present time statisticians are actively involved in comprehensive final analyses of the conventional chromosome aberration data, assessment of the data on various somatic mutation assays, and the provision of advice and support for a broad range of fairly routine statistical analyses carried out by the researchers in the laboratories. Analyses of the laboratory data present a number of challenging statistical problems including issues related to over-dispersion (due to dosimetry error or unmeasured covariates) and correlated data. Over the next few years there will be a need for significant additional statistical support for the analyses of the 2-DE DNA study data (pattern recognition), for the planning and analysis of molecular epidemiological studies, and for work on the comparison of various potential biodosimeters.

A-4 Database development

The Department of Statistics has taken a leading role in the design and documentation of the new RERF research database. While the ITD is responsible for the actual implementation of the database, much of the design work involves issues of direct concern to the Department of Statistics. These issues include clarification of study population definitions, specification of contents of and relationships between individual database tables, and the identification of appropriate data sources, and, in some cases, the development of new coding schemes for specific items. At the present time the RERF research database includes most of the epidemiological follow-up data and basic dosimetry data for the major cohorts. Current efforts are focused primarily on the integration of the mail survey, clinical follow-up data, laboratory data and detailed dosimetric data (including shielding history and acute effects data), into the RERF research database.

A-5 Dosimetry (Work on dosimetry is covered by RP 18-59, Shielding Survey and Dosimetry Study.)

The Department of Statistics is responsible for management of the basic dosimetry data and for the computation of dose estimates for individual survivors. Current work includes the development of an expanded roster of persons whose exposure status is of interest to RERF (in addition to LSS cohort members, this roster includes mothers of in-utero cohort members and parents of F₁ cohort members) and the restructuring of the shielding history and acute effects data. As a part of this effort we are also working on an updated description of cohort definitions and dose estimation procedures. In the decade since the introduction of DS86 a number of questions have been raised about certain aspects of

777 current survivor dose estimates (including errors in Hiroshima neutron estimates,
778 problems with gamma doses levels in both cities, and possible biases in estimated doses
779 for Nagasaki factory workers). RERF has been asked to develop and maintain a database
780 related to physical measurements as a part of the ongoing reassessment of DS86. It now
781 appears likely that this reassessment will lead to the introduction of a new dosimetry
782 system within the next five years. Even though current efforts to reorganize RERF's basic
783 dosimetric data will make it easier to implement a new dosimetry system, the introduction
784 of the new system will still require significant effort on the part of staff from the
785 Department of Statistics and the ITD.

786 787 **B. Special research activities**

788
789 Most of the work of the Department of Statistics arises from projects undertaken in
790 relationship to our core activities which revolve around collaborations with researchers from other
791 departments. At this time there are only five time-limited special research projects and one
792 outside contract for which the department has primary responsibility. While the department will
793 continue to deal with new statistical problems that arise in the course of work related to our core
794 activities, there is little likelihood that department members will initiate new research protocol-
795 based projects in the coming years.

796 797 **Priority 2**

798 799 *B-1 Blood groups in Adult Health Study and in-utero ATB subjects, Hiroshima and* 800 *Nagasaki (RP 63-63):*

801
802 The study is intended to examine blood group frequencies in the LSS and to investigate
803 the relationship between serological type and mortality or morbidity for selected diseases.
804 Following a long period of inactivity, a manuscript describing blood group frequencies for
805 members of the AHS and F₁ cohorts has been prepared. Over the next two years we hope
806 to work with members of the Departments of Clinical Studies to plan and conduct
807 analyses of the relationship between blood group and cause-specific mortality.

808 809 *B-2 Cancer studies of occupational and environmental radiation exposure in the Mayak* 810 *Nuclear Facility and the surrounding areas in the South Urals, Russia (NIH Contract* 811 *N01-CP-51025, Principal Investigators: Preston DL, Mabuchi K, Koshurnkova NA,* 812 *Kossenko MM).*

813
814 When the extent of radioactive contamination at the Mayak Nuclear Facility and the
815 surrounding area became clear, the Foundation was approached to assist in the design and
816 implementation of studies to determine the health consequences of exposure to this
817 contamination. This contract supports joint work with the US National Cancer Institute
818 and scientists at the Branch Laboratory 1 (Ozersk) and the Urals Research Center for
819 Radiation Medicine (Chelyabinsk) in the Russian Federation on improvements to the
820 epidemiological follow-up data risk estimation procedures for the Russian studies. It is
821 hoped that by the end of this three year contract in September 1998 we will be able to
822 complete some solid cancer and leukemia risk assessments for the Mayak worker and
823 Techa River populations. During the first year of the contract, significant progress has

3824 been made on improvements in the quality of the follow-up data for these cohorts. A
3825 paper describing the nature of the Techa River cohort just prior to the beginning of the
3826 NCI-RERF collaboration including comparison of the demographics of the LSS and
3827 Techa River cohorts has been completed.
3828

3829 **Priority 3**

3830
3831 *B-3 Radiation effects on the brain and central nervous system (RP 5-87 and RP 8-89).*
3832

3833 One of these studies is intended to search for physical evidence of radiation-related
3834 damage to the brain among in-utero survivors (RP 5-87) based on magnetic resonance
3835 imaging of a small number of in-utero survivors. The second (RP 8-89) was to make use
3836 of autopsy material to investigate the late effects of A-bomb exposure on aging of the
3837 central nervous system and to obtain basic data which would improve understanding of
3838 the anatomic and functional brain changes that may have resulted from atomic bomb
3839 exposure. There has been no significant activity associated with either of these projects
3840 for several years. Without the active involvement of physicians, pathologists and others
3841 responsible for obtaining the cooperation of the in-utero survivors for the first study or
3842 the specimens required for the second, these studies cannot continue. With the retirement
3843 of the Assistant Department Chief, Masanori Otake, earlier this year, no one at RERF is
3844 actively involved in either of these projects. It is unlikely that there will be any progress
3845 on either of these projects in the next five years. In view of the current level of support
3846 for these projects and the needs of other projects, it would probably be best to terminate
3847 them.
3848

3849 **Personnel requirements**

3850
3851 The number of research scientist positions has decreased from 10 to 7 as a result of
3852 retirements and the general cutbacks that have taken place over the past few years without any
3853 diminution in the workload. It is likely that we will lose another statistician within the next few
3854 months. These losses have seriously reduced our ability to meet RERF's needs for statistical
3855 support in all areas, but particularly with regard to analysis of the clinical and laboratory data.
3856 Recently we have been able to take some steps to deal with the impact of these losses. These
3857 steps include recruiting (through NAS) one or two additional statisticians, seeking approval of
3858 the Executive Committee to hire an experienced statistician to work part time under contract on
3859 problems related to analysis of the AHS clinical and laboratory data, and contacting statisticians
3860 at various Japanese institutions to solicit support (and candidates) for post-doctoral training in the
3861 Department of Statistics. Prior efforts to recruit qualified Japanese statisticians have been only
3862 moderately productive and as a consequence the Department has had and continues to have a
3863 need for a high proportion of non-Japanese statisticians, who tend to turnover frequently. This
3864 turnover gives us the flexibility to seek statisticians who can meet current needs, but it also means
3865 that we need to have the ability to employ qualified statisticians in anticipation of all upcoming
3866 losses.
3867

3868 In view of the nature of the department's work the table below is designed to reflect
3869 personnel needs associated with each of the core activities.
3870

Hiroshima and Nagasaki

Area	Fiscal Year					
	Current	1997	1998	1999	2000	2001
<i>Research Associates</i>						
Epidemiologic Studies	3	3.5	3.5	4	4	4
Clinical Studies	1	2	2.5	2.75	2.75	2.75
Laboratory Studies	1	1.5	2	2.5	2.5	2.5
Database design	1	1	0.5	0.25	0.25	0.25
Dosimetry	1	1	1.5	0.5	0.5	0.5
<i>Total</i>	7	9	10	10	10	10
<i>Research Assistants</i>						
Epidemiologic Studies	0.75	0.75	0.75	0.75	0.75	0.75
Clinical Studies	0.5	0.5	0.5	1	1	1
Laboratory Studies	0.25	0.25	0.5	0.5	0.75	0.75
Database design	1	1	0.75	0.5	0.25	0.25
Dosimetry	0.5	0.5	0.5	0.25	0.25	0.25
<i>Total</i>	3	3	3	3	3	3
Clerical	2	2	2	2	2	2

Space requirements (m²)

The space requirements for the Department of Statistics are summarized in the following table. The totals do not include hallways.

Area	Fiscal Year					
	Current	1997	1998	1999	2000	2001
Office	125 [†]	142	142	142	142	142
Clerical Support	18	18	18	18	18	18
Other Support [‡]	57	40	40	40	40	40
<i>Total</i>	200	200	200	200	200	200

† in square meters

‡ Includes half of the area of the conference, computer, and copier rooms which are shared with the Department of Epidemiology and of the visiting scientists office, which is also shared with Epidemiology.

Equipment budget (x ¥ 1,000)

Computer hardware and software are the primary equipment used by the staff of the Department of Statistics. Because of the size and complexity of many RERF data sets it is important for the statisticians to have access to versatile and powerful computers. In preparing these budget estimates a three year schedule for the replacement of computers and a continuing need to expand network storage capacity have been assumed. It has also been assumed that it will be necessary to replace or upgrade other hardware and software on a continuing basis. It should be noted that, as in recent years, Department of Statistics computers that are replaced can usually be used by other departments with less demanding computational needs for additional years. The following table presents estimates of the total costs for computer equipment and software for the Department for the next five years.

3921	Fiscal Year					
	Budget Category	1997	1998	1999	2000	2001
3922	Replacement hardware and software	4,000	4,500	4,215	4,715	4,400
3923	New hardware and software	1,075	775	1,195	875	1,275
3924	Total	5,075	5,275	5,410	5,590	5,675

3925
3926
3927
3928
3929
3930
3931

Since this hardware and software is used for both and administrative purposes, it seems reasonable to assume that some fraction of these costs should be considered as administrative rather than research expenses. Based on the recommendations formulated by the ITD, the following table shows the research portions of the estimated equipment budget.

3932	Fiscal Year					
	Budget Category	1997	1998	1999	2000	2001
3933	Replacement hardware and software	2,700	3,050	2,850	3,220	2,970
3934	New hardware and software	950	650	1,040	720	1,110
3935	Total	3,650	3,700	3,890	3,940	4,080

3936
3937
3938
3939

SUPPORTING SERVICES

3940
3941

Department of Information Technology

3942
3943

Program objectives

3944
3945
3946
3947
3948
3949
3950
3951
3952
3953

The Information Technology Department (ITD) provides the necessary computing and data tools to all RERF departments to support the Foundation's research and administrative activities. Responsibilities are to maintain computer systems and software, manage the RERF research database, provide user support, and introduce new technology as appropriate to meet evolving needs. Although located in Hiroshima, planning, development, and support work extends to the Nagasaki Laboratory, and ITD coordinates activities with the two Nagasaki computer staff in the Department of Epidemiology. ITD also is responsible for operation of the library in Hiroshima, another information service at RERF. The Hiroshima library provides support to the library in Nagasaki as well.

3954
3955
3956
3957
3958
3959
3960
3961

To ensure that computing resources remain relevant and to play a leading role in ascertaining technology and user support needs, a key aspect of ITD activities is to maintain effective liaison with all RERF departments. ITD also must seek collaboration to utilize the technical skills of staff in other departments and that outside RERF to complement and supplement technical capabilities within the department. These are extremely important for making effective progress on multidisciplinary projects such as those involving database design, systems development, and support of laboratory research projects.

42 Because many of the activities undertaken by ITD reflect its technical support role in
43 research activities, ITD project content within some of the core activity categories will change as
44 research program emphasis evolves and changes. Project content listed below represents known
45 major foci within the upcoming five-year period.

46
47 **A. Core activities**

48
49 • *Maintain and keep current the RERF computing environment*

50
51 ITD is responsible for the management and maintenance of all personal computers, Unix
52 workstations, disk and tape data storage, printers, scanners, and other peripheral
53 equipment. Network design and support responsibilities include the TCP/IP Ethernet
54 network that links all computing resources within the Hiroshima and Nagasaki
55 laboratories, the communications line linking the two laboratories, and the
56 communications line linking RERF to the Internet. ITD provides maintenance and support
57 of all operating systems, application software, and Internet services for these computer
58 systems. With an increased awareness of the role that computers can play in the
59 workplace, demand for resources and support continues to rise in all departments as they
60 seek ways to automate work activities and increase staff productivity, partially in response
61 to coping with personnel downsizing that has occurred (and continues) at the Foundation.
62 It also is anticipated that the research demand for these resources and services will
63 continue to increase as new research techniques increasingly rely on interfacing computers
64 with laboratory equipment to process data.

65
66 ITD staff play an active role in assessing new technology and its relevance to RERF
67 activities. The introduction of new tools to users ensures that the most recent and
68 appropriate technologies are available to enable researchers to work competitively in their
69 research fields and ensures that the RERF computing environment will remain compatible
70 with future computer technology.

71
72 The RERF computing system has expanded greatly over the past few years, both within
73 the two laboratories and in terms of outside linkage via connection to the Internet and
74 dial-in lines to RERF. Because all RERF departments now rely quite heavily on computing
75 resources to carry out their work, it is important that efforts be undertaken to review and
76 strengthen system security. This includes additional measures to guard against
77 unauthorized access to the RERF system by outsiders, to maintain confidentiality both
78 within and outside RERF of personal identification data on study participants, and to
79 ensure that appropriate disaster prevention/recovery plans and procedures are in place.
80 These are necessary to protect the unique repository of data accumulated during the
81 existence of ABCC/RERF, minimize system down time, and minimize user productivity
82 loss resulting from damage to equipment, software, and data.

83
84 • *Engage in design and implementation efforts for the RERF research database*

85
86 As indicated in the Database Development section within The Structure of Research at the
87 Foundation, the installed hardware and software that now comprise the RERF distributed
88 computing system has resulted in great progress in building a new research database using

4009 modern relational database technology. This technology has made it much easier for
4010 researchers to access data, link information from different sources, and extract the desired
4011 items for analysis. The new system has simplified data flow procedures for much of the
4012 mortality and incidence data follow-up activities. This, together with the elimination of
4013 redundant data storage, has contributed to improved data quality. The database system
4014 also supports direct links with certain analysis software packages, eliminating the need to
4015 create interim work files for analysis. However, much work remains to ensure that the
4016 database will serve the wide array of research needs at RERF.

4017
4018 Of utmost importance over the next several years is continued development of a
4019 comprehensive picture of study participants by clarifying study populations and
4020 incorporating more information into the database. As described earlier, more detailed data
4021 related to the major cohorts, such as clinical data, mail surveys, and dosimetry will be
4022 added. Biological materials collected over the years are a valuable resource for current
4023 and future studies. It is important to create a centralized registry of these materials and
4024 link it to other study participant data so that these samples are efficiently and effectively
4025 shared and used by the different RERF research programs. It also will be important to
4026 address both the volume of data and special data management issues that are expected to
4027 arise from data generated from the Department of Genetics DNA studies. All database
4028 work is being undertaken as a joint effort of the ITD and the departments responsible for
4029 collecting and using the data. These efforts involve major input on design issues from the
4030 Departments of Statistics and Epidemiology.

4031
4032 Together with developmental activities, it is important to provide information and training
4033 that will ensure that researchers are aware of the capability of the system and how to use
4034 it. In addition, researchers must have adequate information about the data in order to use
4035 it properly. Thus, it also is important to make suitable documentation available on paper
4036 and on-line to meet that need. Together with the Departments of Statistics and
4037 Epidemiology, ITD will be working toward that end.

4038
4039 • *Develop and maintain application systems*

4040
4041 Application systems are developed, as necessary, to meet specific needs at RERF, but, as
4042 much as possible, they are developed using commercial software packages to minimize
4043 time- and labor-intensive custom programming and maintenance efforts.

4044
4045 ITD has developed and supported the Adult Health Study (AHS) patient tracking and
4046 clinical management system. The hardware and software for this system are over ten years
4047 old, and efforts already are underway to develop a replacement system that will be
4048 compatible with the new network and software used for all other RERF activities.

4049
4050 ITD developed and currently maintains a name matching system used by the Departments
4051 of Epidemiology for its follow-up activities. With this system, individual follow-up
4052 information received from outside sources is matched with RERF database records so that
4053 mortality and incidence data can be updated accordingly.

4054
4055 ITD provides support to the Department of Statistic management and maintenance of

56 dosimetry-related data and the system used for computing dose estimates for individual
57 survivors. Increased support for this activity is anticipated because of the likelihood that
58 dosimetry reassessment activities will result in implementation of a new dosimetry system.

59
60 A significant increase in programming and data management support will be needed for
61 the Department of Genetics' two-dimensional electrophoresis image analysis of DNA
62 fragments. This work will involve a joint effort among the Departments of Genetics, and
63 Statistics, and ITD.

64
65 The development of a new business system has enabled most day-to-day business
66 computing activities to be carried out by staff in the Secretariat. ITD staff continue to play
67 an integral role in troubleshooting, maintenance, and, as necessary, providing some of the
68 more complex enhancements that users are not able to implement on their own.

69
70 • *Expand training and information outreach for users*

71
72 The distributed computing environment has provided users with direct access to many
73 powerful hardware and software tools. An effective program of training and information
74 dissemination is essential to enable users to make optimal use of these tools. While
75 important initial progress has been made, many important subject areas still need to be
76 covered or further supplemented. Thus, additional emphasis is being placed on organizing
77 additional training courses and information seminars. Planning, preparation of materials,
78 and actual instruction must involve those most familiar with software to ensure training
79 and content is effective and relevant for RERF users. ITD has adopted a multi-
80 departmental approach to this activity and has received collaborative support of
81 departments who have staff expertise in pertinent areas. This has been a very effective way
82 to meet educational needs. The user response to training courses conducted thus far has
83 been overwhelming. Training could be conducted more efficiently and timely if room
84 space and equipment could be expanded to better accommodate participant demand.

85
86 ITD also disseminates information to users outside a class or seminar setting. With the
87 recent elimination of RERF's in-house publishing capabilities, ITD uses email and plans
88 to expand its use of the Intranet as a means to providing a greater amount of reference
89 information and announcements in a timely manner.

90
91 • *Support expansion of RERF information dissemination to outside communities*

92
93 ITD is providing technical support to the Publication and Documentation Center in its use
94 of the Internet World Wide Web to widen accessibility and visibility of RERF's research
95 activities to the outside. The RERF Web pages recently were reorganized and expanded,
96 and information on those pages addresses issues of interest to both the scientific
97 community and the general public. To widen accessibility and to provide a faster and less
98 expensive method of distribution, ITD is working on enhancements that will allow Web
99 users to download RERF public data and documentation files already available on floppy
100 disk, such as those used in analyses conducted for Life Span Study Report 12.

101
102 • *Maintain the RERF library and archive*

4103 Much of the institutional memory regarding ABCC and RERF has been and continues to
4104 be lost due to the many retirements occurring. Although efforts to establish a centralized
4105 archive have been initiated by various groups in the past, currently there exists no
4106 institutional archive documenting historical decisions, procedures, and materials that bear
4107 significance to the unique activities of the institution and that provide important
4108 background perspectives to current research efforts. If RERF is to retain its history, it is
4109 important to renew efforts in establishing the archive. The first step would require that
4110 RERF obtain outside expertise to obtain guidance in the planning, database cataloging,
4111 and management of archives for research institutions. As information services, the library
4112 and archive activities ideally should be coordinated and integrated with each other.

4113
4114 Due to staff losses, it has become difficult for the library to keep pace with the work
4115 needed to provide journals and books to researchers in a timely fashion. Together with
4116 the need to investigate and introduce new services that will give researchers wider access
4117 to research information, this provides a strong basis for reassessing library activities. The
4118 aim should be to identify the services that researchers find essential to their work and to
4119 determine how the library can provide those services effectively. With this information,
4120 the Foundation can ascertain what the appropriate resources are in terms of equipment,
4121 services, and personnel to meet those needs. This process should include streamlining and
4122 modernizing in-house library activities and establishing additional links to outside services
4123 for more effective and efficient operation. It will be extremely important to supplement
4124 or replace current on-line services with those that provide continuous update of
4125 publication and other research reference materials. It would be helpful to seek outside
4126 expertise in recent library technology to guide the efforts of library staff. Collaborative
4127 support from ITD computing staff will be needed for library and archive efforts.

4128
4129 **Personnel requirements**

4130
4131 Over approximately the last two years, ITD has lost a total of 5 computer
4132 professional/technical staff. This represents a 40% and 60% loss, respectively, among the two
4133 fastest growing areas of demand, database management and systems administration. During this
4134 period, ITD workload has increased dramatically. With the transition from a mainframe to a
4135 distributed computing environment, computing resources have become an integral part of the
4136 Foundation infrastructure upon which research, support, and business activities depend. The
4137 amount of equipment and software that must be maintained and the demand for support and
4138 services continues to grow out of the need to remain competitive on the research front and to
4139 automate activities to cope with personnel downsizing occurring throughout the Foundation. The
4140 introduction of modern database technology has renewed efforts by both computer and scientific
4141 staff to re-examine and reorganize data, and to expand and document the new research database
4142 to increase accessibility and usability of data, much of which has never been fully utilized. All
4143 these efforts to support research have been hindered because of staff shortages. In other cases,
4144 such as providing support for 2-DE image analysis, ITD currently has no personnel resources to
4145 undertake application development requirements. Without further action, the situation will worsen
4146 rapidly, and many of the core activity needs will go unmet. The department chief will depart at
4147 the beginning of 1997, and another two staff will leave within the coming 12 months. Anticipated
4148 attrition by 1999 will leave only one-third the original computing staff from two years ago.
4149

To deal with the situation, recruitment is underway through NAS for a department chief and systems administrators. To seek additional personnel and expertise, steps have been taken to explore collaborative and post-graduate research/training relationships with regional Japanese universities. Additional recruitment of experienced database management personnel and qualified Japanese computer technical staff is essential.

Although reassessment of the library has not yet been undertaken, it is evident that establishment of the archive and proper operation and maintenance of the library will require one additional staff for the combined library/archive. During full-scale development and cataloging phases for the archive, additional staff will be required, most likely on a temporary basis.

Area	Fiscal Year					
	Current	1997	1998	1999	2000	2001
Computer	13	16	18	19	19	19
Professional/Technical						
Library/Archives	2	3	3	3	3	3
Clerical Administrative	3	2	2	2	2	2
Total	18	21	23	24	24	24

Space requirements (m²)

Estimates reflect space for new staff and for the assortment of computers and peripheral equipment in their immediate work area for development, testing, and troubleshooting activities. A small increase in support space is needed to guarantee that all computer servers are installed in a temperature-controlled, restricted access area for security purposes, and to permit use of a projection panel in the training room to provide effective instruction on methods and procedures. Initial archives work most likely can be accommodated in the existing library space. The increase indicated in future years assumes that methods and resources can be introduced that would enable the library to reorganize and economize how it uses its current space, so that once the archive is in the full implementation phase, additional space required to house those materials is minimized.

Area	Fiscal Year					
	Current	1997	1998	1999	2000	2001
Office	180	228	228	228	228	228
Clerical Administrative	31	31	31	31	31	31
Library/Archives	337	337	337	357	357	357
Other Support ¹	166	183	183	183	183	183
Total	714	779	779	799	799	799

¹ includes server, user training, diagnostic workbench, and conference rooms

4189 **Equipment budget (x ¥ 1,000)**

4190
4191
4192
4193
4194
4195
4196
4197
4198
4199
4200
4201
4202
4203
4204

In the table below, computer hardware and software used by ITD staff to carry out development and support work are distinguished from resources used to provide RERF-wide services to users. In order to perform development, testing, and technical support, it is necessary for ITD to have within the department a variety of equipment and software used in other departments. Estimates are based on a three year schedule for replacement of computers. A faster turnaround is built in for systems administrators, who must troubleshoot problems on new systems installed in other departments. Functional equipment rotated out of service will be used to help keep the training room current, moved to meet needs in other departments, and serve as emergency replacements to minimize down time on critical work activities. Also accounted for is the ongoing need to expand network storage capacity. In the area of RERF-wide services and resources, the regular upgrading and replacement of hardware and software are an essential aspect of maintaining a modern computer environment, ensuring that it keeps pace with future technology developments and provides state-of-the-art tools for research.

4205
4206
4207
4208
4209
4210
4211
4212
4213
4214
4215
4216

Budget category	Fiscal Year				
	1997	1998	1999	2000	2001
<i>ITD staff</i>					
Replacement hardware and software	7800	8520	9095	9095	9550
New hardware and software	1100	900	1155	945	1210
<i>ITD staff total</i>	<i>8900</i>	<i>9420</i>	<i>10250</i>	<i>10040</i>	<i>10760</i>
<i>RERF-wide services</i>					
Computer and networking hardware/software replacement	36000	36000	37800	37800	39700
Grand Total	44,900	45,420	48,050	47,840	50,460

4217
4218
4219
4220

+ Support fees that cover Unix workstation hardware maintenance contracts, annual software license fees, and network line lease fees are included in the Secretariat operations budget.

4221 **Publication and Documentation Center**

4222
4223
4224
4225
4226
4227

Dissemination of the findings of the Foundation's research to the scientific and lay communities, nationally and internationally, is centered in the Publication and Documentation Center. Broadly stated, the duties of the Center are the following: editing, production, preservation and management of publications; translation and interpretation services.

4228 **Specific roles**

4229
4230
4231
4232
4233
4234
4235

- (1). Preparation of technical reports on the results of RERF research and studies, and distribution of them to interested organizations as well as to researchers worldwide.
 - a). Administrative procedures for the review of research manuscripts up to publication thereof in journals; administrative support for research scientists by documentation

36 of research results and by preserving and making available to them research
37 protocols, abstracts for scientific meeting presentation, and reprints.

- 38
- 39 b). Publication of English and Japanese Newsletters, annual reports, and bibliographies
40 of publications; management of RERF's World Wide Web site.
- 41
- 42 c). Proofreading and editing of English manuscripts; translation and interpreting services
43 requested by departments; preparation of figures, diagrams, and slides using
44 computers; photographic activities
- 45

46 **Organization (see the following page)**

47

48 **Personnel strength at PDC for the past six years and projection of changes**

49

50

	Fiscal Years					
	1990	1991	1992	1993	1994	1995
51 Research	1	2	4	2	2	1
52 Clerical	30	25	26	28	27	25
53 Technical	1	0	0	0	0	0

54

55

56 PDC's operational requirements cannot be fulfilled if replacements for retiring employees
57 are not employed. Continued operation at current level requires at least maintenance of the
58 current personnel strength.

59

60 **Radioisotope Facility**

61

62 The duties of the RI Facility are 1) management of the facility in accordance with Japanese
63 laws, 2) maintenance of a safe working environment, and 3) summarization and realization of
64 requests from facility users. It should be noted that until recently the Foundation maintained two
65 radioisotope facilities, one in Hiroshima and one in Nagasaki. With the closure of the
66 radiobiology program in Nagasaki, the facility there was no longer needed and was placed on
67 inactive status. It has not, however, been formally closed. Whether it should be closed or merely
68 maintained in an inactive status hinges on two considerations, namely, future use and cost. If this
69 facility should be needed in the future for RERF research purposes, it would be cheaper in the
70 long run to continue to maintain it. At present, the annual maintenance costs are between ¥
71 700,000-800,000 but this will diminish in the future. If the facility is formally closed, the space
72 and equipment must be decontaminated in accordance with Japanese regulations. This has been
73 estimated to cost ¥ 8,000,000. Formal closure would, of course, free the space for other uses,
74 and this is an important consideration given the size of the Nagasaki Laboratory. As yet no
75 decision has been made about the fate of this facility.

76

77 The remarks to follow pertain only to the Hiroshima facility.

78


79 **Management of the RI facility**

80

81 The RI Facility is being operated in accordance with various national laws. Detailed
82 record-keeping on many aspects of the RI facility operation (e.g., measurements of air dose rate,
83 concentration of RI in drainage, and the radiation dose to which the user is exposed) is mandated

Present


Staff: Professional 1
Administrative 20
 Total 21



Revised Organizational Structure (draft)

1 January 1998

1 January 1999



Integrated into Secretariat
 on the basis of one section
 and one office

284 by law for safe operation of the facility. It is obligatory to submit summary reports of these data
285 to the Science and Technology Agency. Preparation of these documents has been completely
286 computerized. However, the equipment being used to record and manage these data has
287 exceeded its service life and should be replaced.

288 289 **Maintenance of a safe working environment**

290
291 The RI facility supports the activities of the Departments of Clinical Studies, Genetics, and
292 Radiobiology. At present, 31 users are sharing a laboratory space of 75 m². Space per user at
293 our laboratory is less than that at laboratories of other institutions. Furthermore, the equipment
294 being used in our laboratory, such as the 2D-DNA electrophoretic apparatus, is larger than usual
295 and occupies more space. In addition, studies being conducted at RERF are mainly conducted
296 on a large scale, and many samples are simultaneously examined. Therefore, lots of different
297 pieces of equipment are used simultaneously. It is dangerous to perform many experiments in
298 such a small place. Expansion of the facility has been requested, but no action has been taken due
299 to a shortage of funds.

300 301 **Future of RI facility**

302
303 The RI facility will be used for many aspects of the molecular studies newly proposed by
304 the Blue Ribbon Panel. With future technical developments, it is likely that some of these studies
305 will be less dependent on the RI facility than is present necessary (for example, DNA sequencing,
306 use of the Southern blot method, and chemiluminescent procedures). However, it can be easily
307 imagined that more new experiments will be performed at the RI facility, offsetting the number
308 of experiments that require the use of radioisotopes and will cease due to using the above-
309 mentioned new techniques. Expansion of laboratory space to accommodate these added needs
310 is essential.

311
312 Replacement of equipment is also necessary. The current automatic developing machine
313 for X-ray film and the γ -well counter may cease to function at any time. Repair is impossible
314 because no spare parts are available for these old models. One possible option to replacement
315 purchase is to relocate the γ -well counter from the Nagasaki Laboratory to Hiroshima. If this is
316 feasible, measuring contamination on the surface of the equipment and transportation of the
317 equipment to Hiroshima are the only two expenses that must be borne and neither should be
318 unduly onerous.

319
320 Renovation of the facility is necessary to satisfy the need to change the type and amount
321 of radioisotopes being used. Installation of a larger drainage tank is especially necessary.

322 323 **Personnel requirements**

324 325 Fiscal Year	1996	1997	1998	1999	2000	2001
326 Research Scientists	0.1 ¹	0.1	0.1	0.1	0.1	0.1
327 Technicians	0.7 ²	1	1	1	1	1

328
329 ¹ One scientist is concurrently assigned to the Department of Genetics (90%) and the RI Facility (10%).

4330
4331
4332
4333

² One technician is concurrently assigned in the RI Facility (70%) and the Department of Clinical Studies (30%).

Space requirements (m²)

Fiscal Year	1996	1997	1998	1999	2000	2001
Bench Research	75	120 [*]	120	120	120	120
Support Space						
Darkroom	12.5	12.5	12.5	12.5	12.5	12.5
Contamination inspection room	7.7	7.7	7.7	7.7	7.7	7.7
RI depository	5.5	5.5	5.5	5.5	5.5	5.5
Storage disposal room	9.1	9.1	9.1	9.1	9.1	9.1
Waste disposal room	6.8	6.8	6.8	6.8	6.8	6.8
Exhaust facility	9.9	9.9	9.9	9.9	9.9	9.9
Stock room	6.0	6.0	6.0	6.0	6.0	6.0
Office	12.5	12.5	12.5	12.5	12.5	12.5
Total	145	190	190	190	190	190

4345
4346
4347
4348

^{*} Space for stairs and corridor is included.

Equipment budget (× ¥ 1,000)

4350
4352
4353
4354
4355
4356
4357
4358
4359
4360
4361
4362
4363
4364
4365

Fiscal Year	New/ Repl	Item	Q'ty	Unit Cost	Total
1997	N	PC	1	570	570
	R	Printer	1	220	220
	R	Software version up	1	50	50
1998	R	PC	1	500	500
1999	R	Software version up	2	50	100
2001	R	PC	1	500	500
	R	Printer	1	220	220
	R	Software version up	2	50	100

4366
4367
4368
4369

^{*} Other equipment items requested for each fiscal year are shown in Annex J.

4370
4371
4372
4373
4374

Secretariat

The Secretariat, as the administrative department for the Foundation's operations, is responsible for the procurement of human and material resources required for the smooth conduct of research activities. As of 1 April 1996, the Hiroshima Secretariat was composed of 48

75 employees in four sections (General Affairs, Personnel, Accounting, and Supply and Property),
76 and the Nagasaki Secretariat of 17 employees in two sections (General Affairs and Accounting).

77
78 **Organization and personnel strength (as of April 1, 1996)**

79
80 The numbers in parentheses indicate personnel strength, and "+" indicates section chiefs
81 or other managerial positions.

82		
83	[Hiroshima]	
84	Assistant Chiefs and others (3)	
85		Director's Office (5) +2
86	General Affairs Sec. (18)	General Affairs Unit (7)
87		Document and Archive Unit (2)
88		External Affairs Unit (2)
89		
90	Personnel Sec. (6)	Personnel Unit (3) +1
91		Payroll Unit (2)
92		
93	Accounting Sec. (7)	Accounting Unit (3) +1
94	Secretariat (65)	Receipts & Disbursement Unit (3)
95		
96		Supply Unit (4) +1
97	Supply & Property Sec. (14)	Physical Plant Unit (5)
98		Welfare Unit (4)
99		
00	[Nagasaki]	
01	Assistant Chief (1)	
02		Public Relations Office (2) +2
03	General Affairs Sec. (11)	General Affairs Unit (4)
04		Employees Unit (3)
05		
06	Accounting Sec. (5)	Accounting Unit (2) +1
07		Supply Unit (2)

08
09
10 **Duties**

11
12 **Hiroshima Laboratory**

13
14 **1. General Affairs Section**

15
16 Administrative duties in support of the Directors' Offices; administrative support for meetings
17 and official functions of the Foundation; management of administrative documents; labor safety and
18 health, security and safety; and external affairs and public relations activities.

19
20 **2. Personnel Section**

21

4422 Duties concerning employment and dismissal, payroll, social and labor insurance, and
 4423 administrative procedures for appointment of consultants, etc.

4424
 4425 3. Accounting Section
 4426

4427 Duties concerning preparation and execution of budget, settlement of accounts, management
 4428 of cash and special accounts, and management of assets.

4429
 4430 4. Supply and Property Section
 4431

4432 Duties concerning purchase and management of supplies and equipment, maintenance of the
 4433 facilities, heat control and energy conservation, employee welfare, and management of lodging
 4434 facilities of the Foundation.

4435
 4436 **Nagasaki Laboratory**

4437
 4438 1. General Affairs Section
 4439

4440 Duties corresponding to those discharged by the Hiroshima General Affairs Section and
 4441 Personnel Section; administrative duties concerning functions of the Foundation; payroll and labor
 4442 insurance, labor safety and health; and employee welfare.

4443
 4444 2. Accounting Section
 4445

4446 Duties correspond to those discharged by the Hiroshima Accounting Section and Supply and
 4447 Property Section; purchase and management of goods; maintenance of facilities; security and safety.

4448
 4449 **Personnel of Secretariat, Hiroshima and Nagasaki laboratories**

4450
 4451 (1) Changes of personnel strength (actual) (1990 - 1996)
 4452

	1990	1991	1992	1993	1994	1995	1996
Total	93	99	93	90	84	71	65
Total (Hiroshima)	70	76	67	66	62	50	48
Attached to the Secretariat	5	6	4	4	4	3	3
General Affairs Section Total	24	25	24	22	21	17	18
Personnel Section	6	8	9	8	7	7	6
Accounting Section	6	5	6	7	7	7	7
Supply and Property Section Total	29	29	24	25	23	16	14
Total (Nagasaki)	23	23	26	24	22	21	17
Attached to the Secretariat	1	1	2	1	2	1	1

464	General Affairs Section	Total	14	15	16	15	13	13	11
465	Accounting Section	Total	8	7	8	8	7	7	5

466
467 2) Personnel strength required for the next five years

468
469 a) Secretariat

470
471 The Secretariat will support continued improvement of work procedures to cope with
472 personnel reduction. However, considering the workload of the present organization, a staff of 46
473 and 14, respectively, for Hiroshima and Nagasaki, 60 in total, is necessary. In the event of relocation
474 to new facilities, personnel strength can be reduced by 7 in the area of security and maintenance of
475 the facilities.
476

4477

4478

4479

4480

4481

4482

4483

4484

4485

4486

4487

4488

4489

4490

4491

4492

4493

4494

4495

4496

4497

4498

4499

4500

b) Necessary personnel strength by section and projection of change in personnel number (1996 - 2001)

	Necessary personnel	1996			1997			1998			1999			2000			2001			02
		Apr. 1	Ret.	Rep	Apr. 1	Ret.	Rep	Apr. 1	Ret.	Rep	Apr. 1	Ret.	Rep	Apr. 1	Ret.	Rep	Apr. 1	Ret.	Rep	Apr.
Total	60	65	6	0	59	2	0	57	6	0	51	2	0	49	4	0	45	3	0	42
Total (Hiroshima)	46	48	3	0	45	1	0	44	4	0	40	2	0	38	4	0	34	2	0	32
Attached to the Secretariat	1	3	1		2			2			2			2			2			2
General Affairs Sec.																				
Clerical	15	14			14	1		13			13	1		12	1		11	1		10
Technical	3	4	1		3			3	1		2	1		1			1			1
Total	18	18	1	0	17	1	0	16	1	0	15	2	0	13	1	0	12	1	0	11
Personnel Sec.	6	6			6			6	1		5			5	1		4			4
Accounting Sec.	7	7	1		6			6	1		5			5			5			5
Supply & Property Sec.																				
Clerical	9	9			9			9			9			9	2		7	1		6
Technical	5	5			5			5	1		4			4			4			4
Total	14	14	0	0	14	0	0	14	1	0	13	0	0	13	2	0	11	1	0	10
Total (Nagasaki)	14	17	3	0	14	1	0	13	2	0	11	0	0	11	0	0	11	1	0	10
Attached to the Secretariat	1	1			1			1	1		0			0			0			0
General Affairs Sec.																				
Clerical	7	10	3		7	1		6			6			6			6	1		5
Technical	1	1			1			1			1			1			1			1
Total	8	11	3	0	8	1	0	7	0	0	7	0	0	7	0	0	7	1	0	6
Accounting Sec.	5	5			5			5	1		4			4			4			4

Note: "Retirement" in 1996 includes employments, transfers and retirements up to July 1.

Ret. = Retirement; Rep. = Replacement

31
32 c) Relationship with duties of the Publication and Documentation Center
33

34 Despite the research support aspects of PDC, better results can be expected by removing the
35 division between the duties of the Secretariat and those of PDC. Therefore, in the future, translation
36 which is done at PDC at present and the public relations activities will be put under the charge of the
37 Secretariat together with the Document and Archive Unit and the External Affairs Unit for better
38 utilization of talent. The duties relating to research protocols and technical reports will be placed
39 under the direct charge of the Chief of Research for better coordination of activities. These
40 arrangements should be further discussed. However, they are not considered in the estimation of
41 personnel strength required.
42

43 **Changes in the Foundation's overall personnel strength**
44

45 1. Actual changes (1990 - 1996)
46

47

Personnel no. as of April 1	Total	Directors	Chief of Secretariat	Research Scientists	General Employees
1990	427	6		57	364
1991	433	6		61	366
1992	437	5		64	368
1993	435	6		62	367
1994	412	6		57	339
1995	373	4	1	48	320
1996	335	4	1	47	283

48
49
50
51
52
53
54

55 **MAINTENANCE OF AN ADEQUATE INFRASTRUCTURE**
56

57 Three needs are paramount if the Foundation is to fulfill its mission as set out in the preceding
58 pages. First, there must be adequate staff and these individuals must have the appropriate skills to
59 meet an evolving research program. Second, there must be the requisite equipment to support the
60 research activities of that staff. Finally, there must be sufficient, suitable space in which to house the
61 staff and equipment. Given the recent pace of technological developments it is difficult to project
62 these needs over the next five years with the assurance that is desirable. Nonetheless, some
63 projection is obviously necessary and to make that projection assumptions must be made. We now
64 set out the assumptions that underlie the projections to follow.
65

66 **Personnel**
67

68 First, some further reduction in staff from that presently obtaining is possible. However, this
69 assertion tacitly assumes that the future, through increasing use of computer technology, automated
70 laboratory equipment, and better, faster means of communication, will make some current positions
71 that are labor intensive redundant and others less time-consuming. But, it is our view that this
72 reduction should be an orderly one and not so precipitous as to jeopardize the Foundation's research
73
74

4545 and capacity to fulfill its charge either in the short or the long run. Accordingly, we have projected
4546 staff needs on the assumption that to maintain a viable staff size it will be necessary to replace two
4547 out of every three retirements over the next five years. This will amount to a further reduction in staff
4548 of about 10% over this period of time; however, the impact of this further loss in personnel must be
4549 seen in the context of the 25% reduction that has occurred in the past five years and to which we are
4550 still adjusting.

4551
4552 These replacements will be recruited on the basis of demonstrated need and will not be
4553 automatically made to the department or unit from which the retiree(s) came. Emphasis will be
4554 placed upon technical staff, such X-ray technicians, clinical and research laboratory personnel, and
4555 clinical and public health nurses with due allowance for changing workloads with time. However,
4556 it is clear that an adequate cadre of support staff is also essential and replacements will be made in
4557 the Secretariat, the Information Technology Department, and the Publication and Documentation
4558 Center to ensure this end.

4559
4560 Second, there are staff inequities between Hiroshima and Nagasaki that need to be resolved.
4561 For example, with the closure of the Radiobiology Department in Nagasaki, all of the technicians
4562 employed in this laboratory were transferred to the Clinical Laboratory there. This has resulted in
4563 a staff that is actually larger than the one in the Clinical Laboratory in Hiroshima despite the much
4564 heavier workload of the latter. These technicians should be offered transfer to Hiroshima or to other
4565 positions as retirements occur in lieu of a replacement. Other instances of inequity can be cited.
4566

4567 Third, particularly detrimental to the Foundation's research activities has been the loss of
4568 professional employees. Over the past five years, when no replacements of any sort occurred, their
4569 number has fallen from 64 to 47. Since it is precisely these employees that are essential to the
4570 Foundation's mission we propose increasing this number to 50.

4571
4572 Projected yearly staff changes by broad work categories are given in the tables at the end of
4573 this section. These tables should be seen as guides, and not as firm commitments which will, as
4574 previously said, be determined by need.

4575 4576 **Equipment**

4577
4578 Contemporary science rests on increasingly complex and sophisticated equipment both in the
4579 laboratory and as a means of communication, data management and analysis. Much of this equipment
4580 has, unfortunately, a relatively short useful life, arguably three to five years in most instances. This
4581 implies, in turn, that replacements will be necessary periodically. Again, it is our intent to make these
4582 replacements on the basis of need and relevance to the current research program. Wherever
4583 equipment is outdated for use in one department, if circumstances permit, it will be transferred to
4584 another department with less demanding needs.

4585
4586 Clearly high on the list of priorities will be the maintenance of a strong computing capability
4587 including the continued cost of transition from a mainframe environment to a distributed system. This
4588 is essential not only to research but to the proper administration of that research. As the body of
4589 information available at the Foundation grows, which is inevitable, the need for efficient data
4590 management grows too. Moreover, significant staff reduction appears possible only if some of the
4591 current routine work can be automated, and delegated to computers.

02 Budget projections for the next quinquennium will be found at the end of this section. These
03 projections set forth personnel and operating costs as well as equipment needs. However, in
04 departure from previous budget projections, equipment expenditures have been divided into those
05 supporting research and those supporting administrative needs. In the past, administrative equipment
06 needs, primarily computing capability, have generally been funded out of operating costs and
07 therefore, not reflected in the overall equipment forecasts. This accounts for much of the seemingly
08 larger equipment projections seen in these tables. It should also be noted that the bulk of the
09 equipment expenditures predicted are for the replacement of outdated apparatus and not new devices,
10 new in the sense of not previously in use at the Foundation.

01 02 **Space**

03
04 Although planning for the relocation of the Foundation's facilities in Hiroshima continues,
05 there is as yet no firm date for this to occur. Accordingly, for the purposes of this document, we have
06 assumed that the relocation will not occur in the next five years. However, if this should prove to
07 be incorrect, clearly additional costs over those here projected would occur. It is important to note
08 that the Hiroshima facilities are old, and barely adequate; however, we continue to review space
09 allocations and strive for the most efficient use of the space that is available. This process of review
10 will continue.
11
12

4613
4614
4615
4616

**Changes of personnel strength
(2/3 replacement of retirements)**

		Total	Director	Research Scientist	Clerk	Computer Specialist	B	C	D	
4617	FY1996	As of Apr. 1	335	5	47	178	12	16	57	20
4618		Retirement	10			4		2	3	1
4619		Replacement	6		3	1		1	1	
4620	FY1997	As of Apr. 1	331	5	50	175	12	15	55	19
4621		Retirement	30	4	1	18	1		3	3
4622		Replacement	22	4	1	12	1		2	2
4623	FY1998	As of Apr. 1	323	5	50	169	12	15	54	18
4624		Retirement	14			10	1	2	1	
4625		Replacement	9			6	1	1	1	
4626	FY1999	As of Apr. 1	318	5	50	165	12	14	54	18
4627		Retirement	14	4	1	7	1	1		
4628		Replacement	11	4	1	5	1			
4629	FY2000	As of Apr. 1	315	5	50	163	12	13	54	18
4630		Retirement	12			11				1
4631		Replacement	9			8				1
4632	FY2001	As of Apr. 1	312	5	50	160	12	13	54	18
4633		Retirement	10		2	7				1
4634		Replacement	8		2	5				1
4635	FY2002	As of Apr. 1	310	5	50	158	12	13	54	18

- 4636 1) The expiration of directors' terms of office is considered as mandatory retirements, and replacements for all of the
4637 retiring directors will be employed.
4638 2) Number of research scientists is 50 and the replacements for all terminating will be employed.
4639 3) 2/3 of replacement of retirements of general employees will be employed as of 1 April of the next year.
4640 4) B: Technical staff C: Clinical radiology technicians and medical technicians
4641 D: Nurses and public health nurses

Comparison of personnel strength between actual and requested (Total)
(2/3 replacement of retirements)

		Total	Director	Research	General	A	B	C	D
FY1996	as of Apr. 1	335	5	47	283	190	16	57	20
	Retirement	10			10	4	2	3	1
	Sub-total	325	5	47	273	186	14	54	19
	Requested	331	5	46.5	279.5	188	11	60.5	20
FY1997	Replacement	6		3	3	1	1	1	
	as of Apr. 1	331	5	50	276	187	15	55	19
	Retirement	30	4	1	25	19	0	3	3
	Sub-total	301	1	49	251	168	15	52	16
	Requested	342.5	5	50.5	287	195	11	62	19
FY1998	Replacement	22	4	1	17	13		2	2
	as of Apr. 1	323	5	50	268	181	15	54	18
	Retirement	14			14	11	2	1	0
	Sub-total	309	5	50	254	170	13	53	18
	Requested	346.5	5	51.5	290	198	11	63	18
FY1999	Replacement	9			9	7	1	1	
	as of Apr. 1	318	5	50	263	177	14	54	18
	Retirement	14	4	1	9	8	1	0	0
	Sub-total	304	1	49	254	169	13	54	18
	Requested	348.5	5	52.5	291	199	11	63	18
FY2000	Replacement	11	4	1	6	6			
	as of Apr. 1	315	5	50	260	175	13	54	18
	Retirement	12			12	11	0	0	1
	Sub-total	303	5	50	248	164	13	54	17
	Requested	347.5	5	52.5	290	199	10	63	18
FY2001	Replacement	9			9	8			1
	as of Apr. 1	312	5	50	257	172	13	54	18
	Retirement	10		2	8	7	0	0	1
	Sub-total	302	5	48	249	165	13	54	17
	Requested	347.5	5	52.5	290	199	10	63	18

4675
4676
4677
4678
4679
4680
4681
4682
4683
4684
4685
4686
4687
4688
4689
4690
4691
4692
4693
4694
4695
4696
4697
4698
4699
4700
4701
4702
4703
4704
4705
4706
4707
4708
4709
4710
4711
4712
4713
4714
4715
4716
4717
4718
4719
4720
4721

SUMMARY

Investigations have been in progress for 50 years to ascertain the health effects produced by radiation in the survivors of the atomic bombings of Hiroshima and Nagasaki. It is appropriate to ask (1) what the results of these studies have been, (2) what more is to be done, and (3) what changes, if any, are anticipated in the future for RERF. One purpose of this document is to address these issues.

The long-term follow-up of this unique population has provided results of considerable value to the medical as well as the radiobiological community. Significant associations between radiation dose and cancer have been seen among the survivors for most types of cancer, including leukemia, multiple myeloma and cancers of the thyroid, lung, breast, stomach, skin, colon, esophagus, liver, urinary tract, and ovaries. The RERF data provide unique, quantitative information on how these risks are affected by sex, age-at-exposure, and time. The excess relative risks for most solid cancers are found to be higher for men than women and to increase with decreasing age at exposure. There is weak evidence that the high relative risks seen for those exposed as children have decreased with time while the relative risks for those exposed as adults have remained constant. Recent analyses of the LSS data indicate that excess rates increase throughout life and that these rates do not vary much with sex and age-at-exposure. The RERF data also provide evidence of a positive association between radiation dose and noncancer disease mortality. While this effect is small, it does not appear to be an artifact of misclassification of cause of death on death certificates. Clinical studies of cardiovascular disease morbidity and related endpoints have been carried out using the RERF clinical data. The results of these studies also support the notion of a radiation effect on some noncancer diseases. Over the next few years we must develop a more unified approach for combining the epidemiological and clinical data on radiation and noncancer disease morbidity. The presence of dose-dependent developmental effects on survivors who were exposed in-utero is well-documented and it is now becoming clear that radiation exposure is associated with elevated risks of cancer later in life for this group of survivors. If, as seems likely, these risks continue throughout life the coming decades will provide further information on the extent and nature of these risks. It is also important to follow-up earlier findings that the developing human brain is extremely sensitive to teratogenic effects of relatively low doses of ionizing radiation since this vulnerability might manifest itself in earlier onset of cognitive disorders and an increased frequency of senile dementia.

Evidence is still lacking that radiation induces heritable genetic damage in humans. Research with experimental animals, however, has clearly demonstrated that heritable changes are positively associated with radiation exposure. In general, RERF's findings in various genetic studies are as expected if the atomic-bomb radiation exposure has produced mutations. But, to date, the differences between the children of proximally and distally exposed survivors are far from significant. However, none of the strategies to assess mutation risk used thus far has addressed the full gamut of possible genetic damage. For example, the program of clinical examinations of the newborn was designed to identify congenital abnormalities demonstrable soon after birth but could not identify those abnormalities that are not readily detectable until later in life, nor those simply or complexly inherited disabilities that do not manifest themselves until adolescence or later. The latter represent by far the largest proportion of all inherited handicaps, and there has been no systematic program of health examinations of the F_1 after the first year of life which might

72 detect an increase in these diseases and disorders.
73

74 Developments in molecular biology have identified a number of new approaches that will
75 permit mutations at the level of nucleotide bases in DNA to be detected in human populations in
76 the foreseeable future. Although these techniques are not available for use at the present time to
77 monitor human mutation rates, cells from exposed and unexposed parents and their children are
78 being collected now. Some of these cells are being immortalized using the Epstein-Barr virus,
79 cultured, and stored for use when the new molecular approaches to mutation detection can be used
80 cost-effectively.
81

82 Continuation of the investigations at RERF will (1) strengthen evidence about the cancer
83 dose-response, (2) clarify the impact of exposure on cancer risks for the survivors exposed as
84 children in-utero, (3) provide additional information on the nature of radiation effects on
85 cardiovascular and other noncancer diseases, and (4) offer new insights into the role of biological
86 and environmental factors on radiation risks.
87

88 Initial efforts to develop a database that contains information on family relationships
89 among members of the LSS and other RERF cohorts suggest that these data can be useful for
90 studies of the interaction between hereditary factors and radiation- or nonradiation-related cancer
91 risks. This work will continue during the next five years provided that adequate computing and
92 personnel resources are available.
93

94 Public concern over the potential risks of exposure to ionizing radiation shows no sign of
95 abating; indeed it is possibly even greater now than in the past largely due to a series of accidents
96 at nuclear power generating facilities, and increased medical usage. To allay this concern will
97 require greater knowledge of how radiation affects somatic and genetic diseases in human beings.
98 While there are experts in most disciplines related to understanding radiation effects on humans
99 at many institutions all over the world, the Foundation is the only one with many of these experts
100 in one place, and with access to the largest, well-defined and studied population of
101 radiation-exposed individuals. To not maintain this "critical mass" of interested scientists focused
102 on this important human problem would create a serious setback to the Foundation and the
103 successful prosecution of its mission. In addition, with the increasing concern of the effects of
104 environmental chemicals on human health, RERF scientists have the potential to use the
105 information from this unique population to determine how chemical and radiation effects might
106 interact.
107

108 With the decrease in the numbers of the A-bomb survivors occurring, and the current lack
109 of sensitive and fully validated techniques to measure mutational effects in both somatic and germ
110 cells, emphasis has been and should continue to be placed on the long-term storage of biological
111 material until appropriate techniques to measure important parameters can be developed. In
112 addition, research should be directed towards the incorporation of new molecular biological
113 approaches in the study of the F₁ generation and the incorporation of new concepts and techniques
114 from molecular and cell biology to study the non-mutagenic mechanisms that may modify radiation
115 effects, aspects that are not, at present, part of the Foundation's current research base.
116

117 The development of such new molecular biological techniques; of new conceptual
118 understanding of chronic diseases, including cancer; of the deeper insights into the role of

4769 oncogenes and tumor suppressor genes; and an understanding of chemicals which enhance or
4770 suppress tumor growth can be expected to stimulate new laboratory approaches and new
4771 epidemiological studies.

設備費の増減 (1996年～2001年)
Equipment Requests by Research Departments

(単位：千円) (UNIT: ¥1,000)

部・局	DEPARTMENT	FY1996	FY1997	FY1998	FY1999	FY2000	FY2001	合計
疫学部	EPIDEMIOLOGY	0	7,690	6,930	6,990	7,050	7,050	35,710
臨床研究部	CLINICAL STUDIES	0	8,372	4,485	16,210	712	11,565	41,344
遺伝学部	GENETICS	0	21,011	10,347	30,381	2,794	4,002	68,535
放射線部	RADIOBIOLOGY	0	49,412	83,652	20,682	13,572	6,882	174,200
統計部	STATISTICS	0	5,075	5,275	5,410	5,590	5,675	27,025
広島合計	HIROSHIMA TOTAL	0	91,560	110,689	79,673	29,718	35,174	346,814
臨床研究部	CLINICAL STUDIES	0	20,117	1,052	2,252	3,452	852	27,725
疫学部	EPIDEMIOLOGY	0	6,198	3,344	3,544	844	5,944	19,874
長崎合計	NAGASAKI TOTAL	0	26,315	4,396	5,796	4,296	6,796	47,599
① 両市合計	BOTH TOTAL	0	117,875	115,085	85,469	34,014	41,970	394,413

サポート部門備品要求表 (1996年～2001年)

Equipment Requests by Supporting Departments

部・局	DEPARTMENT	FY1996	FY1997	FY1998	FY1999	FY2000	FY2001	合計
出版資料センター	PDC	0	8,860	3,640	4,960	2,540	3,200	23,200
研究情報センター	ITD	0	44,900	45,420	48,050	47,840	50,460	236,670
放射線同位 RI	RI FACILITIES	0	2,500	0	450	360	700	4,010
事務局	SECRETARIAT	1,770	6,240	8,320	4,690	2,950	1,420	25,390
広島合計	HIROSHIMA TOTAL	1,770	62,500	57,380	58,150	53,690	55,780	289,270
事務局	SECRETARIAT	2,720	2,620	440	2,220	1,040	0	9,040
長崎合計	NAGASAKI TOTAL	2,720	2,620	440	2,220	1,040	0	9,040
② 両市合計	BOTH TOTAL	4,490	65,120	57,820	60,370	54,730	55,780	298,310

①+② 合計		4,490	182,995	172,905	145,839	88,744	97,750	692,723
--------	--	-------	---------	---------	---------	--------	--------	---------

現金購入	PURCHASE COST	4,490	110,655	86,872	86,021	73,344	87,967	449,349
リース支払い	LEASE CHARGE	0	16,754	36,680	50,533	54,100	56,365	214,431
従来のリース支払	CURRENT LEASE CHARGE	17,095	5,082	5,082	5,082	4,598	2,177	39,116
合計	TOTAL	21,585	132,491	128,634	141,636	132,042	146,509	702,896

コンピューター関係分 For Computer 4,490 94,381 80,017 82,462 73,314 86,797 421,461

ANNEX A

THE PROJECTED SIZE OF THE LIFE SPAN STUDY COHORT, 1995-2020.

	Year					
	1995	2000	2005	2010	2015	2020
Age at exposure (y)						
0-9	16,450	15,990	15,290	14,280	12,710	10,390
10-19	14,500	13,540	12,040	9,800	6,780	3,620
≥ 20	12,800	8,910	5,430	2,710	970	100
Total	43,750	38,440	32,760	26,790	20,460	14,110
Average attained age (y)						
	64.7	67.9	71.3	74.7	78.0	81.3
Average age at time of bombing (y)						
	14.7	12.9	11.3	9.7	8.0	6.3

ANNEX B

WORKSHOPS SINCE 1988

- Radiation susceptibility workshop, 18-20 March 1988 RERF Hiroshima
- Immunology workshop, 28-29 November 1988 RERF Hiroshima
- Radiation carcinogenesis workshop, 16-18 March 1989 RERF Hiroshima
- Aging workshop, 29-31 March 1990 RERF Hiroshima
- Human germline mutagenesis workshop, 12-14 November 1991
RERF Hiroshima
- Health monitoring workshop, 25-27 January 1993 RERF Hiroshima
- US Department of Energy and RERF scientific
research activity exchange workshop, 14-16 April 1993 Beckman Center, Irvine,
California, USA

ANNEX C

SELECTED REFERENCES

- Pierce, D. A., Shimizu, Y., Preston, D. L., Vaeth, M., and Mabuchi, K.: Studies of the Mortality of Atomic Bomb Survivors. Report 12, Part I. Cancer: 1950-1990. Radiat. Res. 146: 1-27, 1996.
- Preston, D. L., Kusumi, S., Tomonaga, M., Izumi, S., Ron, E., Kuramoto, A., Kamada, N., Dohy, H., Matsuo, T., Nonaka, H., Thompson, D. E., Soda, M. and Mabuchi, K.: Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat. Res. 137: S68-S97, 1994.
- Schull, W. J.: Effects of Atomic Radiation: A Half Century of Studies from Hiroshima and Nagasaki. New York: John Wiley and Sons, Inc., 1995.
- Shigematsu, I., Ito, C., Kamada, N., Akiyama, M., and Sasaki, H. (Eds.): Effects of A-Bomb Radiation on the Human Body. Tokyo: Bunkodo Co., Ltd., 1995.
- Thompson, D. E., Mabuchi, K., Ron, E., Soda, M., Tokunaga, M., Ochikubo, S., Sugimoto, S., Ikeda, T., Terasaki, M., Izumi, S. and Preston, D. L.: Cancer incidence in atomic bomb survivors. Part II. Solid tumors, 1958-1987. Radiat. Res. 1327: S17-S67, 1994.

ANNEX D

MASTER SAMPLE, PROPER AND RESERVE BY EXPOSURE CATEGORY AND CITY

Exposure Group (M)	Proper Part	Reserve Part	Total
HIROSHIMA	90,697	30,403	121,100
0-1999	21,329	4,845	26,174
2000-2499	11,524	3,019	14,543
2500-9999*	36,023	8,455	44,478
10000 or NIC*	21,821	14,084	35,905
NAGASAKI	35,495	7,125	42,620
0-1999	6,801	858	7,659
2000-2499	5,144	805	5,949
2500-9999*	15,642	2,510	18,152
10000 or NIC*	7,908	2,952	10,860
TOTAL	126,192	37,528	163,720
0-1999	28,130	5,703	33,833
2000-2499	16,668	3,824	20,492
2500-9999*	51,665	10,965	62,630
10000 or NIC*	29,729	17,036	46,765

* Matched by sex and age to those exposed between 0 and 1999 meters

ANNEX E

LIFE SPAN STUDY SAMPLE, ORIGINAL AND EXTENDED

City	Original (LSS)	Extended (LSS-E85)
Hiroshima	74,356	82,220
Nagasaki	25,037	37,912
Total	99,393	120,132

ANNEX F

ADULT HEALTH STUDY SAMPLE
BY CITY, SEX, AND EXPOSURE GROUP

City and sex	Exposure Group				Total
	With symptoms	Without symptoms	Distal	Not exposed	
HIROSHIMA	3,431	3,417	3,429	3,441	13,718
Male	1,315	1,307	1,309	1,319	5,250
Female	2,116	2,110	2,120	2,122	8,468
NAGASAKI	1,567	1,558	1,559	1,559	6,243
Male	682	676	673	675	2,706
Female	885	882	886	884	3,537
TOTAL	4,998	4,975	4,988	5,000	19,961
Male	1,997	1,983	1,982	1,994	7,956
Female	3,001	2,992	3,006	3,006	12,005

ANNEX G

IN UTERO SAMPLE BY CITY, IDENTIFICATION SOURCE,
AND STUDY COHORT MEMBERSHIP

Cohort membership	Source	Hiroshima	Nagasaki	Total
In utero mortality (only)	Birth records	1,104	247	1,351
	ABCC records	183	34	217
	1960 Census	416	62	478
In utero clinical (only)	Birth records	0	0	0
	ABCC records	578	259	837
	1960 Census	0	0	0
In both cohorts	Birth records	515	83	598
	ABCC records	167	6	173
	1960 Census	0	0	0
Total	Birth records	1,619	330	1,949
	ABCC records	928	299	1,227
	1960 Census	416	62	478
Grand total	All sources	2,963	691	3,654

ANNEX H

F₁ MORTALITY SAMPLE, ORIGINAL AND EXTENDED

Sample	City		Total
	Hiroshima	Nagasaki	
Original	34,790	18,731	53,521
Extended	13,225	10,074	23,299
Total	48,015	28,805	76,820

ANNEX I

ACTIVE RESEARCH PROJECTS BY RERF PROGRAM

As of 31 August 1996

LIFE SPAN STUDY

- RP 2-61 Study of mortality in children exposed in utero
- 1-75 Research plan for RERF study of Life-Span of A-bomb survivors, Hiroshima and Nagasaki
- 6-88 Comparative analysis of the LSS population and a cohort of 265,000 Japanese men and women
- (Inactive) 4-91 Mail survey on epidemiologic factors in the Extended Life Span Study sample, 1991

ADULT HEALTH STUDY

- 2-75 Research plan for RERF Adult Health Study, Hiroshima and Nagasaki

IMMUNOLOGY

- 36-63 Blood groups in Adult Health Study and in utero ATB subjects Hiroshima and Nagasaki
- (Inactive) 16-81 Establishment of specific reagents for detection of human cancers through in vitro immunologic and biochemical assays
- 3-87 Cellular immune function and its relationship to in vitro T-lymphocyte radiosensitivity and MN blood group locus mutation frequency in A-bomb survivors: Precursor frequency analysis of mitogen- and antigen-responsive blood lymphocytes
- 7-87 X-ray radiosensitivity of lymphocytes in vitro from A-bomb survivors. Part 3: Transformation of B-cells by Epstein-Barr virus and their cryopreservation (addendum to RP 3-86)
- 7-88 Study of somatic mutations at the glycoprotein A locus in erythrocytes of atomic bomb survivors
- 7-89 Screening of stem cell mutation in lymphoid lineage among A-bomb survivors and its characterization
- 9-89 Detecting erythrocyte mutations at the glycoprotein A locus in Nagasaki A-

- bomb survivors and in Hiroshima area poison gas workers (addendum to RP 7-88)
- 11-89 A pilot study for detection of somatic mutations at the HLA-A locus in lymphocytes
- 2-90 Cryopreservation of blood cells from Hiroshima and Nagasaki Adult Health Study participants
- 4-90 Establishment of a method for HLA-DQ and DP gene typing using the polymerase chain reaction (Inactive)
- 1-93 Study on T-cell antigen receptor repertoire and hematopoietic progenitor cell activity in peripheral blood of atomic bomb survivors (addendum to RPs 3-87, 4-87 and 7-89)
- 2-93 Development of assay for somatic mutation at the locus of the neutrophil Fcy receptor III gene and preliminary study on atomic-bomb survivors

SPECIAL CLINICAL STUDIES

- 4-85 Incidence and risk factors of coronary heart disease (CHD) in Japanese men living in Japan and Hawaii, 1966-78 (addendum to Research Plan TR 12-71)
- 6-85 Study of M-proteinemia in the Adult Health Study sample (addendum to RP 9-79)
- 4-86 Evaluation of index of physiological measurements: A predictor of mortality or morbidity associated with aging
- 5-86 Dietary habit survey using a simple and computerized diet survey system (addendum to RP 8-83)
- 11-86 Prevalence of hyperparathyroidism in atomic bomb survivors during AHS cycle 15, Hiroshima and Nagasaki
- 5-87 Radiation-related damage to the developing human brain
- (Inactive) 9-87 The effect of pulmonary function on the subsequent risk of coronary heart disease in Japanese men living in Hiroshima and Nagasaki, Japan and Hawaii, 1966-78 (addendum to RP 4-85)
- 1-89 Prevalence of radiation-related skin lesions in the Adult Health Study population, Hiroshima and Nagasaki
- 2-89 Hypercalcemia in A-bomb survivors, Hiroshima and Nagasaki

- (addendum to RP 11-86)
- 3-89 Osteoporosis in Hiroshima atomic bomb survivors
- (Inactive) 6-89 Incidence of radiation-related skin lesions in the Adult Health Study populations of Hiroshima and Nagasaki, 1958-89
- 3-90 The association of serum cholesterol with noncardiovascular mortality and morbidity in the Adult Health Study population
- 3-91 A comparative study of vertebral fracture prevalence among Japanese, Japanese-Americans in Hawaii, and Caucasians in Minnesota
- 5-92 Study on senile dementia among the Adult Health Study subjects in Hiroshima and Nagasaki
- 6-92 Establishment and operation of a system for collecting and storing leukemia cells
- 9-92 Study of liver diseases in the Adult Health Study sample. Relationship between radiation dose and infection by B and C hepatitis virus
- 5-93 A longitudinal study of hormone indicators of menopause in female A-bomb survivors of perimenopausal age
- 1-95 Effects of menopause on risk factors for ischemic heart disease - a longitudinal study of the Nagasaki Adult Health Study sample (addendum to RP 5-93)
- 2-95 Pilot study: characterization of monoclonal gammopathy by studying the role of BSAP gene in CD19 antigen expression

HISTO-PATHOLOGY

- 5-89 Pathology studies in Hiroshima and Nagasaki, revised research plan (Formerly RP 3-75)
- 8-89 Senile changes of the brain in Hiroshima and Nagasaki A-bomb survivors

CELL BIOLOGY

- 18-81 Pathophysiology and radiation response of human thyroid cells in culture and in grafts in athymic nu/nu mice
- 7-92 Molecular analysis of the p53 tumor-suppressor gene in breast cancers of

atomic bomb survivors (with addendum)

- 3-93 Molecular analysis of skin cancers in atomic bomb survivors
- 7-93 Molecular analysis of thyroid cancers among atomic bomb survivors
- 2-94 Molecular analysis of hepatocellular carcinoma among atomic-bomb survivors

BIOCHEMICAL GENETICS

- 5-85 Culture of permanent lymphocyte cell lines as sources of biological samples for investigation of genetic effects of radiation on children of atomic bomb survivors
- 7-85 Study to develop methods of DNA analysis for detection of mutations in children of atomic bomb survivors

CYTOGENETICS

- 8-93 Cytogenetic study in the Adult Health Study population by fluorescence in situ hybridization (FISH)

F1 STUDIES

- 4-75 Research plan for RERF studies of the potential genetic effects of atomic radiation; Hiroshima and Nagasaki. Part 1. Mortality study of children of atomic bomb survivors

SPECIAL CANCER STUDIES

- 29-60 Detection of leukemia and related disorders
- 7-76 The value of Adult Health Study family history records in the determination of genetic influences on the development of cancer and other disorders
- 14-79 Interaction between radiation dose and host factors. An epidemiological case-control study of female breast cancer in atomic bomb survivors
- (Inactive) 15-81 Case-control study of lung cancer among atomic bomb survivors
- 8-85 Incidence study on malignant and benign genital tumors among females,

Hiroshima and Nagasaki, 1950-80

- (Inactive) 11-85 Hormone status in relation to cancer: A prospective epidemiologic study using stored sera
- 2-86 Collection of surgically removed cancer tissues from A-bomb survivors: Special reference to thyroid and breast cancers
- 6-86 Ultrasonographic screening of Adult Health Study participants to detect cancer and other diseases
- 9-88 Guidelines for the conduct of site-specific cancer incidence studies among A-bomb survivors, Hiroshima and Nagasaki
- 5-90 Primary liver cancer incidence study among atomic bomb survivors, 1958-87
- 1-91 Studies of salivary gland tumors among the RERF Extended Life Span Study cohort, Hiroshima and Nagasaki, 1950-87
- 2-91 Studies of skin cancer incidence among the RERF Extended Life Span Study cohort, Hiroshima and Nagasaki, 1950-87
- 6-91 Studies on thyroid tumor incidence among the RERF Extended Life Span Study cohort, 1950-87
- 2-92 Studies on ovarian tumor incidence among the RERF Extended Life Span Study cohort, 1950-87
- 4-92 Incidence study of tumors of the central nervous system among atomic-bomb survivors
- 6-93 Breast cancer incidence study among atomic bomb survivors, 1950-90
- 1-94 Studies on lung cancer incidence among A-bomb survivors, 1950-90
- 3-94 Incidence of lymphoid malignancies among A-bomb survivors, 1950-90

A-BOMB DOSIMETRY STUDIES

- 18-59 Shielding survey and dosimetry study
- 10-86 Radiation dose estimates using tooth samples. Part 1. Collection of tooth samples from A-bomb exposed people in Hiroshima and Nagasaki

- 1-92 Radiation dose estimates using tooth samples. Part 2. Use of electron spin resonance on tooth enamel from Hiroshima atomic bomb survivors

MEDICAL DOSIMETRY STUDIES

- (Inactive) 7-81 Radiation therapy among Life Span Study subjects
- 7-86 Doses to Adult Health Study participants from RERF radiological examinations, Hiroshima and Nagasaki
- 8-86 Ionizing radiation for medical reasons reported by Adult Health Study participants, Hiroshima and Nagasaki
- 8-87 Organ doses from medical x-ray exposures (addendum to RP 8-84)
- 5-91 Radiation-therapy-related cancer among Life Span Study subjects (addendum to RP 7-81)

TUMOR REGISTRY AND TISSUE REGISTRY

- 18-61 Tumor registry study in Hiroshima and Nagasaki [Editor's note: See ABCC Technical Report 2-61 for the full text.]

Following are tissue registry-related protocols that are also listed under the category Special Cancer Studies.

- 29-60 Detection of leukemia and related disorders
- 9-88 Guidelines for the conduct of site-specific cancer incidence studies among A-bomb survivors, Hiroshima and Nagasaki
- 5-90 Primary liver cancer incidence study among atomic bomb survivors, 1958-87
- 1-91 Studies of salivary gland tumors among the RERF Extended Life Span Study cohort, Hiroshima and Nagasaki, 1950-87
- 2-91 Studies on skin cancer incidence among the RERF Extended Life Span Study cohort, Hiroshima and Nagasaki, 1950-87
- 6-91 Studies on thyroid tumor incidence among the RERF Extended Life Span Study cohort, 1950-87
- 2-92 Studies on ovarian tumor incidence among the RERF Extended Life Span

Study cohort, 1950-87

- 4-92 Incidence study of tumors of the central nervous system among atomic-bomb survivors
- 6-93 Breast-cancer incidence among atomic-bomb survivors, 1950-90
(supersedes RP 1-90)
- 1-94 Studies on lung-cancer incidence among the atomic-bomb survivors, 1950-90
- 3-94 Incidence of lymphoid malignancies among the atomic-bomb survivors, 1950-90

ANNEX J

ITEMIZED EQUIPMENT LISTS

Department of Clinical Studies

Hiroshima

Fiscal year	New/ Repl	Item	Q'ty	Unit Cost (x¥1000)	Total (x¥1000)
1997	R	Autoclave	1	3,360	3,360
	N	Laser printer	1	400	400
1998	R	Deep freezer	1	2,533	2,533
1999	R	High pressure sterilizer	1	3,358	3,358
	R	Dryer	1	770	770
	R	Ultrasonography	1	9,400	9,400
2001	R	Freeze dryer	1	4,750	4,750
	R	Deep freezer	1	2,533	2,533
Total					<u>27,104</u>

1. Autoclave (for Departments of Clinical Studies):

The autoclave currently in use was purchased in 1980 and being used beyond its expected life-span. The early replacement is requested.

2. Personal computer and laser printer (for Departments of Clinical Studies):

At present, there is no IBM PCs available for research scientists in the department. @ Since there are many research projects to be studied, an early distribution of PCs to some of the key investigators is one of the items with higher priority in the department.

3. Deep freezers (for Departments of Clinical Studies):

Two of the deep freezers currently in use for storage of biological materials, such as serum and plasma, were purchased in 1972 and 1973. These two freezers have been used beyond their life-span and it is expected to break down in the near future.

4. High pressure sterilizer (for Departments of Clinical Studies, Genetics and Radiobiology):

The high pressure sterilizer currently in use was purchased in 1986 and being used beyond its

expected life-span. The early replacement is requested.

5. Dryer (for Departments of Clinical Studies, Genetics and Radiobiology):

The dryer for glassware and other laboratory equipments currently in use was purchased in 19 and being used beyond its life-span. The early replacement is requested.

6. Ultrasonography (for Departments of Clinical Studies):

The ultrasonography currently in use was purchased in 1989. Since this is one of the equipments which have been providing direct benefits to the AHS participants, it is requested to replace before it breaks down.

6. Freeze dryer (for Departments of Clinical Studies):

The freeze dryer of serum currently in use was purchased in 1988. Since storage of serum is one of the most important activities in the department, the replacement is requested.

Nagasaki

Fiscal year	New/ Repl	Item	Q'ty	Unit Cost (x¥1000)	Total (x¥1000)
1997	R	Portable ECG	1	1,350	1,350
	R	Autoclave	1	650	650
	R	X-Ray Camera Ident.	1	302	302
	R	X-Ray Microreader	1	550	550
	R	Ultrasonography (Abdomen)	1	8,000	8,000
	R	Magazine for Imaging Camera	1	564	564
	R	Freezer (-40°C)	1	785	785
	R	Freezer (-80°C)	1	1,845	1,845
	R	Refrigerator	2	200	400
	R	Autodiluter	1	1,055	1,055
	R	Oven Drying	1	520	520
	R	Freeze Dryer	1	1,550	1,550
	R	Ampoule Seare	1	314	314
	R	Multi Tube, Ampoule	1	230	230
	R	Centrifuge Refrig	1	930	930
2000	R	ECG	1	3,000	3,000
				Total	<u>22,045</u>

Department of Genetics

977

ents

Fiscal year	New/ Repl	Item	Q'ty	Unit Cost (x¥1000)	Total (x¥1000)
1997	N	Software for 2-DE Analysis	1	10,000	10,000
	R	Pulsed Field Gel Electrophoresis Apparatus	1	3,000	3,000
	R	Refrigerated Centrifuge	1	1,270	1,270
	R	Refrigerator (with freezer)	1	94	94
	R	Centrifuge (for microtubes)	2	45	90
	R	Spectrophotometer	1	695	695
1998	R	Refrigerator (with freezer)	1	869	869
	R	Autoclave	2	580	1,160
	R	Water bath (with cooling system)	1	379	379
	R	Water bath (with cooling system)	1	447	447
	R	Power supply	4	150	600
	R	Centrifuge	1	240	240
	R	Photon camera	1	5,000	5,000
1999	N	Bio-Imaging Analyzer with Imaging Plates and Cassettes	1	22,880	22,880
	R	PCR equipment	1	4,000	4,000
	R	Water bath (with cooling system)	1	675	675
	R	Refrigerator (with freezer)	1	94	94
Total					51,493

Department of Radiobiology

Fiscal year	New/ Repl	Item	Q'ty	Unit Cost (x¥1000)	Total (x¥1000)
1997	R	Deep Freezer	1	2,200	2,200
	R	Thermal Cycler	2	850	1,700
	R	Clean Lack for Animal Facility	2	2,650	5,300
	R	Autoclave	1	700	700
	R	Confocal laser microscope	1	25,000	25,000
	R	X-ray Generator ⁽¹⁾	1	10,000	10,000

1998	R	Thermal Cycler	2	850	1,700
	R	Autoclave	1	700	700
	R	Laser for FACScan	1	1,300	1,300
	R	Laser for FACStar	1	3,500	3,500
1999	R	Cell Sorter (FACSVantage) ⁽²⁾	1	75,000	75,000
	R	Deep Freezer	1	2,200	2,200
	R	Thermal Cycler	2	850	1,700
	R	Power Supply	2	550	1,100
	R	FACScan ⁽²⁾	1	15,000	15,000
2000	R	Refrigerated Microcentrifuge	1	900	900
	R	Clean Bench	2	2,200	4,400
	N	Image Analyzer	1	8,000	8,000
2001	R	Fluorescence Microscope	1	2,500	2,500
	R	Thermal Cycler	2	850	1,700
				Total	<u>164,600</u>

Note: (1) The X-ray generator is for interdepartmental use. These items are not included in the total cost. (2) The FACSVantage and FACScan will be obtained on a lease-purchase basis to reduce annual equipment costs. The FACSVantage is basically a replacement for an earlier model flow cytometer that is now 13 years old.

A. Deep freezer (-80_°C)

Long term preservation of DNA, RNA and serum of the atomic-bomb survivors are necessary for the molecular epidemiology/oncology and immunology studies. The current equipment (15 years old) should be replaced before it breaks down to assure that the samples are safe.

B. Thermal cyclers

Thermal cyclers (program cell cycler) are essential machines for molecular epidemiology/oncology and immunology in the department of radiobiology. These machines can amplify DNA and RNA from very small amounts of materials obtained from A-bomb survivors. Eight machines are currently working in the department of radiobiology. Four of the 8 have been used longer than 5 years. The life span of this machine is 5 years because the cyclic raising and lowering of the temperature causes metal exhaustion.

C. Clean rack for mouse cages

Since the present mouse racks are very old (15 years) and severely deteriorated, they should be

replaced to maintain clean conditions in the cages.

D. Autoclave

The autoclave currently used in the immunology laboratory is seriously deteriorated and should be replaced.

E. X-ray generator

The 250 KV X-ray generator is for interdepartmental use; the current machine is badly in need of repair and cannot be expected to last more than a few years in its present condition, but this model is no longer being manufactured and parts are unavailable to effect the needed repair.

F. Laser tube for the FACScan

A laser tube unit for one of two FACScan flow cytometer should be replaced in FY98, because its expected life will be up within two years.

G. Laser tube for FACStar cell sorter

The laser tube unit for the FACStar should be replaced in FY98, because its expected life will be up within two years. If we can purchase FACS vantage through a lease in FY98, this replacement laser will not be needed.

H. FACS Vantage (dual laser model) cell sorting system

The present cell sorter, FACStar installed in the Radiobiology Department was purchased more than 10 years ago. Because this apparatus often breaks down, it should be replaced as soon as possible. This cell sorter is essential for conducting immunology and molecular oncological studies of A-bomb survivors. Also, it can be used to analyze somatic mutations in exposed people for international collaboration.

I. Power supply

Electrophoresis for detection of point mutation and identification of HLA alleles requires a stable electric power supply. Because, currently, we are using outdated power supplies, some replacements may be needed in a few years.

J. FACScan

The FACScan machine currently used in the Radiobiology Department was installed 8 years ago. Since this apparatus is essential for conducting immunological analyses of lymphocytes from A-bomb survivors, it should be replaced.

K. Refrigerated Microcentrifuge

duce

or
s

gy
A

5

For studies of molecular oncology/epidemiology, extraction of DNA, RNA and proteins from micro-samples is necessary. Considering the frequency of use, it is expected at least one refrigerated microcentrifuge will break down within a few years, because two of five centrifuges currently used in the Department of Radiobiology is older than 10 years.

L. Clean bench

The clean bench in use in the Immunology Laboratory is used for multiple purposes such as separation, culture and manipulation of the biological materials of A-bomb survivors. This was purchased more than ten years ago and needs to be replaced to assure safety of the staff from biohazardous agents.

M. Image analyzer and video system for microscope

This system is required for precise analysis of cellular functions of lymphocytes and stem cells from the survivors blood. Also, this system is needed for quantitative immunohistochemical analysis of the expression of tumor associated genes in survivors' tumor specimens.

N. Fluorescence Microscope

The microscope in use for 14 years is deteriorated and should be replaced. The fluorescence microscope is essential for cytological and histological examination in the immunological laboratory.

O. Personal Computer

In the Department of Radiobiology, we are currently using 7 PCs in total. Since 6 of them were purchased prior to last year, they should be replaced by new models during the next 5 years. Furthermore, 4 new computers for data analysis, manuscript preparation, literature search and e-mail need to be installed in 4 offices used by research scientists.

Radioisotope Laboratory

Fiscal year	New/ Repl	Item	Q'ty	Unit Cost (x¥1000)	Total (x¥1000)
1997	R	Automatic X-ray Film Processor	1	2,500	2,500
1999	R	GM-Survey Meter	1	450	450
2000	R	Survey Meter with Ionization Chamber	1	360	360
2001	R	Scintillation Survey Meter	1	700	700
			Total		<u>4,010</u>

Publications and Documentation Center

Fiscal Year	New/ Repl	Item	Q'ty	Unit Cost (x¥1000)	Total (x¥1000)
1997	R	PC DX-33	1	500	500
	R	PC DX/66	3	500	1,500
	R	PC P5-90	2	500	1,000
	R	PC P5-166	1	570	570
	R	Printer NEC PR-3000ps/4	1	400	400
	R	Printer JBCC PW5036	1	400	400
		Printer Brother HL-8PSJ	1	400	400
	R	Scanner set	1	410	410
	R	Software	14	50	700
	R	Canon EZPS	1	2,980	2,980
1998	R	Color copier, A Color 635	1	1,500	1,500
	R	Software	7	20	140
	R	PC P5-90	4	500	2,000
1999	R	PC P5-90	2	500	1,000
	R	Printer QMS825PS	1	480	480
	R	Software	10	50	500
	R	Canon EZPS	1	2,980	2,980
2000	R	PC P5-90	3	500	1,500
	R	PC P5-100	1	500	500
	R	Printer Xerox 4150	1	400	400
	R	Software	7	20	140
2001	R	PC P5-133	2	500	1,000
	R	Printer Zerox 4150	1	400	400
	R	Printer Canon LBP-203PS	1	1,300	1,300
	R	Software	10	50	500
			Total		<u>23,200</u>

25

ail

Secretariat, Hiroshima

Fiscal Year	New/ Repl	Item	Q'ty	Unit Cost (x¥1000)	Total (x¥1000)
Director's Office					
1996	N	Printer	3	400	1,200
1997	N	PC	2	570	1,140
	R	Software	12	50	600
1998	R	PC	2	500	1,000
1999	R	PC	4	500	2,000
2000	R	Printer	2	400	800
	R	Software	14	50	700
2001	R	Printer	3	400	1,200
General Affairs Section					
1997	R	PC	2	500	1,000
	R	Software	8	50	400
1998	R	PC	2	500	1,000
	R	Printer	2	220	440
2000	R	Software	8	50	400
Personnel Section					
1996	N	PC	1	570	570
1997	N	PC	1	570	570
1998	R	PC	2	500	1,000
	R	Printer	2	220	440
2000	R	Printer	1	750	750
	R	Software	6	50	300
Accounting Section					
1997	R	Printer	1	220	220
	R	Software	7	50	350
1998	R	PC	4	500	2,000
	R	Printer	1	220	220
1999	R	PC	3	500	1,500
	R	Printer	1	220	220
	R	Software	7	50	350
2001	R	Printer	1	220	220
Supply & Property Section					
1997	N	PC	3	570	1,710
	R	Software	5	50	250
1998	R	PC	4	500	2,000
	R	Printer	1	220	220
1999	R	Printer	1	220	220
	R	Software	8	50	400
Total					25,390

Secretariat, Nagasaki

Fiscal Year	New/ Repl	Item	Q'ty	Unit Cost (x¥1000)	Total (x¥1000)
General Affairs Section					
1996	N	PC	2	570	1,140
	N	Printer	1	220	220
1997	R	PC	2	500	1,000
	R	Printer	1	220	220
	R	Software	6	50	300
1998	R	Printer	2	220	440
1999	R	PC	4	500	2,000
2000	R	Printer	1	220	220
	R	Software	8	50	400
Accounting Section					
1996	N	PC	2	570	1,140
	N	Printer	1	220	220
1997	R	PC	2	500	1,000
	R	Software	2	50	100
1999	R	Printer	1	220	220
2000	R	Printer	1	220	220
	R	Software	4	50	200
Total					9,040

Department of Clinical Studies (Hiroshima)
5-Year Computer Equipment Summary

Year	Item	Qty	Unit Cost	Research Use Total	Admin and Service Use Total
1997	PC DX2-66 (Replace)	3	500	-	1,500
	PC P5-166 (Add)	4	570	1,824	456
	Laser printer (Add)	1	400	320	80
	Basic Software version up	1	50	25	25
	Basic Software version up	5	50	-	250
	Exceed Software version up	2	6	12	-
	Origin Software version up	2	20	40	-
	Corel Draw Soft. version up	2	40	80	-
	Total			2,301	2,311
1998	PC P5-90 (Replace)	3	500	-	1,500
	Laser printer (Replace)	1	400	-	400
	Exceed Software version up	2	6	12	-
	Origin Software version up	2	20	40	-
	Total			52	1,900
1999	PC P5-133 (Replace)	1	500	400	100
	PC P5-133 (Replace)	2	500	-	1,000
	Laser printer old Xerox	1	400	-	400
	Basic Software version up	5	50	125	125
	Basic Software version up	8	50	-	400
	Exceed Software version up	2	6	12	-
	Origin Software version up	2	20	40	-
	Corel Draw Soft. version up	2	40	80	-
	Total			657	2,025
2000	Laser printer (Replace)	1	400	-	400
	Software version up (OS)	5	20	50	50
	Software version up (OS)	8	20	-	160
	Exceed Software version up	2	6	12	-
	Origin Software version up	2	20	40	-
	Total			102	610
2001	PC P5-166 (Replace)	4	500	1,600	400
	PC P5-166 (Replace)	3	500	-	1,500
	Basic Software version up	5	50	125	125
	Basic Software version up	8	50	-	400
	Exceed Software version up	2	6	12	-
	Origin Software version up	2	20	40	-

	Corel Draw Soft. version up	2	40	80	-
	Total			1,857	2,425
	Grand Total			4,969	9,271

**Department of Clinical Studies (Nagasaki)
5-Year Computer Equipment Summary**

Year	Item	Qty	Unit Cost	Research Use Total	Admin and Service Use Total
1997	PC DX-33 (Replace)	1	500	-	500
	Laser printer (Replace)	1	220	-	220
	Basic Software version up	3	50	75	75
	Basic Software version up	3	50	-	150
	Exceed Software version up	2	6	12	-
	Origin Software version up	2	20	40	-
	Total			127	945
1998	PC P5-90 (Replace)	1	500	400	100
	PC P5-90 (Replace)	1	500	-	500
	Exceed Software version up	2	6	12	-
	Origin Software version up	2	20	40	-
	Total			452	600
1999	PC P5-133 (Replace)	1	500	400	100
	PC P5-133 (Replace)	2	500	-	1,000
	Laser printer (Replace)	1	400	-	400
	Basic Software version up	3	50	75	75
	Basic Software version up	3	50	-	150
	Exceed Software version up	2	6	12	-
	Origin Software version up	2	20	40	-
	Total			527	1,725
2000	Laser printer (Replace)	1	400	-	400
	Exceed Software version up	2	6	12	-
	Origin Software version up	2	20	40	-
	Total			52	400
2001	PC P5-166 (Replace)	1	500	400	100
	Basic Software version up	3	50	75	75
	Basic Software version up	3	50	-	150
	Exceed Software version up	2	6	12	-
	Origin Software version up	2	20	40	-
	Total			527	325
	Grand Total			1,685	3,995

Department of Epidemiology (Hiroshima)
5-Year Computer Equipment Summary

Year	Item	Qty	Unit Cost	Research Use Total	Admin and Service Use Total
1997	PC replacement	8	500	2,800	1,200
	Printer replacement	1	500	400	100
	New Hardware	1	500	421	79
	Software upgrades	26	60	1,092	468
	New software	4	40	128	32
	Mocrotome (Path)	1	600	600	-
	Incubator (Path)	1	240	240	-
	Paraffin cleaner (Path)	1	130	130	-
	Total			5,811	1,879
	1998	PC replacement	8	500	2,800
Printer Replacement		1	500	350	150
New Hardware		1	500	421	79
Software upgrades		25	60	1,050	450
New software		7	40	196	84
Path equipment replacement		1	150	150	-
Total				4,967	1,963
1999		PC replacement	8	525	2,940
	Printer Replacement	1	500	400	100
	New Hardware	1	520	440	80
	Software upgrades	25	60	1,050	450
	New software	3	40	96	24
	Path equipment replacement	1	150	150	-
	Total			5,076	1,914
	2000	PC replacement	8	525	2,940
Printer Replacement		1	500	350	150
New Hardware		1	520	440	80
Software upgrades		16	90	1,008	432
New software		6	40	168	72
Path equipment replacement		1	150	150	-
Total				5,056	1,994
2001		PC replacement	8	525	2,940
	Printer Replacement	1	500	400	100
	New Hardware	1	520	416	104
	Software upgrades	16	90	1,008	432
	New software	6	40	192	48

	Path equipment replacement	1	150	150	-
	Total			5,106	1,944
	Grand Total			26,016	9,694

**Department of Epidemiology (Nagasaki)
5-Year Computer Equipment Summary**

Year	Item	Qty	Unit Cost	Research Use Total	Admin and Service Use Total
1997	PC withfull set of standard software	1	570	456	114
	PC 486DX/66 (Replace)	2	500	800	200
	PC 486DX/33 (Replace)	2	500	800	200
	PC 386/33 (Replace with full set of	1	570	456	114
	Laser printer (Replace by 4-year lease)	1	700	560	140
	Laser printer (Replace)	3	400	960	240
	Exceed software (New)	1	40	40	-
	Origin software (New)	1	50	50	-
	Basic software version up	2	50	100	-
	Basic software version up	2	50	-	100
	Basic software version up	13	50	520	130
	Exceed software version up	2	6	12	-
	Exceed software version up	2	6	-	12
	Exceed software version up	9	6	43	11
	Origin software version up	2	20	40	-
	Chameleon software (New)	1	100	80	20
	Total			4,917	1,281
1998	PC P5-130 (Replace)	1	500	500	-
	PC P5-90 (Replace)	1	500	-	500
	PC P5-90 (Replace)	3	500	1,200	300
	Laser printer (4-year lease)	1	700	560	140
	Exceed software version up	3	6	18	-
	Exceed software version up	2	6	-	12
	Exceed software version up	9	6	43	11
	Origin software version up	3	20	60	-
	Total			2,381	963
1999	PC P5-130 (Replace)	2	500	800	200
	Laser printer (4-year lease)	1	700	560	140
	Laser printer (Replace)	2	400	640	160
	Basic software version up	3	50	150	-
	Basic software version up	2	50	-	100
	Basic software version up	13	50	520	130
	Exceed software version up	3	6	18	-
	Exceed software version up	2	6	-	12

	Exceed software version up	9	6	43	11
	Origin software version up	3	20	60	-
	Total			2,791	753
2000	Laser printer (4-year lease)	1	700	560	140
	Exceed software version up	3	6	18	-
	Exceed software version up	2	6	-	12
	Exceed software version up	9	6	43	11
	Origin software version up	3	20	60	-
	Total			681	163
2001	PC P5-166 (Replace)	6	500	2,400	600
	Laser printer (4-year lease)	1	700	560	140
	Laser printer (Replace)	3	400	960	240
	Basic software version up	3	50	150	-
	Basic software version up	2	50	-	100
	Basic software version up	13	50	520	130
	Exceed software version up	3	6	18	-
	Exceed software version up	2	6	-	12
	Exceed software version up	9	6	43	11
	Origin software version up	3	20	60	-
	Total			4,711	1,233
	Grand Total			15,482	4,392

Department of Genetics (Hiroshima)
5-Year Computer Equipment Summary

Year	Item	Qty	Unit Cost	Research Use Total	Admin and Service Use Total
1997	PC (Add)	4	500	1,600	400
	PC hontai (Replace)	4	300	960	240
	Workstation (Replace)	1	1,500	1,500	-
	Hard disk (New)	2	200	400	-
	Software version up	18	20	181	181
	Software (New)	4	100	200	200
	Total			4,841	1,021
1998	PC (Add)	1	500	400	100
	Hard disk (New)	2	200	400	-
	Software version up	19	34	326	326
	Software (New)	1	100	50	50
	Total			1,176	476
1999	PC (Add)	1	525	420	105
	PC hontai (Replace)	3	315	756	189
	Hard disk (New)	2	210	420	-

	Software version up	20	37	371	371
	Software (New)	1	100	50	50
	Total			2,017	715
2000	PC (Add)	1	550	440	110
	Printer (Replace)	2	440	704	176
	Hard disk (New)	2	220	440	-
	Software version up	21	39	412	412
	Software (New)	1	100	50	50
	Total			2,046	748
2001	PC hontai (Replace)	2	330	528	132
	Workstation (Replace)	1	2,000	2,000	-
	Hard disk (New)	2	220	440	-
	Software version up	21	38	401	401
	Software (New)	1	100	50	50
	Total			3,419	583
	Grand Total			13,499	3,543

Department of Radiobiology (Hiroshima)
5-Year Computer Equipment Summary

Year	Item	Qty	Unit Cost	Research Use Total	Admin and Service Use Total
1997	PC DX-66 (Replace)	3	500	-	1,500
	PCP5-166(Add)	4	570	1,824	456
	Laserprinter(Replace)	1	400	-	400
	BasicSoftwareversionup	2	50	50	50
	BasicSoftwareversionup	2	50	-	100
	ExceedSoftwareversionup	2	6	12	-
	OriginSoftwareversionup	2	20	40	-
	CorelDrawSoft.versionup	2	40	80	-
	Total			2,006	2,506
1998	PCP5-90(Replace)	2	500	-	1,000
	Laserprinter(Replace)	1	400	-	400
	ExceedSoftwareversionup	2	6	12	-
	OriginSoftwareversionup	2	20	40	-
	Total			52	1,400
1999	BasicSoftwareversionup	6	50	150	150
	BasicSoftwareversionup	5	50	-	250
	ExceedSoftwareversionup	2	6	12	-

	OriginSoftwareversionup	2	20	40	-
	CorelDrawSoft.versionup	2	40	80	-
	Total			282	400
2000	Softwareversionup(OS)	6	20	60	60
	Softwareversionup(OS)	5	20	-	100
	ExceedSoftwareversionup	2	6	12	-
	OriginSoftwareversionup	2	20	40	-
	Total			112	160
2001	PCP5-90(Replace)	4	500	1,600	400
	BasicSoftwareversionup	6	50	150	150
	BasicSoftwareversionup	5	50	-	250
	ExceedSoftwareversionup	2	6	12	-
	OriginSoftwareversionup	2	20	40	-
	CorelDrawSoft.versionup	2	40	80	-
	Total			1,882	800
	GrandTotal			4,334	5,266

Department of Statistics (Hiroshima)
5-Year Computer Equipment Summary

Year	Item	Qty	Unit Cost	Research Use Total	Admin and Service Use Total
1997	PC replacement	6	500	2,000	1,000
	Network Disk Storage	1	300	300	-
	New Hardware	1	475	400	75
	Software upgrades	12	83	700	300
	New software	6	50	250	50
	Total			3,650	1,425
1998	PC replacement	6	500	2,000	1,000
	Printer Replacement	1	500	350	150
	New Hardware	1	475	400	75
	Software upgrades	12	83	700	300
	New software	6	50	250	50
	Total			3,700	1,575
1999	PC replacement	6	525	2,100	1,050
	Network Disk Storage	1	320	320	-
	New Hardware	1	520	440	80
	Software upgrades	12	89	750	315
	New software	6	59	280	75

	Total			3,890	1,520
2000	PC replacement	6	525	2,100	1,050
	Printer Replacement	1	500	370	130
	New Hardware	1	520	440	80
	Software upgrades	12	89	750	315
	New software	6	59	280	75
	Total			3,940	1,650
2001	PC replacement	6	550	2,200	1,100
	Network Disk Storage	1	330	330	-
	New Hardware	1	565	480	85
	Software upgrades	12	92	770	330
	New software	6	63	300	80
	Total			4,080	1,595
	Grand Total			19,260	7,765

Department of Information Technology (Hiroshima)
5-Year Computer Equipment Summary

Year	Item	Qty	Unit Cost	Research Use Total	Admin and Service Use Total
1997	PC (Add)	3	520	-	1,560
	PC(Replace)	7	520	-	3,640
	Network disk storage	1	200	-	200
	Printer (Replace)	1	500	-	500
	New hardware	1	500	-	500
	Software (New)	21	19	-	400
	Software version up	21	100	-	2,100
	ITD Staff Total			-	8,900
	<i>RERF-wide services:</i> computer and network hardware/software replacement	1	36,000	-	36,000
	Grand Total			-	44,900
1998	PC (Add)	2	520	-	1,040
	PC(Replace)	9	520	-	4,680
	Printer (Replace)	1	500	-	500
	New hardware	1	500	-	500
	Software (New)	23	17	-	400
	Software version up	23	100	-	2,300
	ITD Staff Total			-	9,420

	<i>RERF-wide services:</i> computer and network hardware/software replacement	1	36,000	-	36,000
	Grand Total			-	45,420
1999	PC (Add)	1	550	-	550
	PC(Replace)	10	550	-	5,500
	Network disk storage	1	210	-	210
	Printer (Replace)	1	525	-	525
	New hardware	1	525	-	525
	Software (New)	24	18	-	420
	Software version up	24	105	-	2,520
	ITD Staff Total			-	10,250
	<i>RERF-wide services:</i> computer and network hardware/software replacement	1	37,800	-	37,800
	Grand Total			-	48,050
2000	PC(Replace)	11	550	-	6,050
	Printer (Replace)	1	525	-	525
	New hardware	1	525	-	525
	Software (New)	24	18	-	420
	Software version up	24	105	-	2,520
	ITD Staff Total			-	10,040
	<i>RERF-wide services:</i> computer and network hardware/software replacement	1	37,800	-	37,800
	Grand Total			-	47,840
2001	PC(Replace)	11	577	-	6,350
	Network disk storage	1	220	-	220
	Printer (Replace)	1	550	-	550
	New hardware	1	550	-	550
	Software (New)	24	18	-	440
	Software version up	24	110	-	2,650
	ITD Staff Total			-	10,760
	<i>RERF-wide services:</i> computer and network hardware/software replacement	1	39,700	-	39,700
	Grand Total			-	50,460
	Five-Year Total			-	236,670

Actual Personnel Strength and Projected Changes

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Grand Total	427	433	437	435	412	373	335	331	323	318	315	312
Director & Other	6	6	5	6	6	5	5	5	5	5	5	5
Professional Staff	57	61	64	62	57	48	47	50	50	50	50	50
General Staff	364	366	368	367	349	320	283	276	268	263	260	257

Actual Personnel and Operating Costs and Budget Estimates (Unit:¥1,000)

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Personnel costs (Term. allowance)	3,227,676 (208,852)	3,304,603 (163,105)	3,742,938 (391,230)	3,635,153 (274,021)	3,559,650 (405,884)	3,881,353 (947,102)	2,781,100 (27,137)	3,692,476 (789,902)	3,296,604 (446,993)	3,170,297 (314,997)	3,301,463 (427,976)	3,252,828 (335,835)
Operating costs	802,336	858,687	871,424	851,988	799,292	851,549	725,385	819,419	825,866	849,327	850,348	875,590
Total	4,030,012	4,163,290	4,614,362	4,487,141	4,358,942	4,732,902	3,506,485	4,511,895	4,122,470	4,019,624	4,151,811	4,128,418

Actual Costs of Equipment and Supplies and Budget Estimates (Unit:¥1,000)

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Equipment	98,262	110,204	81,072	96,180	125,014	95,965	51,808	132,491	128,634	141,636	132,042	146,509
Supplies(Reagent)	67,587	61,305	70,879	70,154	55,953	49,908	49,908	50,656	51,416	52,187	52,970	53,765
Supplies(Lab)	82,770	71,923	77,649	93,165	83,247	58,413	66,129	67,121	68,128	69,150	70,187	71,240

Note: Personnel and operating costs are actual up to FY95, estimate from FY96 and after. For calculation of personnel costs, 1% base up is assumed for FY96, 2% for FY97 and after. Operating costs in FY96 were estimated to be ¥725,385,000 and a 1.5% yearly increase in FY97 and after.
The number of employees as of 1 January 2002 is 310.

FIVE YEAR STRATEGIC RESEARCH PLAN AND PROGRAM MANAGEMENT

ERRATA

line 343: "Among this later group" should read "Among this latter group"

line 717: "facilitate RERF" should read "facilitate this end RERF"

lines 735-740 should be replaced with the following:

One of the major sources of tissues from the A-bomb survivors is from the on-going collection of blood samples. This supply of viable cells from the survivors is a valuable resource for the study of many diseases including those with immune system dysfunction. Reduced immune function can potentially lead to a variety of pathologic consequences including cancer, which is known to show heightened risk among the survivors. RERF has a matchless opportunity to investigate the late effects of radiation exposure on the immune system.

We plan to continue our studies of the features and mechanisms of radiation-induced disorders in the hematology system at the cellular and molecular levels. These studies include radiation effects on the distribution of T-cell subsets in the survivors and of radiation effects on endocrine and hematopoietic growth factor levels as well as the study of stem cells, the progenitors of cells which constitute the immune system.

line 941: After clinical management system insert "is being developed"

line 1518: After the word example, insert "we have been able to obtain "

line 2701: "FISH examination or survivors" should read "FISH examination of survivors"

line 2942: The superscript after 17.3 should read 4,5

line 4610: read 64 to 47 rather than 60 to 47

line 4693: the row in the table labeled "sub-total" under the column "Directors" should have the number 5 inserted

line 4287: After **Organization** please insert the accompanying table of organization that begins with the word Present


Replace the table occurring between page 103 and 104 with the new one attached

Replace the very last table beginning with "Actual Personnel Strength and Project Changes" with the new one with the same heading that is attached

RECEIVED
DEC 01 1999
OSTI

Present


Staff: Professional 1
Administrative 20
 Total 21



Revised Organizational Structure (draft)

1 January 1998

1 January 1999



研究部門備品要求表 (1996年～2001年)
Equipment Requests by Research Departments

(単位：千円) (UNIT: ¥1,000)

部・局	DEPARTMENT	FY1996	FY1997	FY1998	FY1999	FY2000	FY2001	合計
疫学部	EPIDEMIOLOGY	0	7,690	6,930	6,990	7,050	7,050	35,710
臨床研究部	CLINICAL STUDIES	0	8,372	4,485	16,210	712	11,565	41,344
遺伝学部	GENETICS	0	21,011	10,347	30,381	2,794	4,002	68,535
放射線部	RADIOBIOLOGY	0	49,412	83,652	20,682	13,572	6,882	174,200
統計部	STATISTICS	0	5,075	5,275	5,410	5,590	5,675	27,025
広島合計	HIROSHIMA TOTAL	0	91,560	110,689	79,673	29,718	35,174	346,814
臨床研究部	CLINICAL STUDIES	0	20,117	1,052	2,252	3,452	852	27,725
疫学部	EPIDEMIOLOGY	0	6,198	3,344	3,544	844	5,944	19,874
長崎合計	NAGASAKI TOTAL	0	26,315	4,396	5,796	4,296	6,796	47,599
① 両市合計	BOTH TOTAL	0	117,875	115,085	85,469	34,014	41,970	394,413

サポート部門備品要求表 (1996年～2001年)
Equipment Requests by Supporting Departments

部・局	DEPARTMENT	FY1996	FY1997	FY1998	FY1999	FY2000	FY2001	合計
出版資料センター	PDC	0	8,860	3,640	4,960	2,540	3,200	23,200
研究情報センター	ITD	0	44,900	45,420	48,050	47,840	50,460	236,670
放射線同位 RI	RI FACILITIES	0	2,500	0	450	360	700	4,010
事務局	SECRETARIAT	1,770	6,240	8,320	4,690	2,950	1,420	25,390
広島合計	HIROSHIMA TOTAL	1,770	62,500	57,380	58,150	53,690	55,780	289,270
事務局	SECRETARIAT	2,720	2,620	440	2,220	1,040	0	9,040
長崎合計	NAGASAKI TOTAL	2,720	2,620	440	2,220	1,040	0	9,040
② 両市合計	BOTH TOTAL	4,490	65,120	57,820	60,370	54,730	55,780	298,310

①+② 合計		4,490	182,995	172,905	145,839	88,744	97,750	692,723
--------	--	-------	---------	---------	---------	--------	--------	---------

現金購入	PURCHASE COST	4,490	110,655	86,872	86,021	73,344	87,967	449,349
リース支払い	LEASE CHARGE	0	16,754	36,680	50,533	54,100	56,365	214,431
従来のリース支払	CURRENT LEASE CHARGE	17,095	5,082	5,082	5,082	4,598	2,177	39,116
合計	TOTAL	21,585	132,491	128,634	141,636	132,042	146,509	702,896

コンピューター関係分 For Computer 4,490 94,381 80,017 82,462 73,314 86,797 421,461